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Human papillomavirus (HPV) is the most common sexually transmitted infection. The 
infection is higher in certain racial/ethnic groups and those who are 
immunocompromised including pregnant women. Because immune system is 
suppressed during pregnancy, women are at higher risk of various types of infection 
including HPV, a known risk factor for pregnancy complications. However, its role in 
adverse pregnancy outcomes is unclear. Another high risk population is Northern Plain 
American Indian. In the Northern Plains region, American Indian women have 
significantly higher rate of HPV infection than white counterparts and are infected with 
different types of HPVs than the general population. Because the prevalence of infection 
with these HPV types are higher in American Indian population, the impact of HPV 
vaccine on cervical cancer cases is expected to vary from other populations.  
The objectives of this study were to explore the relationship between HPV infection and 
adverse pregnancy outcomes and to estimate the number of cervical cancer cases 
reduced by 9-valent vaccine among Northern Plains American Indian women. To 
achieve these objectives, an analysis was conducted using Pregnancy Risk Assessment 
and Monitoring System (PRAMS), in a population-based survey of pregnant women from 
iv 
 
2004 to 2011. In addition, a hospital-based data analysis was conducted on women who 
delivered a live birth at Nebraska Medical Center between 2012 and 2014. HPV infection 
was diagnosed on the basis of a Pap test report. PROC SURVEYLOGISTIC (or logistic) 
procedures were used to examine the relationship between HPV infection and adverse 
pregnancy outcomes such as low birth weight, preeclampsia, preterm birth, and 
premature rupture of membrane. Additionally, to project the impact of 9-valent vaccine 
on the American Indian population, a compartmental deterministic model was 
developed. Our study found low prevalence of HPV infection among pregnant women. 
Significant associations were found between HPV infection and adverse pregnancy 
outcomes, including preeclampsia, preterm birth, and low birth weight. In addition, this 
study found that the 9-valent vaccine is associated with a greater reduction of cervical 
cancer cases among white women than among American Indian women. Overall, this 
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1.1. Human Papillomavirus Overview  
1.1.1 Discovery of HPV 
Human papillomavirus (HPV) is a small (50–55 nm in diameter), nonenveloped, 
double-stranded, circular DNA virus that infects the skin or mucosal epithelium. 
Throughout evolution, diseases associated with HPV infection were well documented. 
Greek and Roman physicians were well aware of skin and genital warts. In those days, 
the term condyloma (a word of Greek origin), meaning “a round swelling around the 
anus,” was used for genital warts.1 In 1842, an Italian physician, Rigoni-Stern, analyzed 
the death certificates of individuals who died as a result of cancer in Verona during the 
period 1760–1839. He found that deaths related to cervical cancer were rare among 
virgins and nuns, as compared to married women or widows. This study indicated the 
possible association of cervical cancer with sexually transmitted disease.1  
Since ancient times, genital warts have been considered a result of sexual 
promiscuity and have been regarded as infectious. However, their link to sexual behavior 
was not firmly established until 1954. At the end of the 19th century, the infectious nature 
of common warts was confirmed by Payne. Their infectiousness was also confirmed by 
Heidingsfield, who described a prostitute who had developed condyloma lesions on her 
tongue as a result of oral sex.2  In 1907, Ciuffo demonstrated the infectious nature of 
human warts by using a cell filtrate of a common wart to transfer the infection.3 This 
experiment also established the viral nature of the responsible agent.  
By the end of the 1960s, herpes simplex virus type 2 was thought to be the 
cause of cervical cancer, but further studies failed to confirm it.4 The interest of 
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researchers in HPV arose when HPV was visualized in HPV warts with the help of 
electron microscopy. The role of HPV in the development of cervical cancer was 
postulated and analyzed by Harald zur Hausen. In 1983–1984, the first HPV types, 16 
and 18, were isolated from cancer biopsies of the cervix and were later cloned.5  In 
2008, zur Hausen was awarded the Nobel Prize for Medicine, for the discovery of the 
infectious etiology of cervical cancer.  
1.1.2 High- and Low-Risk HPV Types 
During the 1970s, the multiplicity of HPV types became apparent. The plurality of 
HPV was established by a series of research studies by zur Hausen and his colleagues 
as well as by Gerard Orth’s group in Paris. These researchers discovered the first four 
HPV types in cutaneous warts and numbered them 1 through 4.6-8 Soon, serological 
evidence was provided to support this plurality, because there seemed to be no link 
between HPV types 1–4 and the HPV types found in condylomata accuminata, laryngeal 
papillomas, or any of the malignant tumors tested.9 For the identification of new 
papillomavirus types, the most conserved region within the genome, L1 ORF, is used. If 
the DNA sequence of the L1 ORF differs by more than 10% from the closest types and 
the complete genome is cloned, then a new papillomavirus is recognized.10 Differences 
in homology ranging between 2% and 10% define a subtype, whereas those of less than 
1% define a variant.11  
More than 100 types of HPV have been identified, and 40 of those types infect 
the genital tract.12 HPV types are categorized as high-risk and low-risk groups. High-risk 
types are oncogenic and more persistent than low-risk types.  High-risk types cause 
cervical intraepithelial lesions and cancers of the cervix, anus, head and neck, penis, 
and vulva. High-risk types currently include HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 68, 69, 73, and 82. High-risk types 16 and 18 are responsible for 70% of 
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cervical cancers. The remaining types are considered to be low risk because they do not 
cause cancer. These low-risk types can cause skin warts, or condylomata acuminata, on 
or around the genitals or anus. 13   
1.1.3 Structure and life cycle of HPV 
The HPV viral genome consists of approximately 8000 base pairs14 and is 
organized into three regions: the early region I, which incorporates E1, E2, and E4-E7 
and constitutes 50% of the genome; the late region (L), consisting of the L1 and L2 
region, which forms 40% of the genome; and the genomic regulatory region, which 
represents 10% of the genome.15 The early region is involved in the DNA replication (E1, 
E2), transcription (E5), and cell transformation (E5, E6, and E7), while the late region 





Figure1 Structure of HPV. Adapted from Malik H, et al. 2013.17 
 
The papillomavirus structure does not contain any enzymes, lipids, or 
saccharides. The virus becomes inactivated at 70° Celsius, is stable at a pH of 3–7, and 
is killed after 30 minutes if kept at a temperature above 50° Celsius. HPV is resistant to 
solvents, acids, and X-rays.10  Because papillomaviruses initiate productive infections 
only within stratified epithelia of the skin, oral cavity, and anogenital tract, they are 
considered highly epitheliotropic. The life cycle of the virus is thought to begin when the 
basal epithelium cells become infected, probably at the site of injury.  
1.1.4 Life cycle of HPV  
The life cycle of HPV (Figure 2) begins when infecting viral particles reach the 
germinal cells in the basal layer through a small abrasion to the mucosa during sexual 
intercourse.18  The virus starts binding and then undergoes a conformational relaxation 




hours. As soon as the virus enters the basal cells, the protein envelope is decomposed, 
and the viral DNA moves to the nucleus. Within the nucleus, the viral DNA exists in 
episomes but is separate from the host DNA. This is usually linked with the presence of 
low virus copy numbers and no cytological abnormalities.19  
In the maturing squamous epithelium, viral assembly occurs as the virus 
amplifies its DNA to high copy numbers and synthesizes capsid proteins.20 This in turn 
results in the release of amplified virus from terminally differentiated squamous cells.  
Next, the HPV early genes E6 and E7, which are required for malignant transformation, 
are produced in both the lower and the upper layers of the epithelium. The HPV L1 and 
L2 proteins form the viral capsid. These proteins are produced and assembled into 
virions that stimulates the immune response and are released only in the terminally 
differentiated outer epithelial layer.21 In very few scenarios, persistence, integration, and 
transformation occur. Usually, in order to integrate into the host cell DNA, the HPV DNA 
disrupts the E2 gene, enabling the circular genome to become linear. This disruption of 
E2 gene results in cessation of viral synthesis and also activates the deregulation of E6 
and E7. The E6 gene binds and degrades p53 while the E7 gene inactivates the 
retinoblastoma gene.  Retinoblastoma and p53 are both tumor suppressor genes, and 
inactivation of these genes causes genetic instability, prevention of apoptosis, and 
uncontrolled cellular proliferation, which may result in cancer.21  
Unlike other infections, the life cycle of HPV is actually hidden from the host 





Figure 2. Life cycle of HPV. Adapted from Moody CA, et al., 2010 22 
 
1.1.5 HPV Risk Factors 
Sexual activity is one of the major risk factors for acquiring HPV infection. Having 
multiple sex partners is associated with greater risk of infection. However, having sex 
with only one partner does not entirely eliminate the risk of procuring the infection.23 
Some of the other risk factors for HPV include co-infection with other sexually 
transmitted diseases, smoking, and a weakened immune system. In addition, use of 
hormonal contraceptives for longer duration is believed to be associated with increased 
risk of infection.24  
 Age is another major risk factor, in that HPV infection is most common in 
sexually active men and women who are 21-24 years old. Although this association 




association may have biological causes.23 Squamous cells are the most common type in 
adults, whereas columnar and metaplastic cells are predominant in adolescents. 
Neonates are born with an abrupt squamo-columnar junction present on the ectocervix.  
At the time of puberty, the columnar epithelium gradually transforms into the squamous 
epithelium. This process is known as squamous metaplasia. During this process, large 
areas of transitional squamous, glandular, and metaplastic cells are formed, all of which 
support HPV replication.25  
1.1.6 Transmission of HPV 
HPV is usually transmitted during sexual intercourse through contact with 
infected cervical, vaginal, vulvar, penile, or anal epithelium. However, it can also be 
transmitted through nonpenetrative sexual contact, such as oral-genital or digital-genital 
contact.26 Inconsistent use of condoms also increases the risk of transmission of the 
virus. However, condom use is only 70% effective in preventing the transmission of HPV 
because there is still contact with genital skin.13 
In addition to horizontal transmission, rarely vertical transmission of HPV from 
mother to fetus can also occur.27 When transmitted vertically, HPV can cause juvenile-
onset recurrent respiratory papillomatosis and laryngeal papillomatosis in infants.28 A 
study conducted by Tenti et al. investigated HPV type-specific concordance between 
mother-infant pairs and observed that HPV types carried by HPV-positive newborns 
were identical to those found in their mothers.29 
1.1.7 Infectivity and Incubation  
The probability of transmission of HPV infection per sexual act is independent of 
the type of HPV and is quite high. A previous study found that genital warts are highly 
infectious because of the high viral load, and up to 65% of sexual contacts develop an 
infection.30 The incubation period of genital warts is usually 3 weeks to 8 months, with an 
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average of 2.9 months.30  Longitudinal studies have indicated that most HPV infections 
are transient and no longer detectable within 1–2 years.31 High-risk infections usually 
persist longer than low-risk infections.31 In high-risk infections, HPV 16 seems to persist 
longer than other types. This indicates that high-risk HPV would spread at a greater rate 
than would low-risk HPV in populations with similar sexual patterns and 
transmissibility.26  
HPV infection can be in a latent, subclinical, or clinical phase. During the latent 
phase, the infection is inactive, there are no noticeable symptoms, and the infected site 
remains cytologically normal. In the subclinical phase, HPV infection is generally 
transient, and colposcopically detectable lesions develop that are usually low-grade 
cervical intraepithelial neoplasia (CIN)1.32 In most women the infection resolves by itself 
because of cell-mediated immunity. About 10% to 15% of women whose infection does 
not clear naturally remain HPV DNA positive and have persistent viral infection.23 There 
is not yet a clear definition of persistence. However, follow-up strategies targeting 
abnormalities lasting 1–2 years seem to distinguish infections and associated lesions 
that put an individual at a greater risk of transient infections.33  A study conducted by 
Moscicki et al. indicates that the risk of developing CIN3 is 14 times higher among 
women who have had at least three positive tests for high-risk HPV, compared to 
women with negative HPV test results.34 Older women generally have higher persistence 
of HPV infection than younger women. One reason could be that the acquired infection 
is less likely to clear naturally in older women.35 Additionally, this greater persistence 
could be due to the gradual predominance of longer-duration infection from earlier 
exposures, in comparison with more recent and more transient infection.35  
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1.2 HPV and Cancer 
1.2.1 HPV and cervical cancer 
Virtually all cervical cancers are caused by HPV infection.36 As mentioned earlier, 
HPV types 16 and 18 are responsible for nearly 70% of cervical cancer cases. The 
development of cervical cancer occurs in a series of four steps (Figure 1): HPV 
transmission, viral persistence, progression of a clone of persistently infected cells to 
pre-cancer, and invasion. Persistent HPV infection results in changes in the cervical 
cytology of squamous epithelia that may progress to noninvasive CIN2/3 and, many 
years later, to invasive cervical cancer.36  
Natural History of Cervical Cancer  
 
 





HPV infection tends to cause cancer in areas known as the transformation zone. 
In this zone, one type of epithelium contacts and gradually replaces another by 
transforming itself through a process called metaplasia. Some examples of 
transformation zones that are prone to HPV infection include the cervix, anus, and 
tonsils. In the cervix, the transformation zone is the area of the columnar epithelium that 
transforms into the squamous epithelium.23 The above process is comparatively inactive 
in children but becomes quite active around puberty.  
In all HPV-related cancers, the stage of malignancy is set when HPV DNA 
integrates into the host cell genome. Viral oncoproteins E6 and E7 are released during 
the process. These proteins further bind and degrade host tumor suppressor genes 
TP53 and RB1.37 Although HPV infection can cause various types of cancers, it is a 
primary concern for cervical cancer. Genotypes that cause cervical cancer include HPV 
51 (alpha 5); HPV 56 and HPV 66 (alpha 6); HPV 18, HPV 39, HPV 45, and HPV 59 
(alpha 7); and HPV 16, HPV 31, HPV 33, HPV 35, HPV 52, and HPV 58 (alpha 9).38 All 
HPV genotypes that cause cervical cancer belong to the alpha genus.  
Women who have a persistent infection of high-risk HPV types are at higher risk 
of developing high-grade intraepithelial disease and invasive cervical cancer.39 High-risk 
HPV DNA can be detected in nearly 99.7% of squamous cell carcinomas40 and in about 
94% to 100% of cervical adenocarcinomas and adenosquamous carcinomas.41 Cervical 
squamous cell carcinomas are the most common histological types of cervical cancer 
that develop from pre-existing noninvasive squamous precursor lesions, also known as 
cervical intraepithelial neoplasias (CINs) or squamous intraepithelial lesions (SILs).42 
Lesions are histologically classified based on the atypia of epithelial cells that continue to 
increase from the lower parabasal layers of squamous epithelium up to the whole 
epithelium. CIN1 and SIL correspond to mild dysplasia, CIN2 to moderate dysplasia, and 
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CIN3 to severe dysplasia.42 CIN2 and CIN3 are at high risk of progression or of cancer 
and are thus considered its precursor. The natural history of cervical carcinogenesis is 
shown in Figure 4.  
 
Figure 4: Natural history of cervical carcinogenesis. Adapted from Juckett G et al., 
2010.37 
Adenocarcinoma in situ (ACIS) and adenocarcinoma of the cervix (AdCA) are 
often not detected by Pap Smear, as they are located higher in the cervical canal and 
consequently are less accessible to the brush. Because of this, it might be beneficial to 
add testing for high-risk (HR)-HPV to the cervical cancer screening program in order to 
detect ACIS and AdCA. 41  
1.2.2 HPV and Penile Cancer  
HPV plays an important role in the development of penile cancer. Although penile 
cancer is uncommon in developed countries, the incidence is much higher in developing 
countries such as Uganda (incidence, 4.4 per 100,000) or Paraguay (incidence, 4.2 per 
100,000).43 There are several different histological types of penile carcinomas. Most of 
the penile tumors are well-differentiated, keratinizing squamous cell carcinomas. 
Verrucous carcinoma is the second most common tumor subtype, and its variants are 
basaloid carcinoma and warty carcinoma. About 80% to 100% of basaloid and warty 
penile cancers are HPV positive. However, only a small fraction of verrucous penile 
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carcinomas are the result of HPV infection. Similar to cervical cancer, high-risk HPV 
expresses oncoproteins E6 and E7, which bind to p53 and inactivate the tumor 
suppressor protein Rb.44  
The pre-cancerous penile condition is known as penile intraepithelial neoplasia 
(PIN). Histologically, PIN is similar to CIN. However, the natural history of penile lesions 
is unknown, and therefore there are no standard protocols for diagnosis or management 
of penile cancer.45 
1.2.3 HPV and Head and Neck Cancers  
Head and neck cancer (HNC) is the fifth most common cancer worldwide 46 and the 
eighth most common cause of cancer mortality.47 HNC is a heterogeneous group of 
cancers, including cancers of the lip, oral cavity, nose, paranasal sinuses, oropharynx, 
nasopharynx, hypopharynx, larynx, salivary glands, and esophagus.48  Although tobacco 
and alcohol are considered the two major risk factors for HNC49,5050 about 25% of HNCs 
are associated with high-risk HPV. HPV-positive HNCs are usually less differentiated 
and of basaloid type.51 Although laryngeal and hypopharyngeal cancers are associated 
with smoking and alcohol consumption, oropharyngeal cancers involving tonsils, the 
pharyngeal wall, and the tongue base are mostly associated with HPV infection.52,53 The 
mechanisms of HPV oncogenesis in the oropharynx seems to be similar to those of 
cervical cancer. The differences are related to the anatomic, cellular, and immune 
environments. For instance, there is no transformation region in the oropharynx like that 
in the uterine cervix, in which malpighian epithelium of the exocervix joins the 
unistratified glandular epithelium of the enocervix, where most of the cancer develops. In 
the oropharynx, the tonsil is the most commonly affected anatomical region. So far, the 
exact mechanism of HPV infection in the nongenital region is unclear. However, easy 
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access to tonsillar crypts that have a favorable microenvironment may be the reason for 
the higher prevalence of HPV in this region. 
1.2.4 HPV and Anal Cancer  
Most of the anal squamous cell carcinomas are caused by HPV infection. Anal 
carcinoma is a rare malignancy with an incidence of 0.3 to 0.8 per 100,000 among men 
and 0.5 to 1.0 per 100,000 among women. However, since the 1970s there has been a 
2% increase in the incidence of anal cancer in both men and women.54 The exact reason 
for the increase is still unclear, but it may be the result of a change in sexual behavior.54 
Overall, the incidence of anal cancer is usually higher among men having sex with men 
and individuals who are immunosuppressed.55 
Invasive anal carcinoma develops from anal intraepithelial neoplasia (AIN). 
Similar to cervical intraepithelial neoplasia (CIN), AIN is classified into three categories: 
AIN1, AIN2, and AIN3.  In AIN1, the lower third of the epithelium is affected, while in 
AIN2 and AIN3, two thirds of the epithelium and the entire epithelium, respectively, are 
affected.  
1.2.5 Risk Factors for HPV-Related Cancer 
Tobacco Smoking  
Smoking is one of the risk factors for HPV-related cancers. One possible 
mechanism by which smoking may contribute to cervical carcinogenesis is that there is 
direct exposure of DNA in the cervical epithelial cells to nicotine and cotinine.56,57 
Another proposal is that exposure of DNA in cervical epithelial cells to metabolic 
products resulting from reactions among other components of cigarettes, such as 
aromatic polycyclic hydrocarbons and aromatic amines, may result in 
carcinogenesis.56,57 Studies have demonstrated measurable amounts of cigarette 
constituents and their metabolites such as benzopyrene,58 nicotine, and nicotine-derived 
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nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone are found in cervical mucus 
and DNA adducts in cervical tissues.59 HPV infection genome amplification is increased 
by benzopyrene, which may in turn increase the probability of viral DNA integration into 
the host genome, which is a crucial step in the development of cervical cancer.60  
Additionally, aberrant HPV-induced methylation might be another mechanism of 
smoking-related cervical carcinogenesis. In vitro studies in untransformed and 
transformed cell lines have shown that there are changes in the expression of DNA 
methyltransferases, DNMT1, DNMT3A, and DNMT3B, when the cell lines are exposed 
to nicotine or tobacco smoke for a short period. Aberrant methylation of p16, a tumor 
suppressor gene, is strongly associated with current smoking in women with squamous-
cell cervical cancers and high-grade CIN.61 Furthermore, tobacco smoking is believed to 
facilitate the acquisition or persistence of an HPV infection through a reduced number of 
Langerhans cells and CD4 lymphocytes,62,63 which are markers of local immune 
response in the cervix.64,205 
Immunosuppression 
Previous studies have found that the prevalence of HPV infection is higher 
among those with immunosuppression.65,66 T-helper cells are part of the defense 
mechanism that acts against HPV-transformed cells. Individuals with 
immunosuppression have a lower number of T-helper cells, predisposing them to HPV 
infection. This is one of the major reasons that Human immunodeficiency virus (HIV)-
positive individuals, pregnant women, and organ transplant recipients are at greater risk 
of HPV infection. Studies of HIV-positive women suggest that alteration in cell-mediated 
immunity plays a vital role in the development and progression of CIN, specifically in 
individuals with lower CD4+ T cell counts or with high HIV RNA plasma levels.67-69  
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Use of Oral Contraceptives  
There has been a long debate on the risk of cervical cancer among users of oral 
contraceptives. A pooled analysis conducted by the International Agency for Research 
on Cancer (IARC) to study the association between oral contraceptives and risk of 
cervical cancer among HPV-positive women revealed no excess risk among women who 
had used oral contraceptives for ≤5 years. However, the study found that the relative risk 
of cervical cancer was 2.8 for those who had used oral contraceptives for 5–9 years and 
4.0 for those who had used it for ≥10 years.70 It is believed that oral contraceptives favor 
the progression of pre-cancerous lesions to cervical cancer.71 
Parity 
High parity has been associated with cervical cancer. The independent role of 
high parity has been confirmed by case-control studies of cervical carcinoma.72-74  A 
study conducted by IARC revealed that women with seven or more full-term pregnancies 
had 4 times the risk of developing squamous-cell carcinomas, compared to nulliparous 
women.74 Similarly, another study conducted in Costa Rica showed an increased risk of 
HSIL/CC with increasing number of live births.75  
During pregnancy, the level of estrogens and progesterone in blood increases 
progressively.76 The change in blood hormone levels results in a change in the junction 
between the squamous and columnar epithelium occurring during pregnancy. In early 
pregnancy, eversion of columnar epithelium onto the ectocervix begins and is more 
noticeable during the second and third trimesters.  Since cervical ectopy increases with 
number of full pregnancies, it is believed that high parity might increase the risk of 
cervical carcinoma77 because it maintains the transformation zone on the exocervix for a 
number of years, thus assisting the direct exposure to HPV.74  
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1.2.6 Epidemiology of HPV and HPV-Related Cancers in the United States  
HPV is the most common sexually transmitted infection and affects nearly 80% of 
women at some point in their lives.78 In 2010, the prevalence of HPV among women in 
age group 18-59 years was 42.7% in the United States.79 Although the prevalence of 
HPV varies geographically, the prevalence of both low-risk and high-risk HPV is highest 
in the age group of 21–24 years, compared to other age groups.79 Additionally, the 
incidence of HPV infection is higher in certain racial/ ethnic groups. In the United States, 
non-Hispanic blacks have the highest prevalence of HPV (63.1%), followed by Mexican 
Americans (40.1%).79 Furthermore, a study showed an HPV prevalence of 50.8% among 
women who had ≥3 lifetime partners. Moreover, the prevalence was found to be 74% 
among women who had >2 sexual partners in the past year.79  
HPV among Northern Plains American Indians 
The Northern Plains region of the United States comprises Iowa, South Dakota, 
North Dakota, Minnesota, and Nebraska.  In the Northern Plains, American Indian 
women have a significantly higher rate of HPV infection than their white counterparts 
and are infected with different types of HPV than the general population.80 The incidence 
rate among Northern Plains American Indians is 11.3 per 100,000, which is 1.7 times 
higher than among non-Hispanic whites (7.5 per 100,000). 81    
Despite the fact that cervical cancer is preventable, it is the leading cause of 
cancer death among American Indian women. A study conducted by the Aberdeen Area 
Indian Health Services reported an age-adjusted cervical cancer mortality rate of 15.6 
per 100,000, five times the rate reported in the general U.S. population (3 per 
100,000).82  There is also disparity in the cervical cancer survival rates among American 
Indian women. In 2010, the 5-year survival rate for cervical cancer was reported to be 
81% among American Indian women, compared to 84% among white women.83  
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One of the major reasons for the disparity could be the higher prevalence of HPV 
types other than HPV 16 and 18, which are not covered by the two established vaccines 
(bivalent and quadrivalent). This explanation is supported by studies of infections among 
American Indian women that showed a broad variety and different patterns of HPV 
types, including a higher prevalence of mixed HPV infections.80,84  
1.2.7 Burden of HPV-related cancers 
Worldwide, cervical cancer is the fourth most common cancer in women and the 
seventh overall.85 However, the majority of the burden of cervical cancer is in developing 
nations. Cervical cancer is the most common cancer in women in Eastern and Middle 
Africa.85 In 2012, there were an estimated 528,000 new cases and 266,000 deaths from 
cervical cancer worldwide, accounting for 7.5% of all female cancer deaths.85 American 
cancer society estimates that in 2016 about 12,990 new cases of invasive cervical 
cancer will be diagnosed and 4120 women will die from cervical cancer.86   
Annually, there are approximately 97,215 cases of HPV noncervical cancers 
among men and women worldwide, including 50,780 cancers among men (13,485 anal 
cancers, 26,775 oropharyngeal cancers, and 10,520 penile cancers) and 46,435 cancers 
among women (14,787 anal cancers, 6,048 oropharyngeal cancers, and 25,600 
vaginal/vulvar cancers).87,88 
 
1.3. Impact of HPV on Pregnancy  
1.3.1 HPV among pregnant women 
Pregnancy is a known risk factor for new or recurrent HPV infections.89 In the 
state of pregnancy, the levels of progesterone are elevated, causing an increase in the 
replication of HPV DNA. HPV infection can increase the rate of trophoblast cell death, 
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which can further impair the extravillous trophoblast invasion into the maternal uterine 
wall. This could result in placental dysfunction and other adverse pregnancy outcomes.90  
HPV-related pregnancy outcomes   
Adverse pregnancy outcomes that have been associated with bacterial or viral 
infection include preeclampsia, premature rupture of membrane (PROM), preterm birth, 
and low birth weight.  However, little is known about their association with HPV infection.  
Preeclampsia is characterized by high blood pressure and signs of damage to 
other organ systems during pregnancy and is a major cause of maternal and fetal 
mortality and morbidity.91 Preeclampsia generally begins after 20 weeks of pregnancy in 
a woman whose blood pressure had been normal. It complicates about 3% to 6% of 
pregnancies, and if left untreated, it can lead to serious and even fatal complications for 
both the mother and the unborn baby.92 Although the exact mechanism of preeclampsia 
is unknown, one suggested mechanism is defective placentation with reduced invasion 
of fetal extravillous trophoblast cells, in addition to reduced remodeling of maternal 
uteroplacental spiral arteries.93 Additionally, it is believed that systemic inflammation—as 
illustrated by exaggerated leukocytosis, extensive platelet activation, and increased 
complement activation in preeclampsia—plays a vital role in the development of 
preeclampsia.94-96 It is widely accepted that cervicovaginal HPV infection causes chronic 
inflammation that may result in detrimental pregnancy outcomes. However, its 
association with preeclampsia is still elusive. Some of the known risk factors for 
preeclampsia include pre-existing hypertension, diabetes, older age, multiple 
pregnancies, and obesity.97 
Another adverse pregnancy outcome that may be associated with HPV infection 
is PROM, the rupture of fetal membrane before the onset of labor. It occurs in nearly 3% 
of pregnancies and can lead to respiratory distress syndrome, neonatal sepsis, umbilical 
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cord prolapse, placental abruption, and fetal death. It is a multifactorial disorder, but 
infection is one of the major causes of membrane damage. One possible mechanism for 
rupture as a result of infection is that the cytokines and metalloproteases (especially 
matrix metalloproteinase [MMP]-2) released by an organism can degrade collagen and 
also weaken the fetal membrane, resulting in membrane damage. Few studies have 
examined the association of PROM and MMP with HPV infection. However, because 
HPV in human invasive cervical carcinoma cell lines results in an increase in MMP-2 
expression, HPV may play an important role in regulation of MMP.98  
Preterm birth is one of the leading causes of infant death and occurs in about 
12% of all pregnancies in the United States.99 Although the survival rate of preterm-birth 
babies is high, they are at increased risk of neurodevelopmental impairments and 
respiratory and other complications.100 Some of the risk factors for preterm birth include 
maternal demographic characteristics such as low socioeconomic status, low and high 
maternal ages, infection, nutritional status, and pregnancy history.100 Intrauterine 
infections account for 25% to 40% of preterm births, but this may be an underestimate 
since intrauterine infections can be difficult to detect with conventional techniques. 
Intrauterine infections activate the innate immune response that is believed to lead to 
preterm births.101-103  In addition to preterm birth, intrauterine infections can also result in 
low birth weight, defined as less than 2500 grams. In the United States the prevalence of 
low birth weight is 7.7%.104  Similar to preterm birth, the association of low birth weight 




1.4. Prevention & Control of HPV 
Cervical cancer and other HPV-related cancers are a burden on the health care 
system, yet they are preventable. The probability of acquiring HPV infection can be 
lowered with the help of HPV vaccines, regular HPV testing, and screening. 
1.4.1 Pap test and HPV testing  
Papanicolaou (Pap) test 
 The U.S. Preventive Services Task Force (USPSTF) recommends that women 
in the age group of 21 to 65 years be screened with a Pap smear test every three years. 
Pap test results are reported as normal, inconclusive, or conclusive. The test results are 
considered normal if no abnormal cells are detected in the cervix but are considered 
inconclusive if atypical squamous cells are detected. These cells are divided into two 
categories: atypical squamous cells of undetermined significance (ASCUS) and atypical 
squamous cells for which high-grade squamous intraepithelial lesions cannot be 
excluded (ASC-H). An ASCUS designation means that the squamous cells do not 
appear to be completely normal, but it is unclear what the cell changes indicate.  ASCUS 
is similar to the ASC-H designation, except that ASC-H indicates a possibly higher risk of 
precancerous lesions. The changes could be the result of HPV infection or any other 
infection.  
HPV testing  
HPV testing is used to identify high-risk HPV types in the cervical cells. Since HPV 
cannot be cultured, HPV test depends on the detection of viral nucleic acids in the 
infected tissue.  Most tests are based on direct hybridization or DNA-based amplification 
techniques.105 In women 30 years and older, HPV testing has been shown to be more 
sensitive than Pap testing for the detection of cervical interstitial neoplasia (CIN) grade 
2/3+.106,107 Various HPV tests have been approved for screening purposes. For example, 
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Hybrid Capture 2 is currently the only US FDA approved HPV test. It is a signal-amplified 
hybridization microplate-based assay.108,109 Most tests detect the DNA of high-risk HPV; 
however, one test detects the RNA of high-risk HPV. Currently the HPV test is only for 
women; there is no HPV test for men. 
1.4.2 Screening guidelines  
Women who want to increase the screening interval should be screened with 
both a combination of cytology (Pap smear) and HPV testing every five years. The 
USPSTF recommends against screening for cervical cancer in women younger than age 
21.110 The reason for that is that women in their 20s who are sexually active are much 
more likely to have HPV infection that will clear off on its own. Currently, there is no 
recommended testing for HPV in pregnant women.111  
1.4.3 HPV Vaccines  
There are currently three types of Food and Drug Administration (FDA)-approved 
HPV vaccines recommended for preteen males and females aged 11 or 12 years 
through 26 years.112 All three vaccines consist of recombinant noninfectious virus-like 
particles (VLPs) formed by the HPV L1 capsid protein. The three vaccines that protect 
against certain types of HPV are Gardasil, Cervarix, and Gardasil 9. Whereas Cervarix is 
approved only for females, Gardasil can be given to both male and females. Gardasil is 
a quadrivalent vaccine that protects against HPV 6, 11, 16, and 18. Cervarix is bivalent 
and protects against two types of HPV: 16 and 18.112  In US Gardasil was the only 
vaccine available from 2006 to late 2009.113  
Mechanism of Action of Gardasil  
Each Gardasil dose of 120 mg antigenic protein load comprises L1 VLPs specific 
to HPV 16 and 18 as well as genital warts. The recombinant vaccine is synthesized in 
Saccharomyces cerevisiae, and each 0.5 ml of Gardasil dose contains aluminum 
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hydroxy phosphate sulfate and polysorbate-80. Gardasil is a prophylactic vaccine. It 
induces high initial serum HPV-type specific antibodies.114,114  The antibodies prevent 
endocytosis into the epithelial cells, thus neutralizing the infecting HPV virion. There are 
two ways by which antibodies can reach the denuded basement membrane: via a 
constant transude from the dermal capillary network up through the intact basement 
membrane or via an exudate that is triggered by tissue injury to the cervical epithelium, 
exposing the basement membrane to HPV virions. To neutralize infective type-specific 
virions by any method, high antibody titers are necessary.114 
Mechanism of Action of Cervarix vaccine 
Cervarix is an AS04 adjuvant vaccine that contains recombinant L1 protein, the major 
antigenic protein of capsid and HPV types 16 and 18.115 Each 0.5-ml dose consists of 20 
micrograms of HPV type 16 L1 protein, 20 micrograms of HPV type 18 L1 protein, 50 
micrograms of the 3-O-desacyl-4’-monophosphoryl lipid A, and 0.5 mg of aluminum 
hydroxide. The efficacy of L1 VLP vaccine may be facilitated by the development of IgG 
neutralizing antibodies directed against HPV-L1 capsid protein, produced as a result of 
vaccination.115 
Both Gardasil and Cervarix vaccines are given intramuscularly in a series of 
three doses (scheduled for 0, 1 to 2, and 6 months) and are 90% to 100% effective 
against the respective HPV types.116,117  Gardasil and Cervarix were approved by the 
FDA in 2006 and 2009, respectively. In 2014, the FDA approved the Gardasil 9 vaccine 
by Merck, which consists of high-risk HPV types (HPV 31, 33, 45, 52, and 58) in addition 
to the pre-existing types in the Gardasil vaccine. Gardasil 9 included five additional types 
of HPV that are believed to account for nearly 20% or more of cervical cancer cases.118 
Because these other types of HPV are more prevalent in the American Indian population 
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than in other populations, it is beneficial to study the impact of the 9-valent vaccine in 
that population. 
1.4.4 HPV treatment  
If a woman is found to have an abnormal Pap test result and a positive HPV test 
result, colposcopy (use of an instrument called a colposcope to examine the vagina and 
the cervix) and follow-up testing are usually recommended. If biopsy of cells from the 
affected area shows CIN2 or more severe abnormality, then a Loop Electrosurgical 
Excision Procedure (LEEP), cryotherapy, laser therapy, or conization is performed.   
 
1.5 Gaps in Knowledge  
Although wide research on etiology of cervical cancer has been conducted 
recently, there have been few population-based studies on prevalence of HPV among 
pregnant women in the United States and on the possible adverse health outcomes, 
especially with regard to active HPV infections and adverse pregnancy outcomes. U.S. 
studies have shown that the HPV infection rates among adolescent girls and 
nonpregnant women range from 8.8% to 42.7% among women 14-59 years.79,119-122 
However, the prevalence of HPV among pregnant women since the introduction of 
vaccines is still unknown. It is also important to note that previous research studies 
among pregnant women were mostly conducted before the introduction of the HPV 
vaccine, which should already have a measurable impact on the current population. It is 
essential to estimate the current prevalence of HPV among pregnant women in the post-
vaccination era and to further study the effect of HPV on current pregnancies or later 
pregnancies. 
  Recent studies indicate that the prevalence of HPV infection increases drastically 
among pregnant women, because of the immune suppression that occurs during 
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pregnancy. Additionally, the role of other sexually transmitted diseases such as 
chlamydia and gonorrhea in causing adverse pregnancy outcomes is well documented. 
However, there is little knowledge about the role of HPV infection in adverse pregnancy 
outcomes.  It is crucial to understand that role, because HPV affects nearly 80% of 
sexually active women. 
Another major gap in knowledge is related to the impact of Gardasil 9 vaccine on 
Northern Plains American Indian women. To date, no study has projected the impact of 
HPV vaccine specifically on Northern Plains American Indians. As mentioned in section 
1.2.6, the prevalence of certain types of HPV is higher among American Indian women 
than among white women. It is crucial to know the significance of using Gardasil 9 
compared to the established Gardasil (4-valent) vaccine among Northern Plains 




OBJECTIVE OF DISSERTATION 
This dissertation is focused on two high-risk populations: pregnant women and 
Northern Plains American Indian women. The long-term goal of this dissertation is to 
reduce adverse consequences of HPV infection in high-risk population groups. The 
dissertation has three specific aims.  
Aim 1: To examine the association of HPV infection with adverse pregnancy outcomes 
by using hospital data from 2012 to 2014. 
Aim 2: To examine HPV infection prevalence and its association with perinatal outcomes 
among singleton mothers, by using Pregnancy Risk Assessment Monitoring System 
(PRAMS) data from 2004 to 2010.  
Aim 3: To project the potential public health impact of the Gardasil 9 vaccine on cervical 













Does HPV affect pregnancy outcomes? 
 
2.1 HPV and Adverse Pregnancy Outcomes Overview 
HPV is a huge health problem because of its high prevalence and 
transmissibility.123  Studies conducted in the United States and other countries indicate 
that pregnant women are at higher risk of acquiring HPV infection.124 During pregnancy, 
major physiological and immunological changes take place that regulate the functioning 
of the immune system and may cause alteration in HPV replication.125 These changes 
make clearance of HPV much more difficult. 78 Extravillious or invasive trophoblast cells 
facilitate placental attachment to the maternal uterine wall and are responsible for 
establishing a high-flow, low-resistance maternal circulation supplying the placenta and 
the fetus.90 HPV infection can impair extravillious trophoblast invasion into the uterine 
wall by increasing the rate of trophoblast cell deaths, causing placental dysfunction. As a 
consequence of this placental dysfunction, adverse pregnancy outcomes may occur. 90  
Preeclampsia is one potential adverse pregnancy outcome. It is a main cause of 
maternal and fetal morbidity and mortality. In the last two decades, the rate of 
preeclampsia has increased by 25%.126 Although, age, obesity, and history of 
preeclampsia are some of the known risk factors, the underlying cause of preeclampsia 
is not well understood. However, a study conducted by Redman and Sargent suggests 
that the probability of developing preeclampsia increases when the level of systemic 
inflammatory burden, which is an integral part of pregnancy, transcends the maternal 
capability to compensate for this added stress.127 The researchers believe if this is true, 
then it is possible to hypothesize that infections that increase systemic inflammatory 
burden could result in increased risk of preeclampsia.127 In the past, various 
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epidemiological studies have examined the association between maternal infection and 
preeclampsia,128-131 but few focused on its association with HPV.78   A recent study 
report by McDonnold et al. noted that risk of developing preeclampsia was nearly twofold 
among women infected with HR-HPV.78 However, these findings were contrary to the 
study findings of Cho et al., which showed no significant association between HPV and 
preeclampsia.89  These inconsistent results suggest a need to further investigate this 
association.   
Another adverse pregnancy outcome is preterm birth. An estimated 12% to 13% 
of pregnancies in the United States are preterm.100 Nearly 25% to 40% of these preterm 
births are due to intrauterine infections that activate the inflammatory pathways; 
however, this may be an underestimate, because intrauterine infections are not easily 
detected with conventional culture techniques.132,133 To date, few studies have examined 
the relation of cervical cytology during pregnancy and HPV infection.134-136 Also, previous 
study results were inconclusive regarding the impact of HPV on pregnancy outcomes, 
highlighting the importance of our study.  In addition to preterm birth, intrauterine 
infections can affect fetal development and cause intrauterine growth restriction that 
results in low birth weight.137 Though the association of bacterial infections, including 
gonorrhea and chlamydia, with adverse pregnancy outcomes has been studied before, 
no previous studies have focused on their association with HPV.  
Premature rupture of membrane (PROM), before the onset of labor, is another 
probable adverse pregnancy outcome.138 PROM is a multifactorial condition, with 
infection being one of the major causes of membrane damage.139 One possible 
mechanism suggested by previous researchers is that cytokines such as 
metalloproteases secreted by various organisms degrade the collagen and weaken the 
fetal membrane, causing the membrane to rupture.132  Specifically, MMP-2 degrades the 
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extracellular matrix of the fetal membrane, resulting in PROM. Interestingly, the increase 
in MMP-2 is associated with the presence of HPV in human invasive cervical carcinoma 
cell lines, suggesting the possible role of HPV in regulation of MMP.98 Recent 
epidemiological research has found an association between PROM and colonization of 
the genital tract with Chlamydia trachomatis, Neisseria gonorrhoeae, and group B 
streptococci.140,141 However, the relationship between HPV and PROM remains 
ambiguous. Bopegamage et al. reported no association between viral genomes and 
preterm rupture of membrane (rupturing before 37 weeks),142 whereas another study 
showed that the risk of PROM among women with HR-HPV infection was twofold the 
risk for noninfected women.89  
 The ambiguity in the results of the previous studies may be due to confounding 
factors such as smoking or co-infection with chlamydia or gonorrhea that were not 
controlled for in some studies.  In the present study, we controlled for the necessary 
confounders to examine whether the association would still be significant. The objective 
was to determine if HPV infection is associated with adverse pregnancy outcomes, 
including preeclampsia, preterm birth, low birth weight, and PROM.  
 
2.2 Material and Methods  
In this study, hospital data on adult women (18 years and older) who delivered a 
live birth at Nebraska Medical Center between 2012 and 2014 was analyzed.143 The 
potential subjects were identified based from a query of the hospital patient database, 
and analysis was restricted to women who had a Pap test during pregnancy. Because 
the data were unidentifiable, this study was exempted from Institutional Review Board 
approval.143 Women with multipara were included, with each pregnancy considered 
individually. However, women with multiple births (e.g. twins, triplets, etc) were excluded 
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from our study, because multiple births are more likely to have adverse pregnancy 
outcomes.100,144 This resulted in a total of 4,824 women (5,022 births) in the sample.   
Patients with low/high-grade squamous intraepithelial lesions or atypical 
squamous cells of undetermined significance (ASCUS) on Pap smear were considered 
to be HPV-positive. The outcomes studied in this study were preterm birth, PROM, low 
birth weight, and preeclampsia. Preterm birth was defined as birth before 37 weeks of 
gestation. PROM was defined as rupture of the membrane prior to the onset of labor. 
Low birth weight was characterized as infant weight of less than 2500 gram at the time 
of birth. Preeclampsia was defined by a systolic blood pressure ≥140 mm Hg and/or 
diastolic blood pressure ≥90 mm Hg on two occasions at least 6 hours apart, along with 
proteinuria (an abnormal amount of protein in urine). 
Bivariate analysis was conducted to assess the relationship between HPV 
infection and demographic and clinical variables. Additionally, logistic regression was 
performed to determine the association between HPV infection and each of following 
pregnancy outcomes, after adjustment for demographic and clinical variables: preterm 
birth, PROM, low birth weight, and preeclampsia. The demographic and clinical variables 
were those that were significantly different between the infected and noninfected groups 
or were based on prior knowledge of their association with both HPV infection and the 
outcome. These variables included age, race, smoking, mode of delivery, previous 
preterm birth, infection with chlamydia and gonorrhea, obesity prior to pregnancy and 
previous abortions. 




2.3 Results  
Of the total sample of 5,022 observations, 221 (4.4%) tested positive for HPV. 
Significant differences in demographic and clinical characteristics between HPV-infected 
and noninfected groups are shown in Table1.143 Over 40% of HPV-infected women were 
in the age group of 20 to 24 years, compared to only 23.3% of uninfected women in that 
age category.143 About 30% of women with HPV infection were black, compared to 16% 
of women who were not infected. Close to 20% of HPV-infected women were smokers, 
compared to 6.9% of uninfected women. HPV-infected women were also at higher risk of 
chlamydia and gonorrhea, compared to noninfected women. The HPV-infected group 
had a statistically higher percentage of vaginal delivery than did the noninfected group 
(87.8% vs. 81.9%; p = 0.025).  Finally, the percentages of women with previous preterm 
delivery and previous abortion were higher in the HPV-infected group than in the 
noninfected group (13.8% vs. 8.1% for preterm delivery; 28.6% vs. 22.5% for 
abortion).143 
Pregnancy outcomes and odds ratios (ORs) are shown in Table 2. The crude 
ORs were significant for preeclampsia (OR: 2.37; 95% confidence interval [CI]: 1.11–
5.06), preterm birth (OR: 1.64; 95% CI: 1.15–2.32), and low birth weight (OR: 2.71; 95% 
CI: 1.86–3.94) and remained significant after adjusting for demographic and other 
variables that were believed to confound the association, on the basis of prior studies.143 
HPV-positive women were 2.83 times more likely to develop preeclampsia, compared to 
HPV-negative women (adjusted OR: 2.83; 95% CI: 1.28–6.26), after adjustment for age, 
race, previous preterm birth, gestational age, infection with chlamydia and gonorrhea, 
previous abortions, and delivery type. Women with HPV infection were 1.8 times more 
likely to deliver preterm (adjusted OR: 1.81; 95% CI: 1.15–2.83) and 2.58 times more 
likely to deliver low-birth-weight infants (adjusted OR: 2.58; 95% CI: 1.56–4.27) than 
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were uninfected women, after adjustment for other covariates. Although the odds of 
developing PROM were higher among infected women than among uninfected women, 
the association was not statistically significant (OR: 1.39; 95% CI: 0.54–3.52).143  
 
Table 1. Demographic characteristics according to maternal human papillomavirus 
(HPV) status143 
Characteristics  Infected (%) Uninfected (%) P value 
Total 221 (4.4) 4801 (95.6) - 
Age    <0.001 
≤19 12 (5.4) 392 (8.2)  
20–24 91 (41.2) 1119 (23.3)  
25–29 57 (25.8) 1536 (31.9)  
30–34 35 (15.8) 1215 (25.3)  
≥35 26 (11.8) 539 (11.2)  
Race/Ethnicity   <0.001 
White/Caucasian 113 (51.6) 3140 (67.1)  
Black/African American 69 (31.5) 751 (16.0)  
AI/AN/PI 11 (5.0) 84 (1.8)  
Hispanic 4 (1.8) 139 (2.9)  
Other 21 (9.6) 435 (9.3)  
Unknown 1 (0.5) 133 (2.8)  
Smoking    <0.001 
Yes 39 (17.7) 332 (6.9)  
No 182 (82.4) 4469 (93.1)  
Obese   0.462 
Yes 95 (7.5) 1165 (92.5)  
No 67 (6.5) 963 (93.5)  
32 
 
Chlamydia and Gonorrhea   0.002 
Yes 8 (15.7) 43 (84.3)  
No 213 (4.3) 4758 (95.7)  
Mode of delivery   0.025 
Vaginal 194 (4.7) 3930 (95.3)  
Cesarean (C-section) 27 (3.0) 871 (96.9)  
Previous preterm delivery    0.008 
Yes 30 (7.2) 383 (92.7)  
No 188 (4.1) 4370 (95.9)  
Previous abortion   0.047 
Yes  57 (5.5) 989 (94.5)  
No 142 (4.0) 3400 (95.9)  
 
 
Table 2. Prenatal outcomes among HPV-positive pregnant women143 
Outcomes  Total 
Sample size 
Prevalence 
of HPV (%)  
Crude 
OR 
95% CI Adjusted 
ORδ 
95% CI 
PROM 94 5.3 0.94 0.38–
2.34 
1.39 0.54–3.52 
Preeclampsia 66 12.1 2.37 1.11–
5.06 
2.83* 1.28–6.26 
Preterm birth 626 4.1 1.64 1.15–
2.32 
1.81 τ 1.15–2.83 
Low birth 
weight 
357 10.1 2.71 1.86–
3.94 
2.58 1.56–4.27 
δ Adjusted for age, race, smoking, previous preterm, gestational age, infection with 
Chlamydia and Gonorrhea, previous abortions, delivery type, gestational diabetes and 
chronic hypertension 
τ Preterm birth was not adjusted for gestational age 






This study investigated the association of HPV infection with adverse pregnancy 
outcomes. The overall prevalence of HPV among pregnant women in this study was 
4.4%, remarkably lower than in previous studies conducted in United States.145,146 One 
reason could be that previous studies that showed a higher prevalence of HPV among 
pregnant women were conducted before the inception of HPV vaccination. Additionally, 
there is no recommended screening for HPV among pregnant women.111 Another 
possible factor is the difference in HPV prevalence by geographic regions. For example, 
a study conducted in Austria showed HPV in 24.6% of pregnant women, whereas a 
study conducted in Spain showed a lower HPV infection rate, of 6.5%.147 Interestingly, in 
this study, the prevalence of HPV among whites was higher than among other 
ethnic/racial groups, contrary to the national rates (51.6% vs. 31.5%). A study conducted 
by Dinh et al. indicated that there is a higher prevalence of genital warts among whites 
than among blacks.148  Because most genital warts are the result of HPV, the presence 
of these in pregnant women would likely prompt healthcare professionals to test them for 
HPV. This might be the reason for the higher prevalence of HPV infection among whites 
in our study data. 
Our study results indicate that HPV infection is significantly associated with 
adverse pregnancy outcomes, including preeclampsia, preterm birth, and low birth 
weight, but not with premature rupture of membrane.  After controlling for demographic 
and clinical variables, we observed that HPV-positive women were 2.83 times more 
likely to develop preeclampsia, compared to HPV-negative women. The association 
remained significant after adjusting for confounding factors. Our study results were 
consistent with those of other studies that revealed HPV as a risk factor for 
preeclampsia.78,149 A study conducted by McDonnold et al. 78 was scrutinized for not 
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adjusting for co-infections, leading to concern that HPV may not be the main cause of 
the adverse outcome, but rather a contributing factor to other infections.150 In our study, 
we adjusted for co-infection with chlamydia and gonorrhea and still observed a 
significant association. However, our study results were contradictory to the results of a 
case-control study that found no difference in the detection of HR-HPV from placentas of 
women with preterm severe preeclampsia and controls.90 This could be possible if HPV 
infection present in uterine decidua can still affect uteroplacental function.78  
In addition, we found that HPV-positive women were 1.8 times more likely to 
deliver preterm than were HPV-negative women.  Our study results were consistent with 
the results of a previous study conducted by Zhuang Zuo that revealed a significant 
association between HPV and preterm birth.151 Though the pathophysiology of preterm 
birth is not well understood, systemic and/or local inflammation has been suggested as 
an independent etiological risk factor for preterm birth. According to a study conducted 
by Gomez et al., HPV can infect and replicate in invasive trophoblast cells, and that 
infection by HPV induces pathological sequelae that are associated with placental 
dysfunction and spontaneous preterm delivery. 90 Additionally, some in vitro studies have 
shown that HPV can infect a fetus through transplacental transmission. 152,153 
Trophoblasts are integral cell types of the placenta. It is believed that trophoblasts 
infected with HPV may alter the cellular characteristics and lead to compromised 
gestation.154 Racicot et al. proposed that preterm birth is a polymicrobial disease and 
demonstrated that a viral infection of the cervix during pregnancy reduces the ability of 
the lower reproductive tract to prevent bacterial infection of the pregnant uterus. In the 
study model, pregnancy and sex hormones are responsible for increasing the 
susceptibility of the cervix to the viral infection. As a consequence of viral infection, the 
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protection against ascending bacteria is decreased. This decrease in protection in turn 




Figure 5. Model of polymicrobial disease during pregnancy. Racicot et al., 2013.155  
Furthermore, our results indicate that HPV-infected women were 2.58 times more 
likely to deliver low-birth-weight infants than were women not infected with HPV.  
Although low birth weight has been associated with other sexually transmitted 
diseases,156,157 to our knowledge no other study has examined the association of HPV 
and low birth weight. HPV infection could occur by ascending from the maternal birth 
canal, 152 or it may cross the placenta and cause infection in the fetus. If HPV infection 
occurs at a crucial moment during the development of the fetus, it may affect the fetal 
cells and cause intrauterine growth retardation. In our study, we did not find any 
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significant association between HPV and PROM, even after controlling for other 
covariates. Our study results were contrary to those of a study conducted by Cho et al., 
who reported a significant association between HR-HPV and PROM. One reason for this 
disagreement with results could be that the other study was conducted in Korea, and the 
study sample had a high prevalence of HR-HPV compared to our study (14.1% vs. 
4.4%) The difference in prevalence could also be because of the difference in the HPV 
test detection methods. Additionally, the study does not mention what HR-HPV types 
were included. Furthermore, the study did not adjust for smoking, which has been 
reported to be a strong risk factor for both PROM and HPV.158-160  
Our study findings are important because currently there is no vaccination or 
recommended screening for HPV among pregnant women. Our study results indicate 
that the presence of HPV during pregnancy may cause adverse pregnancy outcomes, 
suggesting the need for understanding the impact of HPV vaccination on pregnant 
women.  A number of limitations should be considered when interpreting the results of 
this study. First, in this findings of ASCUS were assumed to be a result of HPV infection, 
though they could be a result of other factors such as bacterial infection. This may have 
caused misclassification of cases, resulting in overestimation. Second, although we had 
information on current smoking status, we did not know the smoking status prior to 
pregnancy; that missing information may have concealed the true exposure to tobacco.  
Previous researchers have found that the prevalence of HPV varies by 
gestational age. 27,161 Lee et al. detected HPV DNA in 14% of pregnant women in the 
first trimester, 18% in the second trimester, and 10% in the third trimester.27 This 
indicates that the HPV infection may be triggered by hormonal or other effects of 
pregnancy, such as immunosuppression.161 Although our study was unable to account 
for gestational age of infection, future studies might take into account the time point of 
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HPV infection. Despite these limitations, the study has a number of strengths. Because 
the exposure and outcome status were based on obstetric records/ laboratory tests, this 
information was more reliable than self-reported data. 
 
2.5 Conclusion  
The data from this study suggest that HPV infection is associated with adverse 
pregnancy outcomes, including preeclampsia, preterm birth, and low birth weight. From 
a clinical standpoint, this may highlight the health benefits of HPV vaccination for young 
girls and adolescent females prior to pregnancy as well as for young boys and men. 
Also, one priority should be to improve HPV vaccination rates through better education 
and awareness campaigns among the patient population. In addition, policymakers 
should consider mandating HPV testing of pregnant women. Concurrently, there should 
be a close follow-up of HPV-positive women and their fetuses. However, it appears that 
mandating HPV vaccination may be challenging, in light of the experience in Texas. 
Although Governor Rick Perry mandated HPV vaccination for young girls, Texas 
legislators passed H.B. 1098 to override the executive order. Future studies should 
involve larger, more diverse samples of women to enable us to understand the impact of 




Examining the Relationship between HPV and Adverse Pregnancy 
Outcomes at the Population Level 
 
3.1 Introduction 
HPV infection is the most common sexually transmitted disease in the United 
States.162 Some of the known risk factors for HPV infection include early first sexual 
intercourse, multiple sex partners, co-infection with other sexually transmitted diseases, 
and smoking or any form of immune suppression.119 In addition, pregnancy is a risk 
factor for new or recurrent HPV infections.89 During pregnancy, the immune system is 
suppressed, which decreases the ability to resist infections.163, 78 In addition, the level of 
HPV DNA replication is increased in pregnancy because of elevated levels of pregnancy 
hormones such as progesterone. Because of these factors, pregnant women may be 
more susceptible to HPV infection than nonpregnant women.  
There is a lack of population-based data on HPV infection prevalence among 
pregnant women in the United States and on the possible adverse health outcomes 
related to active HPV infections, especially adverse pregnancy outcomes. U.S. studies 
have shown HPV infection rates among adolescent girls and nonpregnant women 
ranging from 8.8% to 42.7% among women in the age group of 18-59 years.79,119-122 It is 
also important to note that previous research on pregnant women was mostly conducted 
before introduction of the HPV vaccine, which may already have a measurable impact 
on the current population. It is essential to estimate the current prevalence of HPV 




HPV causes genital warts, cervical cancer, head and neck cancer, anal cancer, 
juvenile-onset recurrent respiratory papillomatosis, and laryngeal papillomatosis.28  
However, little is known about the potential link between HPV infection and adverse 
pregnancy outcomes such as preterm birth, low birth weight, preeclampsia, and PROM. 
The etiology of such outcomes is still unclear, and the literature on their association with 
HPV infection is contradictory.78,89 It is important to research and learn more about the 
association between HPV infection and adverse pregnancy outcomes, since the little 
information available now is not conclusive. The inconsistencies in the results of the 
previous studies regarding adverse pregnancy outcomes and their association with HPV 
infection necessitate further research.78,89 
Previous studies were based on small sample sizes, which may have caused 
underestimation of the results. Use of the Pregnancy Risk Assessment Monitoring 
System (PRAMS) is the standardized data collection methodology. It includes a 
questionnaire completed by mothers that can provide population-based prevalence 
estimates of HPV infection. Additionally, along with information from birth certificates, the 
PRAMS database can allow us to elucidate the association of HPV with adverse 
pregnancy outcomes. The primary purpose of this study was to estimate the prevalence 
of HPV infection among pregnant women, with use of the most recent data available. 
The secondary purpose was to examine the association of HPV with adverse pregnancy 
outcomes, including preeclampsia, preterm birth, low birth weight, and PROM. 
 
3.2 Methods 
This study used data from the 2004–2011 multi-state PRAMS. The current study 
used PRAMS data from multiple states: Delaware, Florida, Missouri, Mississippi, New 




PRAMS is a state-specific population-based surveillance system that collects 
data from women who delivered live-born infants about their experiences before, during, 
and after pregnancy.164 This database uses a multistage, complex sampling strategy and 
is a mixed-mode surveillance system with standardized data collection methodology. 
Each month, a list of mothers who delivered a live infant in the past 2 to 4 months is 
randomly generated from a file of birth certificate records. Mothers are sent a 14-page 
self-administered questionnaire. Each mother’s response is linked to extracted items 
from the birth certificate file, such as infant’s birth weight, type of delivery, and mother’s 
marital status, race, age, education, and smoking status. The response rate of PRAMS 
is nearly 70%.  
The PRAMS database includes core questions for all states’ surveys and 
optional standard and state-developed questions. In the present study, only states that 
had questions on HPV infection were included.  
3.2.2 Study Definitions  
HPV Infection: The question used to assess HPV infection among pregnant women 
was “During your most recent pregnancy, did a doctor, nurse, or other health care 
worker tell you that you had any of the following diseases?” HPV was defined by a ‘yes’ 
in the Genital warts (HPV) category.  
Perinatal Outcomes: Preeclampsia is a disease characterized by high blood pressure 
during pregnancy and signs of damage to other organ systems and is a major cause of 
maternal and fetal mortality and morbidity.91 Preeclampsia generally begins after 20 
weeks of pregnancy in a woman whose blood pressure had been normal.  For this study, 
it was measured by response to the question “Did you have any of the following 
problems during your most recent pregnancy?” Preeclampsia was defined by a ‘yes’ 
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response in the preeclampsia category. Preterm birth was based on the gestational age 
variable available in the birth certificate file. It was defined as the birth of an infant before 
37 weeks of pregnancy. Low birth weight was defined as a weight less than 2500 grams 
at the time of birth. PROM was defined as the rupture of membrane before the onset of 
labor. Both low birth weight and PROM were obtained from birth certificate files.  
Covariates: Candidate covariates for the statistical models derived from PRAMS 
questionnaire included the following: mother’s age at delivery, mother’s race/ethnicity, 
mother’s education level, marital status, smoking, gestational age, body mass index 
(BMI) prior to pregnancy, gestational diabetes, high blood pressure before pregnancy 
and co-infection with gonorrhea and chlamydia, and previous preterm deliveries.  Race 
was divided into three categories: white, black, and other. BMI prior to pregnancy was 
classified as underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese 
(≥30). Mother’s smoking status was categorized as ‘yes’ or ‘no.’  
 
3.3 Data analysis  
We limited our study to singleton births since multiples are more likely to have an 
adverse outcome such as low birth weight or preterm birth.100,144 To account for the 
complex sampling design of the PRAMS, analyses were completed with SAS Survey 
procedures, software version 9.3. Data were weighted with sampling weights to produce 
population-based estimates. Bivariate analyses were performed to assess the 
relationship between each perinatal outcome and HPV infection. Logistic regression was 
performed to assess the relationship between each perinatal outcome (PROM, preterm 
birth, low birth weight, and preeclampsia) and HPV infection. Multivariable models for 
each of the primary independent variables were built to adjust for confounding variables 
based on the previous literature.  
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Multiple imputation technique was used to impute observations missing at 
random for HPV exposure (n = 200) since HPV information was not missing completely 
at random. This Monte Carlo process involves repeated imputation of each missing 
value and then averaging over imputations. Multiple imputation assumes that data is 
missing at random (MAR), and it creates several copies of the data set, each containing 
different imputed values. A separate analysis was carried out on each dataset that 
yielded multiple sets of parameter estimates and standard errors. For this study, we 
used five multiple imputed datasets to combine into a single set as a result. Multiple 
imputation was conducted in three phases: imputation, analysis, and pooling. The 
multiple imputation process was performed with SAS 9.3. Statistical significance was 
assessed at α = 0.05. Multiple imputation was performed on the database with the 
PROC MI procedure in SAS. To impute HPV status, variables such as smoking status, 
education level, age, bleeding of the mother, and preterm birth were used.   
 
3.4 Results 
Table 3 exhibits the demographic and obstetric characteristics of pregnant 
women infected with HPV.  HPV was present in 1.4% of the PRAMS survey participants 
(N = 26,085). The prevalence of HPV was significantly higher among women ≤19 years 
old (2.7%) than in all other age groups. Additionally, the prevalence was notably higher 
among these groups: smokers (3.5%) versus nonsmokers (1.2%), women who had high 
blood pressure before pregnancy (2.5%) versus those who did not (1.3%), and those 
who were not married (2.5%) versus those who were (0.8%).  Furthermore, the 
prevalence of HPV was significantly higher among women who were co-infected with 
chlamydia or gonorrhea (6.4%) than among women with no such co-infection (1.3%). No 
significant differences in age, pre-pregnancy BMI, previous preterm delivery, or 
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gestational diabetes were observed between women with HPV infection and those 
without.   
Additional analysis was conducted to examine the prevalence of other sexually 
transmitted infections by HPV status. As shown in Table 4, we found that there were 
significant differences in the prevalence of other sexually transmitted infections by HPV 
status. For instance, the prevalence of chlamydia was 9.2% among HPV-positive 
women, compared to 2.1% among HPV-negative women. Similarly, the prevalence of 
Group B streptococci was 21.7% among HPV-positive women, compared to only 10% 
among HPV-negative women.  
Table 5 shows the weighted prevalence, ORs, and 95% CIs for the perinatal 
outcomes among pregnant women. The overall weighted prevalence of low birth weight 
among women who delivered was 7.3%.  In the crude analysis, no association was 
found between HPV infection and low birth weight. After adjustment for demographic 
and obstetric characteristics, low birth weight was not significantly associated with HPV 
infection (adjusted OR: 1.00; 95% CI: 0.83–1.21). However, low birth weight was 
significantly associated with HPV in the nonimputed data (OR: 1.91; 95% CI: 1.13–3.24). 
As shown in Table 6, no significant association was found between HPV infection and 
PROM, pre-eclampsia, or preterm birth in the nonimputed data. In addition, the weighted 
prevalence among women who delivered preterm was 9.4%. The crude OR and 
adjusted OR were not significant for the association between HPV infection and preterm 
birth (OR: 0.98; 95% CI: 0.81–1.19). Furthermore, the weighted prevalence among 
women who had premature rupture of membrane was 2.9%. Although the odds of 
having PROM was higher among HPV-positive versus HPV-negative women, this was 
not statistically significant after adjustment for confounding variables (adjusted OR: 1.46, 
95% CI: 0.53–4.01).  The weighted prevalence of preeclampsia among pregnant women 
44 
 
was 6.2%.  Similar to PROM, the adjusted OR for preeclampsia was higher among those 
infected with HPV versus the uninfected; this was not statistically significant (OR: 1.31; 





















Table3. Demographic and obstetric characteristics of pregnant women who self-
reported HPV exposure status  
Characteristics Unweighted Sample 
Size 
Weighted Prevalence of 
HPV (%, SE)a 
P valueb 
Total 26085 1.44 (0.07)  
Age   <.001 
≤19 2772 2.7 (0.10)  
20–24 7107 2.3 (0.09)  
25–34 13194 0.9 (0.05)  
35+ 3011 0.8 (0.05)  
Race/Ethnicity   0.19 
Non-Hispanic white 16688 1.6 (0.07)  
Non-Hispanic black 3866 1.3 (0.08)  
Non-Hispanic American 
Indian/Alaskan Native 
160 2.2 (0.09)  
Hispanic 4230 0.9 (0.06)  
Non-Hispanic other 997 1.6 (0.07)  
Married   <.001 
Yes 16395 0.8 (0.05)  
No 9686 2.5 (0.10)  
Education, years   .13 
≤11 5560 1.7 (0.09)  
12  7589 1.9 (0.09)  
13–15 6243 1.5 (0.08)  
≥16 6235 0.7 (0.05)  
Smoking   <.001 
Yes 3122 3.5 (0.19)  
No 22768 1.2 (0.06)  
Pre-pregnancy BMI   .48 
Underweight 1523 1.9 (0.10)  
Normal 12433 1.3 (0.06)  
Overweight 5489 1.6 (0.07)  
Obese 4889 1.5 (0.07)  
Pre-high blood pressure   .019 
Yes 926 2.5 (0.58)  
No 8255 1.3 (0.08)  
Previous preterm 
delivery 
  .31 
Yes 488 2.4 (0.59)  
No 12245 1.4 (0.07)  
Co-infection (chlamydia 
and/or gonorrhea) 
  <.001 
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Yes 639 6.4 (0.15)  
No 25446 1.3 (0.07)  
Gestational diabetes   .57 
Yes 755 1.5 (0.33)  
No 8378 1.4 (0.07)  
a Based on imputed data 




Table 4. Type of infection by HPV status 
Type of Infection HPV+ (n = 380) HPV- (n = 25704) P valuea 
Chlamydia 33 (9.23%) 556 (2.12%) <.0001 
Herpes 33 (7.17%) 229 (1.07%) <.0001 
Syphilis 11 (2.95%) 13 (0.04%) <.0001 
Gonorrhea 15 (5.54%) 93 (0.31%) <.0001 
Group B 
streptococci 
64 (21.7%) 2451 (10.04%) <.0001 
Trichomonas 10 (2.34%) 190 (0.69%) .011 
Yeast  87 (26.21%) 2006 (7.76%) <.0001 










Table 5. Weighted prevalence (%), ORs, and 95% CIs of perinatal outcomes among 
pregnant women by HPV exposure, PRAMS, 2004–2011 (based on imputed data) 
Outcomes  Weighted 
Prevalence (SE)  
Crude ORd 95% CId AORa,d 95% CI 
Low birth weight b 7.27 (0.03) 1.09 0.95–1.24 1.08 0.74–1.57 
Preeclampsia c 6.20 (0.21) 0.90 0.67–1.21 1.31 0.95–1.80 
PROM b 2.91 (0.15) 1.12 0.79–1.59 1.08 0.74–1.57 
Preterm birth 9.36 (0.20) 0.96 0.80–1.16 1.01 0.84–1.20 
a Adjusted for age, race, co-infection (with chlamydia or gonorrhea), BMI, smoking, gestational 
age (preterm birth not adjusted for gestational age), married, gestational diabetes. 
b In addition to above confounders, preterm birth, PROM, and low birth weight were adjusted for 
previous preterm birth and preeclampsia. 
c In addition to above confounders, preeclampsia was also adjusted for hypertension before 
pregnancy. 




Table 6. ORs and 95% CIs of perinatal outcomes among pregnant women by HPV 
exposure, PRAMS, 2004–2011 (based on nonimputed data) 
Outcomes  Crude OR 95% CI AORa 95% CI 
Low birth weight b 1.18 0.90–1.54 1.91 1.13–3.24 
Preeclampsia c 0.82 0.45–1.48 0.58 0.19–1.71 
PROM b 1.25 0.62–2.55 1.46 0.53–4.01 
Preterm birth 1.08 0.75–1.56 0.54 0.31–0.95 
a Adjusted for age, race, co-infection (with chlamydia or gonorrhea), BMI, smoking, gestational 
age (preterm birth not adjusted for gestational age), married, gestational diabetes. 
b In addition to above confounders, preterm birth, PROM, and low birth weight were adjusted for 
previous preterm birth and preeclampsia. 







To our knowledge, this is the first study to utilize a multi-state PRAMS database 
to study the prevalence of HPV and its impact on pregnancy outcomes. The prevalence 
of HPV exposure in our study sample was only 1.4%, which varies drastically from a 
meta-analysis that revealed a much higher prevalence of 16.8% among pregnant 
women.124 One of the reasons could be that our study was based on self-reported HPV 
exposure status. Because HPV testing is not recommended for pregnant women,165 
most women may be unaware of their status.  This may have underestimated the true 
prevalence of HPV among these women. Additionally, lower prevalence could be due to 
the impact of HPV vaccination.   
In the present study, we found that HPV-positive women had higher prevalence of other 
sexually transmitted infections. Because this is a cross-sectional study, we cannot infer 
that HPV infection predisposes women to other sexually transmitted infections. However, 
Racicot et al. reported that viral infection of the cervix during pregnancy decreases the 
ability of the lower reproductive tract to prevent bacterial infections.155 In the future, 
prospective studies may explore the relation of HPV infection with other sexually 
transmitted diseases. Also, it would be interesting to know if specific types of HPV may 
be responsible for putting pregnant women at risk for other sexually transmitted 
infections.  
On the basis of nonimputed data, women with HPV infection were 1.91 times 
more likely to have a low-birth-weight infant (Table 4). Although low birth weight has 
been associated with other sexually transmitted diseases,166,167 no studies have 
examined the association of HPV and low birth weight. It is believed that some infections 
can affect fetal cells and restrict intrauterine growth if they occur at a critical moment in 
fetal development.137 If infection occurs during the first trimester, then the consequences 
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of the infection on pregnancy are more serious.137  Future studies should consider the 
time of infection to better understand the role of HPV in adverse outcomes.  
In this study, we did not find any significant association between HPV infection 
and pregnancy outcomes, which is contrary to the findings of previous studies. One 
possible explanation is that in our study the prevalence of HPV infection was low among 
pregnant women (1.4%), in comparison with its prevalence in previous studies that 
examined the association of HPV with pregnancy outcomes such as low birth weight, 
PROM, preeclampsia, and preterm birth.78,89,90,168 Additionally, one study that showed a 
significant association between HPV infection and preterm birth did not control for 
smoking, which can confound the association.90  Although there is no clear process by 
which HPV infection can result in these adverse pregnancy outcomes, some 
mechanisms have been proposed.  It is thought that infection with HPV can result in 
chronic cervicovaginal inflammation that may put the pregnancy at higher risk of an 
adverse outcome.169 Additionally, HPV releases cytokines and metalloprotease 
(specifically MMP-2), which can degrade collagen and also weaken the fetal membrane, 
resulting in membrane damage. 98,170,171 
This study has a few limitations, such as those that apply to PRAMS as a whole. 
Because the study was cross-sectional, we cannot infer causality of the relationship 
between self-reported HPV and perinatal outcomes.  Also, the infection information 
available through PRAMS was limited to seven states that included questions related to 
HPV infection in their state questionnaire.  Additionally, selection bias could have 
occurred if women who were educated or had an infant of normal birth weight were more 
likely to respond to the PRAMS survey. Furthermore, the question used to assess HPV 
infection among pregnant women is non-specific that might be difficult to 
comprehend. In the PRAMS survey questionnaire, HPV infection was measured on the 
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basis of a single multicategorical question: “What disease or infection were you told you 
had?”  One of the response options for this question is “Genital Warts (HPV),” which 
may not be comprehensive for all women. Except for the above question, there is no 
other question related to high-risk HPV or low-risk HPV. Genital warts are the result of 
low-risk HPV such as types 6 or 11 and not the cancer-causing HPV types such as HPV 
16 or 18. So it might be that some women with high-risk HPV did not report their status. 
 
Despite these limitations, this study has a number of strengths. First, the data 
come from a large population-based survey of maternal attitudes and experiences 
before, during, and shortly after pregnancy. Second, the PRAMS survey has a high 
response rate of 70%, reducing the potential for biased estimates. Third, all of the 
outcomes (except for preeclampsia) for this study were derived from birth certificate files, 
which are based on medical information (not self-reported).  
To the best of our knowledge, this is the first study to utilize PRAMS data to 
analyze the prevalence of HPV infection and its relationship with pregnancy outcomes. 
On the basis of this multi-state population-based survey, the prevalence of HPV infection 
was found to be 1.4%. The low prevalence of HPV infection among PRAMS participants 
may be due to the lack of consistent HPV testing among pregnant women. The low 
prevalence of HPV infection may have skewed the results significantly. Although we did 
not find significant associations between HPV and perinatal outcomes, further research 
with use of a large population database is needed. So far, only 7 of 40 states in the 
PRAMS database collect information on HPV. We recommend that other states consider 
including questions on HPV, which would allow researchers to study HPV among 
pregnant women in large population-based investigations and would provide data that 
are more representative of the population. In the future, researchers should also 
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consider conducting longitudinal studies of HPV among pregnant women that would 






















Projecting the potential impact of 9-valent vaccine among Northern Plains 
American Indian women and white women 
 
4.1 Introduction  
Cervical cancer is the second most common cancer in women worldwide. In 
2015, approximately 12,900 women were diagnosed with invasive cervical cancer in the 
United States, and 4,100 died from it.172  With widespread use of an effective screening 
test (i.e., Pap smear), there was a large decline in incidence rates over the last 30 years; 
however, the decline gradually tapered off in the past decade, especially among younger 
women.173 Also, after decades of rapid declines, mortality rates have leveled off, and no 
significant decline was observed for both women younger than 50 years and those 50 
years and older.173  
In addition to the lack of progress in decreasing the burden of cervical cancer in 
the overall population, another concern is a persisting disparity among certain population 
groups in the United States.  One group at particularly high risk of developing and dying 
from cervical cancer is American Indians/Alaska Natives in the Northern and Southern 
Plains regions.  For instance, the incidence rate among Northern Plains American 
Indians/Alaska Natives was 12.5 per 100,000, which put them at 1.7 times higher risk of 
developing cervical cancer than non-Hispanic white women in the same region.81  Other 
publications have documented an incidence rate of cervical cancer among American 
Indian/Alaska Native women in South Dakota as high as 16.2 per 100,000, compared to 
6.1 per 100,000 among non-Hispanic white women in the state, and an age-adjusted 
cervical cancer mortality in the Dakotas of 4.5 per 100,000.174 
HPV is a primary cause of cervical cancer and is responsible for anal, 
oropharyngeal, and vulvar cancer.162 More than 40 types of HPV are considered to be 
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high-risk or can cause cancer. Together, HPV 16 and 18 account for 70% of cervical 
cancer in the United States.13  Five additional high-risk types, HPV 31, 33, 45, 52, and 
58, are believed to account for nearly 20% or more of cervical cancer cases.118 In 2006, 
Gardasil was introduced in the United States as the first prophylactic HPV vaccine. 
Gardasil, a quadrivalent vaccine, protects against HPV 16, 18, 6, and 11 and is licensed 
for administration to individuals between ages 13 and 26. Cervarix, a bivalent vaccine 
subsequently licensed in 2009, protects against HPV 16 and 18 only. Both vaccines are 
90% to 100% effective against the respective HPV types.116,117,175  
In December 2014, Gardasil 9, a 9-valent vaccine including HPV types 16, 18, 6, 
11, 31, 33, 45, 52, and 58, was launched. The 9 types included in the vaccine are 
considered responsible for 90% of cervical cancers worldwide.118,176  A recent study by 
Velde predicted that changing from quadrivalent to a 9-valent vaccine will reduce the 
cumulative number of episodes of anogenital warts by an additional 6.6% over 70 years. 
In addition, the study showed that switching to 9-valent vaccine could further reduce 
precancerous lesions and cervical cancer.177  
Previous research indicated variation in the HPV type distribution among 
population groups within the United States.121 Because of the differences in HPV 
infection, varying degrees of impact are expected from HPV vaccination. Mathematical 
modeling, which incorporates results from epidemiological and clinical studies, has been 
used in public health to project potential benefits of population-level interventions.177-179 
Previously, modelling has been employed to investigate HPV vaccine effectiveness and 
cost effectiveness.178-180 However, none of the published studies have examined the 
potential impact of 9-valent vaccine in high-risk population such as Northern Plains 
American Indians. In addition, of particular interest is the effect that varying vaccination 
rates have in decreasing cervical cancer incidence and mortality. The HPV vaccination 
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completion rate remains low, around 39.7% as of 2014, among female adolescents in 
the United States.181  Given the considerable effort and time it will take to increase the 
vaccine completion rate; it is of interest to estimate with a mathematical model the 
potential benefit of increasing vaccine coverage.   
The purpose of the present study was to estimate the potential impact of 9-valent 
vaccine on cervical cancer cases in the American Indian population. Two specific 
questions were explored: (1) Among American Indian compared with white women, how 
many cases of invasive cervical cancer and cervical dysplasia (CIN2/CIN3) would be 
prevented because of the 5 additional types (HPV 31, 33, 45, 52, and 58) incorporated in 
the 9-valent vaccine? (2) If the 4-valent vaccine coverage rate of three doses among 
Northern Plains American Indian women increased from about 23% currently to 80%, 
how many cases of invasive cervical cancer and cervical dysplasia could be prevented 
in that population? To our knowledge, this is the first study to use mathematical 
modeling to assess the impact of 9-valent vaccine in this high-risk population of Northern 
Plains American Indian women. 
 
4.2 Materials and Methods 
We developed a deterministic compartmental model to evaluate the effects of 9-
valent versus 4-valent vaccine on cervical cancer cases. We modeled 4-valent vaccine 
(not bivalent) because 4-valent vaccine was the sole vaccine from 2006 to late 2009 in 
US.113 Also, it contains HPV types 16 and 18 that are covered by bivalent HPV vaccine. 
The model depicted an open population that begins in 2005, a year before the start of 
HPV vaccination, and ends after 70 years from the start. Because HPV 6 and 11 are 
low-risk viruses that cause genital warts and do not lead to cervical cancer, these were 
not included in any of our models. The population of susceptible women in the Northern 
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Plains (Iowa, Nebraska, Minnesota, South Dakota, and North Dakota) was based on the 
2010 U.S. census. Because the CDC recommends that females aged 12–26 be 
vaccinated, the model population was categorized into three groups: <12 years old, 12–
26 years and 27 years and above.  There were 37,836 American Indians and 976,958 
whites in the 12–26 age group and 99,205 American Indians and 3,458,063 whites in the 
age group 27 and above.182 
In our study, susceptible women were defined as nonvaccinated women at risk of 
getting infected with HPV. HPV-infected women were defined as women who contracted 
HPV infection from their male sex partners. Although in many individuals the HPV 
infection clears naturally, HPV can also avoid attack by the immune system183 and in 
some cases can regress to any of the initial stages. In the absence of regression, 
persistent HPV infection progresses from precancerous lesions (CIN1, CIN2, and CIN3) 
to cervical cancer.184,185 We did not model males in our study, in order to reduce the 
complexity of the model. However, the contact and transmission rate parameter was 
based on heterosexual contact rates.  
4.2.1 Mathematical Model 
On the basis of the biology of HPV and cervical cancer, we developed a system 
of differential equations that captures the dynamics of HPV and cervical cancer (see 
Appendix for model equations). Figure 1 displays the natural history model flow diagram 
as well as the measures taken to mitigate the progression. This epidemiologic model 
begins with 12-year-old females entering the susceptible category. Once HPV 
transmission occurs, susceptible females enter the category of infected females. In 
accordance with mathematical epidemiology convention, the hazard rate at which these 
women contract infection is termed the force of infection. Individuals leave this category 
when the infectious period for HPV ends, and they start entering the cervical 
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intraepithelial neoplasia (CIN) stages. CIN, also known as cervical dysplasia, is the 
premalignant transformation and abnormal growth of squamous cells on the surface of 
the cervix. In a fraction of females, the infection clears naturally, and they will be immune 
for 5 years from the infection. After 5 years, these women will return to the susceptible 
stage, while the rest will either suffer mortality move to the CIN2 stage. Similar to CIN1, 
in some women at CIN2 and CIN3, the infection will clear, and in others it will regress 
back to CIN1 and CIN2, respectively. In addition, some females in these three stages 
undergoing treatment will leave their categories, become immune for 5 years, and then 
be susceptible after the immunity wanes. Some at the CIN3 stage will acquire cervical 
cancer. To reduce the complexity of the model, we assumed that women treated for 
cervical cancer will become immune and not susceptible to HPV infection.  
A fraction of susceptible females in the age group of 12–26 years will be 
vaccinated and thus moved to the vaccination category, and nearly 90% will later be 
immune. However, females in any age group can also acquire other high-risk HPVs, and 
a proportion of them become infected with HPV 31/33/45/52/58, which all follow the 
same natural history as HPV 16/18. 
Specifically, within each population, the model tracks the changing number of 
susceptible, HPV infected, CIN1, CIN2, CIN3, cervical cancer, treatment, vaccinated, 
and immune females. In light of the lower mixing rates between populations, each 
population was stimulated separately. Additionally, within each population model, a 
different model used for HPV types 16/18 and 5-additional types.  Population-level 
vaccine-efficacy predictions are presented for the primary outcome: cervical cancer and 
CIN over time. Outcomes were modeled over 70 years post vaccination because this 
horizon allows enough time to reach a stable post-vaccination equilibrium and shows 
maximum differences in efficacy between the different vaccines. 177 However, the results 
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were reported after 15 and 30 years of vaccination in order to highlight the medium-term 
impact of the vaccine. 
 
 
4.2.3 Model Assumptions 
We assumed homogeneous mixing between the age groups within each 
population and used parameter estimates based on the literature. Rates of progression 
and regression to HPV and cancer were assumed to be independent of age.35,186,187 We 
followed 186 in assuming lifelong immunity in those vaccinated against the infection and 
no therapeutic effect of current vaccines (i.e., it cannot cure the virus or related 
infection). Additionally, we took into account neither cross-protectivity (in which 




immunization with a certain vaccine type provides clinically significant protection against 
infection or disease, or both, due to another HPV type188) nor cross-neutralization (in 
which antibodies elicited by vaccination with an HPV type neutralize virions of another 
HPV type at a variable degree in vitro). One reason for not taking cross-protectivity into 
account was that a comparison of two clinical trials—Females United to Unilaterally 
Reduce Endo/Ectocervical Disease (FUTURE) I and II of the quadrivalent vaccine and 
Papilloma Trial Against Cancer in Young Adults (PATRICIA) of the bivalent vaccine—
suggested that estimates of cross-protectivity of vaccines against infections and lesions 
associated with HPV 31, 33, and 45 were usually higher for the bivalent vaccine than the 
quadrivalent vaccine. 189  
4.2.4 Model Parameters 
Table 1 summarizes the parameter estimates and references. A comprehensive 
search of the literature was performed to find parameter estimates. Prevalence rates for 
both American Indian women (HPV 16/18: 11.3%; HPV 16/18/31/33/45/52:14.8%) and 
white women (HPV 16/18: 5.9%; HPV 16/18/31/33/45/52: 8.3%) were based on 
unpublished data collected among Northern Plains American Indians and whites. 190 
Progression rate, eradication with treatment rate, clearance rate, sensitivity, and vaccine 
efficacy for HPV were derived from several published studies. 186,191-193 Because of the 
lack of race-specific rates, all the above rates were assumed to be the same for both the 
American Indian and the white population (except for the calibrated values). Screening 
rates for the year 2010 were obtained from CDC. 194 A sensitivity analysis was 
performed for various parameters in the model because different values were noted in 
the literature. 186,195,196  Sensitivity and elasticity analysis was conducted on multiple 
parameters to determine the most influential inputs (Table 10). The baseline parameters 
were increased by 10% to determine the percent change in the baseline values for 
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susceptible, HPV infected, CIN3, and cumulative cervical cancer cases. To determine 
the sensitivity, the outcomes were measured at year 2035 (after 30 years from the start 
of the model). 
 
Table 7. Parameter estimates for HPV disease categories 
Parameters in the model American 
Indians 
Whites References 
Number of susceptible     
  12–26 38,736 976,958 177,182 
   27 and above 67313 3,438,989  
Ratio of males to females  0.96 0.98 182 
Infected with oncogenic HPV 
types 
13,945  205,161   
Transmission probability 0.7 (0.4)* 0.7 (0.4)* 195 
Progression hazards per year    
  HPV Infected to CIN1 0.09 (0.16)* 0.09 186 
  CIN1 to CIN2  0.13 (0.24)* 0.13 186 
  CIN2 to CIN3 0.14  0.14 186 
  CIN3 to cervical cancer 0.42 0.42  186 
Fraction of eradications of 
infection with treatment 
   
  CIN1 0.96  0.96 186 
  CIN2 0.92 0.92 186 
  CIN3  0.92 0.92 186 
  Localized cervical cancer 0.92 0.92 186 
Clearance hazards rate    
  CIN1 to Normal 0.32 (0.46)* 0.32 (0.48)* 186 
  CIN2 to Normal 0.21 0.21 186 
  CIN3 to Normal 0.11 0.11 186 
Regression    
  CIN2 to CIN1  0.133  0.133 186 
  CIN3 to CIN2  0.03  0.03 186 
  CIN3 to CIN1  0.03 0.03  186 
Fraction of women screened each 
year 
0.73 0.72 194 
Sensitivity 
  CIN1 0.28 0.28 197 
  CIN2 and CIN3 0.59 0.59 197 
Vaccine efficacy 0.90 0.90 198 
Current vaccination hazard  0.03 0.05 (IHS, unpublished 
data, 2015) 









Prevalence of any oncogenic 
types  
36% 21%  
Prevalence of HPV 16/18 among 
ages 12–26 years  
11.5%  
 
 8.9% 190 
Prevalence of HPV 16/18 among 
ages 27 and above  
5.3% 8.2% 190 
Prevalence of HPV 16, 18, 31, 
33, 45, 52, or 58 
14.8% 8.3% 190 
Prevalence of HPV 31, 33, 45, 
52, or 58 among ages 12–26 
years  
 23.5%  9.8% 190 
Prevalence of HPV 31, 33, 45, 
52, or 58 among 27 and above 
6.3% 0.94% 190 
Fraction of women vaccinated 
(vaccination coverage rate) 





4.3.1 Sensitivity and Elasticity Analysis 
The baseline parameters were increased by 10% to determine the percent change in the 
baseline values for susceptible, HPV infected, CIN3, and cumulative cervical cancer 
cases. For instance, a 10% increase in transmission rate resulted in a 6.49% increase in 
cumulative cervical cancer cases.  Similar results for sensitivity and elasticity analysis 
were obtained for American Indian women (data not shown). Overall, the 10% change in 
transmission rate, screening rate, CIN 1 to CIN2 hazard rate, and CIN2 to CIN3 caused 
the parameter values to deflect more than 5% from the original value.  
The baseline parameters were increased by 10% to determine the percent change in the 
baseline values for susceptible, HPV infected, CIN3, and cumulative cervical cancer 
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cases. For instance, a 10% increase in transmission rate resulted in a 6.49% increase in 
cumulative cervical cancer cases.  Similar results for sensitivity and elasticity analysis 
were obtained for American Indian women (data not shown). Overall, the 10% change in 
transmission rate, screening rate, CIN 1 to CIN2 hazard rate, and CIN2 to CIN3 caused 
the parameter values to deflect more than 5% from the original value.  
Table 9. Sensitivity and elasticity analysis on parameters for white women with HPV 16/18 
 Percent change (Elasticity)* in:  
Parameter Susceptible 
White Women 
HPV infected CIN3 Cumulative 
Cervical Cancer 
Transmission rate -6.57 (0.6) 15.6 (1.5) 12.49 (1.2) 6.49 (0.6) 
Screening rate 0.14 (1.4) -2.7 (0.2) -12.5 (1.2) -9.87 (0.9) 
CIN1 to CIN2 hazard 
rate 
-0.26 (0.02) -1.64 (0.1) 7.95 (0.7) 8.41 (0.8) 
CIN2 to CIN3 hazard 
rate 
-0.26 (0.02) -1.63 (0.1) 7.87 (0.7) 8.34 (0.8) 
CIN3 to cervical 
cancer hazard rate 
-0.25 (0.02) 1.68 (0.1) -4.60 (0.4) 5.88 (0.5) 
Vaccination rate -0.61 (0.06) -3.25 (0.3) -0.68 (0.06) -0.10 (0.01) 
Rate of regression, 
CIN2 to CIN1 
-0.26 (0.02) -1.66 (0.01) -1.45 (0.1) -1.18 (0.1) 
Rate of regression, 
CIN3 to CIN2 
-0.26 (0.02) -1.65 (0.1) -0.26 (0.02) -0.19 (0.01) 
Fraction of CIN1 
cured 
0.12 (0.01) -2.40 (0.2) -3.56 (0.3) -2.51 (0.2) 
Fraction of CIN2 
cured 
0.09 (0.009) -1.91 (0.1) -5.24 (0.5) -4.11 (0.4) 
Fraction of CIN3 
cured 
-0.25 (0.02) -1.72 (0.1) -4.35 (0.4) -3.56 (0.3) 
*After 30 years of vaccination 
4.3.2 Model Fit and Validation 
 The predictive validity of the model was evaluated by comparing model results with 
epidemiologic data from populations in the United States. Table 11 shows the 
comparison of our model predictions with the reference model. Predictions of the model 
62 
 
were similar to the values reported in the literature. The prediction for HPV prevalence of 
five additional types among white women 27 years old and above is different from the 
epidemiological data because the prevalence obtained from the real data seems too low 
to be true. Based on the other population studies in the literature it seems plausible to 
have prevalence of 0.06 instead of 0.0094. 
Table 10 Model validation 





Fraction of American Indian women 12 to 
26 who have been vaccinated  




Fraction of White women 12 to 26 who 
have been vaccinated 
0.39 0.40 178 
HPV 16/18 prevalence among American 
Indian women 12–26 years old 
0.1144 0.115 190 
HPV 16/18 prevalence among American 
Indian women 27 years old and above 
0.07 0.053 190 
HPV prevalence of five additional types 
among American Indian women 12–26 
years old  
0.209 0.235 190 
HPV prevalence of five additional types 
among American Indian women 27 years 
old and above  
0.078 0.063 190 
HPV 16/18 prevalence among white 
women 12–26 years old  
0.09 0.089 190 
HPV prevalence of five additional types 
among white women 12–26 years old 
0.095 0.098 190 
HPV 16/18 prevalence among white 
women 27 years old and above 
0.094 0.082 190 
HPV prevalence of five additional types 
among white women 27 years old and 
above 
0.06 0.0094 190 
 
4.3.3 Model Scenarios 
In this study we examined two different scenarios. The first scenario examined the 
number of CIN3 cases reduced by 9-valent versus 4-valent vaccine among American 
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Indian and White women in the Northern Plains. Table 11 shows the estimated number 
of CIN2/3 cases reduced per 100,000 by vaccine type since the reference year (2014, 
when the 9-valent vaccine was introduced), assuming 20% of cervical cancer cases are 
attributable to the 5 additional types of HPV included in the 9-valent vaccine. The model 
projects that after 30 years of vaccination, 371.4 per 100,000 CIN2 prevalent cases will 
be reduced at that time due to 4-valent vaccine among American Indian women, 
compared to 536 per 100,000 CIN 2 prevalent cases reduced at that time due to the 9-
valent vaccine. Similarly, 132 per 100,000 cases among white women will be reduced by 
4-valent vaccine compared to 284.1 per 100,000 cases that will be reduced by the 9-
valent vaccine. Overall, there is a higher reduction in absolute terms in prevalent cases 
of CIN2 and CIN3 due to 4-valent and 9-valent vaccine among American Indian women 
compared to White women. Table 11 shows similar results for CIN3. Because the 
prevalent cases of CIN3 are much smaller than CIN2, this highlights that the magnitude 
of the impact of HPV vaccines to reduce CIN3 cases will be smaller.   
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Table 11. CIN2/3 cases reduced per 100,000 by 9-valent vs 4-valent vaccine among 
American Indians and whites 
                              4-Valent                   9-Valent 
 American Indians Whites American Indians Whites 
Year¥  15 30 15 30 15 30 15 30 
CIN2 249.67 371.4 74.4 132.0 323.82 536.3 166.5 284.1 
CIN3 71.6 112.5 13.5 27.6 88.9 153.1 35.1  63.9 
            ¥ Years since the reference year of vaccination 
As shown in Table 12, the model further projects that after 30 years from the reference 
year, 16.34 cumulative cervical cancer cases per 100,000 life years lived will be avoided 
by the 4-valent vaccine among American Indian women, while 18.41 cumulative cervical 
cancer cases per 100,000 life years lived will be avoided by the 9-valent vaccine among 
American Indian women. Similarly, the model predicts that 3.64 per 100,000 life years 
lived cumulative cervical cancer cases per 100,000 life years lived will be avoided by 4-
valent vaccine among white women while 5.53 cumulative cervical cancer cases per 










Table 12. Cumulative Cervical Cancer Cases avoided per 100,000 life years lived among 
American Indian women and White women 
 4-valent 9-valent 
 AI White AI White 
Year since the reference 
year of vaccination 
15 30 15 30 15 30 15 30 
Cumulative cervical 
cancer cases avoided per 
100,000 life years lived 
8.51 16.34 1.74 3.64 9.05 18.41 2.25 5.53 
 
Figures 7 and 8 represent the CIN3 cases reduced per 100,000 by vaccine type 
among American Indian women and white women. In absolute terms, the switch to 9-
valent vaccine from 4-valent vaccine further reduced the occurrence of CIN3, from a 
reduction of 112.5 per 100,000 women to a reduction of 153.1 per 100,000 women. This 
is an absolute difference of 40.6 per 100,000 women among American Indian. Among 
whites, the switch to 9-valent from 4-valent vaccine further reduced the occurrence of 
CIN3, from a reduction of 27.6 per 100,000 people to a reduction of 63.9 per 100,000 
women. This is an absolute difference of 36.3 per 100,000 women. From the above 
results, it is clear that American Indian women benefit more from the 9-valent vaccine 
compared to the 4-valent vaccine.  
 Figures 9 and 10 represent the cumulative cervical cancer cases averted over time, by 
vaccine status, among American Indian and white women. Caution should be taken in 
interpreting the results; the scales of the graphs are different because of the large 
difference in population size of American Indians and whites and thus are not 
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comparable. However, it does provide a picture of cumulative cervical cancer cases that 
would result per vaccination status.  
The second scenario noted the number of cervical cancer cases averted by the 4-
valent vaccine when the vaccination coverage is increased to 80%. The model predicts 
that after 30 years, with an increase in the current vaccination coverage from 23% to 
















































































Fig 9 Cumulative Cervical Cancer Cases averted among American Indians, by 































The main aim of this study was to investigate the potential impact of the 9-valent 
vaccine in a high-risk population, using Northern Plain American Indians as an example.  
We used a mathematical model and considered two different scenarios. The first 
scenario examined the cervical cancer cases averted by 4-valent and 9-valent vaccine 
among American Indian and white women in the Northern Plains. The second scenario 
examined the cervical cancer cases reduced among American Indian women if the 
vaccination coverage was increased from 23% to 80%. 
Our study result indicates that incremental gains from introducing 9-valent 
vaccine are higher among American Indian versus white women. The larger gains from 
9-valent vaccination compared to 4-valent vaccination extends to both CIN3 and cervical 
































Fig 11 Cumulative Cervical Cancer Cases Averted among American Indians 
(AI), by increase in vaccination coverage of 4-valent vaccine
AI: Baseline (23% vacc coverage) AI: 80% vacc coverage
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unable to account for certain risk factors, such as the smoking rate.199 Previous studies 
have indicated that persistent HPV infection is strongly associated with higher risk of 
cervical cancer.200 Persistent HPV infection results in inactivation of p53 and pRb tumor 
suppressor genes by the E6 and E7 proteins on the HPV genome. This, in turn, leads 
gradually to severe intraepithelial neoplasia and ultimately to cervical cancer.191  
Because smoking is a major risk factor for HPV persistence, it may be causing the 5 
additional types to persist longer among American Indian women compared to white 
women, resulting in a higher number of cervical cancer cases due to these types. 
Additionally, another factor that needs to be taken into consideration is that there are still 
certain types of HPV that are not included in the 9-valent vaccine (such as HPV 59, 39, 
and 73) that are more prevalent in the American Indian population, 201 which raises an 
important concern about whether the implementation of universal vaccine is the best 
method in managing HPV infection and cervical cancer in specific populations such as 
American Indians. Geographic variation in the HPV distribution can play an important 
role in the effectiveness of the vaccination programs and policy development. On the 
other hand, if future studies after taking into account all the above factors find significant 
reduction in cervical cancer cases among American Indian women, then revaccinating 
the American Indian women with the 9-valent vaccine should be taken into 
consideration. Revaccinating might be more cost-effective, considering the small 
population size.  
Another interesting finding of our study was that with the increase in the current 
vaccination coverage of 4-valent vaccine among American Indian women to 80% (a 
Healthy People 2020 goal), we would be able to reduce 25% of the cumulative cervical 
cancer cases after 30 years of vaccination. This is not a dramatic reduction in cumulative 
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cervical cancer cases, indicating that vaccinating against HPV 16 and 18 alone may not 
be sufficient, thus highlighting the benefit of 9-valent vaccine.  
4.4.1 Strengths and Limitations  
One of the major challenges we faced in conducting this study was lack of data 
on certain parameters (e.g., transmission rate, progression rate, and regression rate), 
specifically for the American Indian population. However, we did use calibrated values 
for certain parameters, as predicted by the model. Another impediment in modelling 
infectious disease is that it is difficult to include all relevant factors.  For instance, we 
were unable to take smoking into account. Smoking is a major risk factor for HPV 
persistence and may be responsible for the higher rate of cervical cancer among 
American Indian women. Tobacco smoking is believed to facilitate the acquisition or 
persistence of an HPV infection through a reduced number of Langerhans cells and CD4 
lymphocytes,62,63 which are markers of local immune response in the cervix.64,205 
Although we were unable to account for this in our current study, future studies should 
include smoking in their model to make the predictions closer to the reality. Second, we 
assumed no cross-protection in our study, which may have affected the predicted 
results. However, this may not be true, since recent studies on HPV vaccine have 
demonstrated cross-protection against related HPV strains.189,202 Third, we did not 
account for HIV in our model, which is a potential modifier of the HPV natural history. We 
believe that since these factors were not taken into account, the results might be 
underestimated. Fourth, the model was not stratified by HPV types and ethnicity but 
instead done separately. This imposed several limitations including the omission of 
mixing between ethnic groups, inability to quantify death over time, unable to take into 
account multiple infections in an individual. Additionally, we were unable to understand 
the effects of death due to one HPV type on the prevalence of the other HPV type. In 
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addition, imprecise biological and behavioral measurements and the extreme sensitivity 
of the systems to small changes in the parameter values are frequently challenging for 
accurate quantitative predictions. Vaccination against HPV not only reduces the 
incidence of the disease in those immunized but also indirectly protects nonvaccinated 
susceptible persons against infection (called herd immunity). However, due to the static 
nature of this model, we could not take herd immunity into account.  Our model is based 
on assumption of life-long immunity from the vaccine, which may not be the case in 
reality. If the immunity against the infection is lost, HPV-infected women may move back 
into the susceptible class, and the epidemiology of the HPV infection would be very 
different; high observed prevalence and sero-prevalence would be possible, with much 
lower basic reproductive number and transmission probability. This may further result in 
reduced vaccine efficacy and coverage required for elimination with a vaccine that did 
generate immune protection.203  
We believe that our modeling approach has several strengths. First, this is the 
first study to project the impact of HPV vaccine on American Indian women. Second, for 
the validation, model results were compared to the data specific to American Indian 
women and white women in the Northern Plains. Third, the vaccination coverage rate 
used in this study was obtained from Indian Health Services and the Department of 
Health, South Dakota, which makes the results more reliable. Finally, the model is 
available to facilitate replication of findings and independent review of the model. 
 
4.5 Conclusion 
In summary, our model shows that 9-valent vaccine will substantially reduce the 
cumulative cervical cancer cases among both American Indian and white women, with 
larger gains among American Indian women. Currently, there is need for more specific 
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data for the American Indian population to have more robust results. Future studies 
should be conducted to collect more data on the Northern Plains American Indian 
population, and a stochastic model should be developed that would allow random 






5.1 Current Research  
The burden and cost of HPV-associated diseases and cancer remain a major 
public health problem.162 The total medical cost of HPV infection for both men and 
women aged 15-24 is estimated to be $2.9 billion, making HPV the second most 
expensive STI after HIV.204 To reduce this burden, we identified two vulnerable 
populations for our study: pregnant women and Northern Plain American Indian women, 
both high-risk groups. Two aims of this project were centered on understanding the role 
of HPV infection among pregnant women, as they are at higher risk of getting infected 
than nonpregnant women. The third aim was focused on projecting the impact of 9-
valent HPV vaccine compared to 4-valent vaccine among American Indian women, since 
the prevalence of certain HPV types is much higher among this group.  
5.1.1 HPV infection and its role in pregnancy 
There is limited research on HPV infection and its association with adverse 
pregnancy outcomes. Recent research indicates that during pregnancy, the immune 
system is suppressed and major physiological changes take place that may result in 
increased HPV DNA replication.125 In an animal model study, a murine form of herpes 
virus, MHV68, induced significant changes in the capacity of the trophoblast to respond 
to additional danger signals. When lipopolysaccharide (at a dose level that has no effect 
on pregnancy outcome) was injected into pregnant mice that were pre-exposed to 
MHV68, the study demonstrated that viral infection modulates the capacity of the 
trophoblast to cause increased inflammatory mediators in response to 
lipopolysaccharides such as MCP-1, G-CSF, and IL-6.150 It is believed that HPV infection 
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impairs the extravillious trophoblast invasion into the uterine wall by increasing the rate 
of trophoblast cell deaths and causes placental dysfunction. As a consequence of this 
placental dysfunction, adverse pregnancy outcomes may occur. To understand the role 
of HPV infection in adverse pregnancy outcomes, the two main objectives of this project 
were (1) to examine the HPV infection prevalence and its association with perinatal 
outcomes among singleton mothers, with use of PRAMS data, and (2) to examine the 
association of HPV infection with adverse pregnancy outcomes, with use of hospital 
data. The results from these objectives will add to the existing body of HPV infection 
knowledge, aid in the development of better future studies, and help to identify adverse 
pregnancy outcomes that may be caused by HPV infection.  
Overall, in both the PRAMS and hospital database studies, we found the 
prevalence of HPV infection among pregnant women was lower than what has been 
previously reported. However, the prevalence of HPV infection was even lower in the 
PRAMS study (1.4%). This might be an underestimate because of certain limitations 
associated with the data collection. This study was based on self-reported HPV 
exposure status, whereas the other studies that have reported higher prevalence of HPV 
infection were based on laboratory test results. Self-reported data are subject to recall 
bias or may be under-reported or over-reported. Another factor that should be taken into 
consideration is that out of 40 states that collect PRAMS data, only seven ask for HPV 
information. HPV prevalence varies geographically, so it could be that the prevalence in 
those seven states is lower than in some other states. Additionally, in the PRAMS survey 
questionnaire, HPV infection is measured on the basis of a single multicategorical 
question: “What disease or infection were you told you had?”  One of the response 
options for this question is “Genital Warts (HPV),” which may not be comprehensive for 
all women. Except for the above question, there is no other question related to high-risk 
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HPV or low-risk HPV. Genital warts are the result of low-risk HPV such as types 6 or 11 
and not the cancer-causing HPV types such as HPV 16 or 18. So it might be that some 
women with high-risk HPV did not report their status. 
On the contrary, our hospital-based study involved laboratory-tested HPV 
infection. The prevalence was found to be 4.4% in the total sample of 5,022 women. 
Although the prevalence in this study was also lower than in previous studies (where it 
ranges from 5.5% to 65%),205 it was still higher than what we found in the PRAMS 
database. This suggests that further exploration is needed. The previous studies that 
reported higher prevalence were conducted in the pre-vaccination era, so the decline in 
the HPV prevalence noted in our study could be the result of vaccination program 
effectiveness. Furthermore, we found that the prevalence of HPV among whites was 
higher than in other ethnic/racial groups (including Black, American Indian, and 
Hispanic), contrary to the national rates (51.6% vs. 31.5%). A study conducted by Dinh 
et al. indicated that there is a higher prevalence of genital warts among whites compared 
to blacks. 148 Because most genital warts are the result of HPV, the presence of these in 
pregnant women would likely prompt healthcare professionals to perform HPV testing on 
these women. This might be the reason for the higher prevalence of HPV infection 
among white women in our study data. 
Another component of both these studies was to examine the relationship 
between HPV infection and adverse pregnancy outcomes, including preterm birth, 
preeclampsia, low birth weight, and PROM. Our study based on the PRAMS database 
did not find any significant association between HPV infection and adverse pregnancy 
outcomes. However, in our hospital based study, we did find significant association 
between HPV infection and adverse pregnancy outcomes, including preeclampsia, 
preterm birth, and low birth weight. After controlling for demographic and clinical 
variables, we observed that HPV-positive women were 2.80 times more likely to develop 
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preeclampsia, 1.80 times more likely to have a preterm birth, and 2.58 times more likely 
to deliver a low-birth-weight infant. In these studies, we controlled for co-infection with 
chlamydia and gonorrhea, which wasn’t adjusted for in some of the previous studies, 
raising some concerns related to the reliability of those results.  
Our study findings also indicate that there is a significant difference in the 
prevalence of other sexually transmitted infections by HPV status. For instance, the 
prevalence of chlamydia was 9.2% among HPV-positive women, compared to 2.1% 
among HPV-negative women. Similarly, prevalence of Group B streptococci was 21.7% 
among HPV-positive women, compared to only 10% among HPV-negative women.  
Although the specific role of these sexually transmitted infections in the natural history of 
HPV is not clear, several mechanisms have been suggested. The most likely 
mechanism is the initiation of cervical inflammation that may lead to genotoxic damage 
through oxidative metabolites.206 Previous studies have found an association between 
chlamydia and HPV.207 Some studies have suggested that co-infection with chlamydia 
reduces the ability of the host to clear HPV infection. The chronic cervical inflammation 
influences HPV persistence through increased production of free radicals and a 
reduction of host-cell-mediated immunity.208,209 Chlamydia is believed to induce a shift in 
the immune response, and the unresolved infections have been associated with a 
humoral immune response, while clearance of HPV lesions have been associated with 
cellular immune response. Thus, modulation of cervical immune response by chlamydia 
may influence the clearance of HPV lesions.209 Because both HPV and chlamydia are 




Although this study did not examine the relationship between HPV and chlamydia 
among pregnant women, we believe that it is beneficial to understand the association 
and its direction (casual inference) among pregnant women in future studies.  
5.1.2 Impact of 9-valent HPV vaccine on Cervical Cancer 
To our knowledge, this is the first published study to project the impact of 9-
valent HPV vaccine among Northern Plains American Indian women. The reason for 
examining the impact on an American Indian population was that Northern Plains 
American Indian/Alaska Native women are at 1.7 times greater risk of developing 
cervical cancer than Non-Hispanic white women in the same region.81 Because the 
prevalence of HPV differs among population groups in the United States, varying degree 
of impact of HPV vaccine is expected. Gardasil 9, a 9-valent vaccine, was introduced in 
December 2014. This vaccine seems to have greater potential to reduce cervical cancer 
cases because it provides immunity against five additional types of HPV: 31, 33, 45, 52, 
and 58.  
Our study indicates that the incremental gains from introducing 9-valent vaccine are 
higher among American Indian women compared to White women. The larger gains 
from 9-valent vaccine compared to 4-valent vaccine extends to both CIN3 and cervical 
cancer. The model predicted that after 30 years from the reference year, 16.34 
cumulative cervical cancer cases per 100,000 life year lived will be avoided by the 4-
valent vaccine among American Indian women, while 18.41 cumulative cervical cancer 
cases per 100,000 life year lived will be avoided by the 9-valent vaccine among 
American Indian women. Similarly, the model predicts that 3.64 per 100,000 cumulative 
cervical cancer cases per 100,000 life years lived will be avoided by 4-valent vaccine 
among white women while 5.53 cumulative cervical cancer cases per 100,000 life years 
lived will be avoided by the 9-valent vaccine. Additionally, the model predicted that in 
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absolute terms the switch to 9-valent vaccine from 4-valent vaccine would further reduce 
the occurrence of CIN3, from a reduction of 112.5 per 100,000 women to a reduction of 
153.1 per 100,000 women, an absolute difference of 40.6 per 100,000 women among 
American Indian. Among whites, the switch to 9-valent from 4-valent vaccine further 
reduces the occurrence of CIN3, from a reduction of 27.6 per 100,000 people to a 
reduction of 63.9 per 100,000 women. This is an absolute difference of 36.3 per 100,000 
women. 
 In this study we also estimated the percent decrease in the cumulative cervical 
cancer cases if the vaccination coverage is increased. The vaccination coverage of HPV 
vaccine is much lower compared to other vaccines such as Tdap and meningococcal 
conjugate vaccine.181 Some of the barriers to vaccination are higher cost of the 
vaccine,211 parent’s negative perception about vaccine,212 health care providers not 
strongly recommending HPV vaccine for young adolescents,213,214 and low vaccine 
acceptance among adolescents.212 Parents are usually influenced by denial of risk 
(believing that their child is not sexually active and therefore is not at risk of HPV212), 
concerns about vaccine safety, and feeling that a vaccine is too new if it was approved 
less than 10 years ago. 213 Moreover, currently only 21 states and D.C. have laws that 
either require HPV vaccination for school entry, provide funding to cover the cost of 
vaccines or support public education about HPV and vaccine (as shown in figure 12).215 
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Figure 12.HPV Vaccination Policies- Mandates, Education, and Funding. Adapted from 
The Henry J. Kaiser Family Foundation, 2015.215 
Because of the low coverage of the HPV vaccine, it is one of the goals of Healthy 
People 2020 to increase the HPV vaccination coverage to 80%. This study finding 
shows that if the vaccination coverage among American Indian women with 4-valent 
vaccine is increased from 23% to 80%, then after 30 years there will be a 25% decrease 
in the cumulative cervical cancer cases.  
Our study results show that 9-valent vaccine will have a greater impact in the 
American Indian population. However, there are few things that need to be taken into 
consideration when interpreting the results of the study. Our model was challenged by 
the lack of parameter values specific to the American Indian population. For our study, 
we had to assume that the parameter values for American Indian women were the same 
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as for white women, which in reality may not be true, considering the environment as 
well as genetic and behavioral differences. For instance, the smoking rates are much 
higher in the American Indian population. Tobacco smoking is believed to facilitate the 
acquisition or persistence of an HPV infection through a reduced number of Langerhans 
cells and CD4 lymphocytes,62,63 which are markers of local immune response in the 
cervix.64,205 
 Additionally, the activity of natural killer cells can be affected by tobacco 
smoking, which may affect the innate immune response. 64 Thus, the progression rate, 
regression rate, and clearance rate might vary drastically from what we see in the white 
population. For the treatment rate we also had to rely on data for the white population. 
However, to reduce the error, we conducted sensitivity analysis and validated our model 
by comparing our model values to historical values. Additionally, in our study, we were 
not able to account for smoking and HIV, which can modify the natural history of HPV 
infection. Furthermore, we did not consider the effect of circumcision among males in the 
model which may have an effect on the transmission probability of HPV infection from 
males to females. Circumcision has been associated with a reduced prevalence and 
persistence of oncogenic HPV infections.216 Since circumcision rates are much lower in 
American Indian women compared to Whites, the transmission rate of HPV infection is 
expected to be very different in the two populations.217  Because we were unable to 
consider these factors in our model, we believe that our results might be 
underestimated, especially among American Indian women. Another key limitation of this 
study was that the model was not stratified by HPV types and ethnicity, but instead done 
separately. This imposed several limitations including omission of mixing between ethnic 
groups, inability to quantify death over time, unable to take into account multiple 
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infections in an individual. Additionally, we were unable to understand the effects of 
death due to one type of HPV on prevalence of the other type of HPV. 
 
5.2 Future Directions 
5.2.1 Future Directions Based On Research of HPV among Pregnant Women  
                We found that there is a relationship between HPV infection and adverse 
pregnancy outcomes, including preterm birth, low birth weight, and preeclampsia. 
However, there is a need for future prospective studies to study these relationships in 
more depth. For instance, a cohort of women who are planning to get pregnant within the 
next 2 years can be selected randomly from the community. The cohort then can be 
divided into two groups: women who have been exposed to HPV and those who have not 
been exposed. These women could be followed up until their delivery. This type of study 
would allow us to analyze behavioral factors along with other factors before and during 
the pregnancy. This would be helpful because women tend to change certain behaviors 
(e.g., smoking, alcohol consumption, physical activity) during pregnancy, which may 
influence their self-reported responses. Additionally, there is a need for a population-
based database that collects HPV information on pregnant women. We recommend that 
other states collecting PRAMS data should include HPV-related questions in their 
questionnaire that would allow researchers to explore the relationship at a population 
level. Also, new questions related to HPV infection should be included in the 
questionnaire, since currently there is only one question, which is very narrow. To get a 
clear picture of HPV infection among pregnant women questions like: “Were you ever 
told by a physician that you have HPV?”  or “Were you ever diagnosed with genital 
warts?” or a more specific question like: “When you were pregnant, were you informed by 
your healthcare provider that you have HPV?” might be useful. 
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          In addition, our study identified factors that should be considered when conducting 
similar research. First, we recommend future studies exclude ASCUS specimens. 
Although 50% of ASCUS specimens demonstrate HR-HPV, 218 other infections can also 
result in ASCUS. Second, gestational age of infection is an important factor that we think 
should be considered. Previous studies have reported that HPV prevalence varies by 
gestational age. Third, vaccination status should be considered since it could confound 
the association between HPV and adverse obstetrics outcomes. Fourth, in addition to 
chlamydia and gonorrhea, bacterial vaginosis should be taken into consideration, as it is 
associated with poor pregnancy outcomes.  
5.2.2 Future Directions Based On HPV Modelling Research 
            We found that the 9-valent HPV vaccine will have a larger impact on American 
Indian women women than white. However, our study identified gaps in knowledge that 
may have caused underestimation of cervical cancer cases among American Indian 
women in the Northern Plains. Further epidemiological studies should be conducted in 
the Northern Plain American Indian population to collect information on the sexual 
behaviors, screening rate, cervical intraepithelial neoplasia treatment rate, transmission 
rate of HPV from men to women and vice versa, progression rate, regression rate, and 
clearance rate of HPV among these women. Information on sexual behaviors can be 
collected with the help of surveys, and for certain parameters such as 
progression/regression/clearance rate, it might be useful to conduct a prospective study. 
This could be done by recruiting a randomly selected cohort of women with HPV 
infection. The cohort can then be divided into two groups (HR-HPV type and LR-HPV 
type), since the rates of progression, regression, and clearance may vary by HPV type. 
Then these women could be followed over time, for 5 years, a time period that would 
allow us to see the necessary changes. Women receiving treatment should also be 
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recorded. Although, this would be the best approach to gather all the necessary 
information, it might be difficult considering the challenges associated with conducting 
research among American Indian populations. Acknowledging this fact, the other 
approach is to conduct a mixed method research. A random sample of women receiving 
care at Indian Health Services should be obtained. All those women who provides their 
consent to participate in the study should be given surveys to gather information on their 
sexual behavior. This information should be later linked to the past health records of an 
individual from the clinic.  
It was challenging for us to conduct a study without population-specific parameters, and 
we believe that this is a void that should be filled for better understanding of HPV 
vaccination. For example, it would be beneficial to study sexual behaviors and calculate 
the transmission rate, based on the sexual activity level. Because not every person has 
the same level of sexual activity, the transmission rate would not be the same across the 
population. Additionally, we recommend that future studies should include smoking as 
one of the parameters because it is known to cause modification in the natural history of 
HPV. Another important factor that should be considered is waning immunity. Given the 
significance of the duration of protection on the effectiveness of HPV vaccination, it 
would be essential to conduct post-vaccination surveillance. If the vaccine immunity 
does wane, then from the health policy standpoint it would be essential to consider 
booster shots, which would help in maintaining vaccine-induced immunity. For simplicity 
of the model and based on previous literature, we assumed life-long immunity after 
vaccination and assumed that after clearance of HPV infection the immunity wanes after 
5 years in both American Indian and white population. However, this assumption may 
not be valid in reality. It could be possible that due to gene-environment interaction the 
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immunity wanes sooner in American Indian than white women. Hence, more studies are 
needed to explore this research area. 
              Furthermore, future studies are recommended to stratify the model by HPV 
types and ethnicity instead of creating a separate model. By doing so, various limitations 
associated with the current model such as the omission of mixing between ethnic 
groups, inability to quantify death over time, inability to account for multiple infections in 
an individual could be avoided. 
5.3 Conclusion   
               Overall, this dissertation fills gaps in knowledge about the impact of HPV on 
two vulnerable populations; pregnant women and Northern Plains American Indian 
women. This is the first population based study that estimated HPV prevalence among 
pregnant women and examined its role in adverse pregnancy outcomes. In addition, this 
project identified the need for consistent HPV testing among pregnant women. In regard 
to American Indian population, this project emphasized the need of epidemiological data 
that would help in making future predictions using mathematical modeling techniques. 
These modeling techniques could also be applied to other vulnerable populations such 
as Black and Hispanics. Because of limitations, the findings of this study cannot be used 
to provide clinical recommendations, but they do provide knowledge that will be useful to 
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HPV Model Equations for American Indian Population 
 "Cancer cases lived per year per 100,000 with five additional types"=Cancer cases 
lived per year five additional types*100000 
 "Cancer cases lived per life year per 100,000 nona"= "Cancer Cases lived per life 
year (nona)"*100000 
 Cancer cases lived per life year per 100000= "Cancer cases lived per year 
(quad)"*100000 
 "vacc rate (FiveAdditionalTypes)"= IF THEN ELSE (Time < 8, 0 , Prospective nona 
vaccination rate) 
 Prospective nona vaccination rate=0.03 
 total population of women nona=total population of women quadrivalent 
 Cumulative count cancer cases nona= Cumulative cervical cancer cases 12 to 26 
FiveAdditionalTypes+Cumulative cervical cancer cases 12 to 26 quad +Cumulative 
Cervical Cancer cases 27 and above FiveAdditionalTypes+"cumulative cervical 
cancer cases quad 27&above" 
 cumulative count of cervical cancer cases five additional types= Cumulative cervical 
cancer cases 12 to 26 FiveAdditionalTypes+Cumulative Cervical Cancer cases 27 
and above FiveAdditionalTypes 
 Cumulative count of cervical cancer cases quad= Cumulative cervical cancer cases 
12 to 26 quad+" cumulative cervical cancer cases quad 27&above" 
 Cancer cases lived per year five additional types= zidz(cumulative count of cervical 
cancer cases five additional types,life years lived five additional types) 
 "Cancer Cases lived per life year (nona)"= zidz(cumulative count cancer cases 
nona,Life years lived nona) 
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 "Cancer cases lived per year (quad)"= zidz(cumulative count of cervical cancer 
cases quad,life years lived quad) 
 Life years lived nona= INTEG (total population of women nona,0) 
 total population of women quad= total population of women quadrivalent 
 Total population of five additonal types= total population of women 12 to 26 
quadrivalent+ total population of women 27 and above FiveAdditionalTypesvalent 
 total population of women five additional types= Total population of five additional 
types 
 life years lived quad= INTEG (total population of women quad,1) 
 life years lived five additional types= INTEG (total population of women five 
additional types,0) 
 Ref rate of clearance of HPV infected quad 27 and above= 0.5922 
 reg1 12 to 26FiveAdditionalTypes= Rate of regression CIN2 to CIN1 five additional 
types*CIN2 12to 26 FiveAdditionalTypes 
 clearance2 FiveAdditionalTypes= "Rate of clearance of CIN2 five additional types 
27&above"*CIN2 27 and above FiveAdditionalTypes 
 "reg1 27&above FiveAdditionalTypes"= Rate of regression CIN2 to CIN1 five 
additional types*CIN2 27 and above FiveAdditionalTypes 
 clearance3 among 12 to 26 quad= Ref Rate of clearance of CIN3 quad 12 to 
26*CIN3 12 to 26 quad*Coefficient of clearance for quad 
 clearance3 FiveAdditionalTypes= Rate of clearance of CIN3 five additional types 27 
and above*CIN3 27 and above FiveAdditionalTypes 
 "reg2 27 &above FiveAdditionalTypes"= Rate of Regression CIN3 to CIN2 five 
additional types*CIN3 27 and above FiveAdditionalTypes 
 reg3 12 to 26FiveAdditionalTypes= Rate of regression CIN3 to CIN1 five additional 
types*CIN3 12to26 FiveAdditionalTypes 
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 Ref rate of clearance of CIN2 quad 27 and above= 0.21 
 "reg3 27&above FiveAdditionalTypes"= Rate of regression CIN3 to CIN1 five 
additional types*CIN3 27 and above FiveAdditionalTypes 
 "clearance1 27&above quad"= Ref rate of clearance of CIN1 quad 27 and 
above*CIN1 27 and above quad*Coefficient of clearance for quad 
 Rate of regression CIN3 to CIN1 five additional types= 0.03 
 Rate of Regression CIN3 to CIN2 five additional types= 0.03 
 "clear2 27 & above quad"= Ref rate of clearance of CIN2 quad 27 and above*CIN2 
27 and above quad*Coefficient of clearance for quad 
 "clear3 27&above quad"= Ref rate of clearance of CIN3 quad 27 and above*CIN3 
27 and above quad*Coefficient of clearance for quad 
 Rate of clearance of HPV infected five additional types 27 and above= 0.47705 
 clearance of HPV infected 27 and above quad= HPV infected 27and above 
quad*Ref rate of clearance of HPV infected quad 27 and above *Coefficient of 
clearance for quad 
 "clearance of infection 27&above FiveAdditionalTypes"= Rate of clearance of HPV 
infected five additional types 27 and above*HPV infected 27 and above 
FiveAdditionalTypes 
 Ref rate of clearance of CIN1 quad 27 and above= 0.4606 
 Rate of clearance of CIN1 five additional types 27 and above= 0.329 
 Rate of regression CIN2 to CIN1 five additional types= 0.133 
 "Rate of clearance of CIN2 five additional types 27&above"= 0.21 
 reg2 26no= Rate of Regression CIN3 to CIN2 five additional types*CIN3 12to26 
FiveAdditionalTypes 
 Rate of clearance of CIN3 five additional types 27 and above= 0.11 
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 "clearance1 27 & above FiveAdditionalTypes"= Rate of clearance of CIN1 five 
additional types 27 and above*CIN1 27 and above FiveAdditionalTypes 
 Ref rate of clearance of CIN3 quad 27 and above= 0.11 
 rx1 12to26 FiveAdditionalTypes= Fraction of CIN1 successfully cured*screening 
rate FiveAdditionalTypes*sensitivity CIN1 *CIN1 12 to26 FiveAdditionalTypes 
 "rx3 27&above quad"= Fraction of CIN3 successfully cured*sensitivity CIN2and 
CIN3*screening rate*CIN3 27 and above quad 
 "rx2 27&above quad"= screening rate*Fraction of CIN2 successfully 
cured*sensitivity CIN2and CIN3*CIN2 27 and above quad 
 "rx1 27&above quad"= Fraction of CIN1 successfully cured*screening 
rate*sensitivity CIN1*CIN1 27 and above quad 
 rx2 12to26 FiveAdditionalTypes= Fraction of CIN2 successfully cured*screening 
rate FiveAdditionalTypes*sensitivity CIN2and CIN3*CIN2 12to 26 
FiveAdditionalTypes 
 rx3 12to26 FiveAdditionalTypes= Fraction of CIN3 successfully cured*screening 
rate FiveAdditionalTypes*sensitivity CIN2and CIN3 *CIN3 12to26 
FiveAdditionalTypes 
 clearance1 among 12to26 quad= Ref Rate of clearance of CIN1 quad 12 to 
26*CIN1 12 to 26 quad*Coefficient of clearance for quad 
 clearance2 among 12to26 quad= Ref Rate of clearance of CIN2 quad 12 to 
26*CIN2 12 to 26 quad*Coefficient of clearance for quad 
 Coefficient of clearance for quad= 0.68 
 HPV infected clearance rate 12 to 26 quad= HPV infected 12 to 26 quad*Ref Rate 
of clearance of HPV infected quad 12 to 26*Coefficient of clearance for quad 
 prog2 12to26FiveAdditionalTypes=CIN1 to CIN2 hazard rate 
FiveAdditionalTypes*CIN1 12 to26 FiveAdditionalTypes 
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 "prog2 27& above FiveAdditionalTypes"= CIN1 to CIN2 hazard rate 
FiveAdditionalTypes*CIN1 27 and above FiveAdditionalTypes 
 clearance2 12to 26 FiveAdditionalTypes= Rate of clearance of CIN2 
FiveAdditionalTypes 12 to 26*CIN2 12to 26 FiveAdditionalTypes 
 prog3 12 to 26FiveAdditionalTypes= CIN2 to CIN3 hazard rate 
FiveAdditionalTypes*CIN2 12to 26 FiveAdditionalTypes 
 clearance3 12to26 FiveAdditionalTypes= Rate of clearance of CIN3 
FiveAdditionalTypes 12 to 26*CIN3 12to26 FiveAdditionalTypes 
 "prog1 27 & above FiveAdditionalTypes"= HPV infected to CIN1 hazard rate 
FiveAdditionalTypes*HPV infected 27 and above FiveAdditionalTypes 
 Rate of clearance of CIN3 FiveAdditionalTypes 12 to 26= 0.11 
 clearance hpv infected 12 to 26FiveAdditionalTypes= Rate of clearance of HPV 
infected FiveAdditionalTypes 12 to 26*HPV infected 12to26 FiveAdditionalTypes 
 Rate of clearance of HPV infected FiveAdditionalTypes 12 to 26= 0.1316 
 CIN3 to cervical cancer hazard rate FiveAdditionalTypes= 0.42 
 CIN1 12 to26 FiveAdditionalTypes= INTEG (prog1 12 to 
26FiveAdditionalTypes+reg1 12 to 26FiveAdditionalTypes+reg3 12 to 
26FiveAdditionalTypes-CIN1 12 to 26 FiveAdditionalTypes aging-CIN1 deaths 12to 
26FiveAdditionalTypes-clearance1 12to26 FiveAdditionalTypes-prog2 
12to26FiveAdditionalTypes-rx1 12to26 FiveAdditionalTypes, Initially HPV infected 
12 to 26 women with FiveAdditionalTypes who are at CIN1) 
 "prog3 27& above FiveAdditionalTypes"= CIN2 to CIN3 hazard rate 
FiveAdditionalTypes*CIN2 27 and above FiveAdditionalTypes 
 rate of clearance of CIN1 FiveAdditionalTypes 12 to 26= 0.329 
 CIN2 to CIN3 hazard rate FiveAdditionalTypes= 0.14 
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 "prog4 27&above FiveAdditionalTypes"= CIN3 to cervical cancer hazard rate 
FiveAdditionalTypes*CIN3 27 and above FiveAdditionalTypes 
 HPV infected to CIN1 hazard rate FiveAdditionalTypes= 0.094 
 CIN1 to CIN2 hazard rate FiveAdditionalTypes=0.136  
 progression4 12to26 FiveAdditionalTypes= CIN3 12to26 FiveAdditionalTypes*CIN3 
to cervical cancer hazard rate FiveAdditionalTypes 
 HPV infected 12to26 FiveAdditionalTypes= INTEG (infection 
12to26FiveAdditionalTypes-clearance hpv infected 12 to 26FiveAdditionalTypes-
deaths infected 12to 26 FiveAdditionalTypes-hpv infected 12 to 
26FiveAdditionalTypes aging-prog1 12 to 26FiveAdditionalTypes initially infected 
HPV women 12 to 26 from US census for FiveAdditionalTypes that are not CIN1) 
 clearance1 12to26 FiveAdditionalTypes= rate of clearance of CIN1 
FiveAdditionalTypes 12 to 26*CIN1 12 to26 FiveAdditionalTypes 
 Rate of clearance of CIN2 FiveAdditionalTypes 12 to 26= 0.21 
 prog1 12 to 26FiveAdditionalTypes= HPV infected to CIN1 hazard rate 
FiveAdditionalTypes*HPV infected 12to26 FiveAdditionalTypes 
 total cumulative cervical cancer cases 5 additional types= Cumulative cervical 
cancer cases 12 to 26 FiveAdditionalTypes+Cumulative Cervical Cancer cases 27 
and above FiveAdditionalTypes 
 total cumulative cervical cancer cases quad= Cumulative cervical cancer cases 12 
to 26 quad+"cumulative cervical cancer cases quad 27&above" 
 women 27 and above who have been vaccinated quad= INTEG (aging into women 
27 and above who have been vaccinated quad-death of women 27 and above who 
have been vaccinated quad, 0) 
 aging into women 27 and above who have been vaccinated FiveAdditionalTypes= 
aging women 12 to 26 who have been vaccinated FiveAdditionalTypes 
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 aging into women 27 and above who have been vaccinated quad= aging number of 
women 12 to 26 who are vaccinated quad 
 death of women 27 and above who have been vaccinated quad= women 27 and 
above who have been vaccinated quad*"death rate for 27&above" 
 death of number of women 12 to 26 who are vaccinated FiveAdditionalTypes= 
women 12 to 26 FiveAdditionalTypes who have been vaccinated*death rate 12 to 
26 
 new vaccination of 12to 26 FiveAdditionalTypes=total population of women 12 to 26 
FiveAdditionalTypesvalent*"vacc rate (FiveAdditionalTypes)" 
 death of women 27 and above who have been vaccinated FiveAdditionalTypes= 
Women 27 and above who have been vaccinated FiveAdditionalTypes*"death rate 
for 27&above" 
 Women 27 and above who have been vaccinated FiveAdditionalTypes= INTEG 
(aging into women 27 and above who have been vaccinated FiveAdditionalTypes-
death of women 27 and above who have been vaccinated FiveAdditionalTypes, 0) 
 fraction of women 12 to 26 who have been vaccinated= women 12 to 26 
FiveAdditionalTypes who have been vaccinated/total population of women 12 to 26 
FiveAdditionalTypesvalent 
 aging women 12 to 26 who have been vaccinated FiveAdditionalTypes= women 12 
to 26 FiveAdditionalTypes who have been vaccinated/mean years until aging 
 women 12 to 26 FiveAdditionalTypes who have been vaccinated= INTEG (new 
vaccination of 12to 26 FiveAdditionalTypes-death of number of women 12 to 26 




 Women 12 to 26 who have been vaccinated quad= INTEG (new vaccinations of 12 
to 26 women-aging number of women 12 to 26 who are vaccinated quad-death of 
number of women 12 to 26 who are vaccinated,0) 
 new vaccinations of 12 to 26 women= total population of women 12 to 26 
quadrivalent*vacc rate 
 aging number of women 12 to 26 who are vaccinated quad= Women 12 to 26 who 
have been vaccinated quad/mean years until aging 
 death of number of women 12 to 26 who are vaccinated= Women 12 to 26 who 
have been vaccinated quad*death rate 12 to 26 
 vacc quad= Susceptible12to26 quad*vacc rate*vaccine efficacy 
 fraction of women 12 to 26 who have been vaccinated quad= Women 12 to 26 who 
have been vaccinated quad/total population of women 12 to 26 quadrivalent 
 vacc rate= 0.03 
 fraction of susceptible women 27 and above FiveAdditionalTypes= Susceptible 
27and above FiveAdditionalTypes/total population of women 27 and above 
FiveAdditionalTypesvalent 
 Fraction of women susceptible 12 to 26 quad= Susceptible12to26 quad/total 
population of women 12 to 26 quadrivalent 
 Fraction of women susceptible 12 to 26 FiveAdditionalTypes= susceptible 12 to26 
FiveAdditionalTypes/total population of women 12 to 26 FiveAdditionalTypesvalent 
 fraction of women that are susceptible for 27 and above quad= Susceptible 27and 
above quad/total population of women 27 and above quadrivalent 
 Inital 27 and above CIN1 infected women from HPV quad infected= fraction of 
women 27 and above who were infected with quad and are CIN1*Initial 27 and 
above HPV quad infected women from US census including CIN1 
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 HPV infected 27 and above FiveAdditionalTypes= INTEG (aging into hpv infected 
FiveAdditionalTypes+"infection 27&above FiveAdditionalTypes"-"clearance of 
infection 27&above FiveAdditionalTypes"-infected 27 and above deaths 
FiveAdditionalTypes-"prog1 27 & above FiveAdditionalTypes", initially HPV infected 
women 27 and above not CIN1 FiveAdditionalTypes) 
 fraction of women 27 from US census who are infected with HPV quad strain= 
(0.0528*0) +0.1 
 initially infected HPV women 12 to 26 from US census for FiveAdditionalTypes that 
are not CIN1=Initially infected HPV women 12 to 26 from US census including CIN1 
for FiveAdditionalTypes-Initially HPV infected 12 to 26 women with 
FiveAdditionalTypes who are at CIN1 
 Initially susceptible women 12 to 26 from US census= Total initial population 12 to 26 
from US census-(Initially CIN1 infected women from HPV infected women+Initially 
HPV infected women from US census for quad not CIN1) 
 HPV infected 12 to 26 quad= INTEG (infection rate among 12to26 quad-aging hpv 
infected 12 to 26 quad-deaths of infected 12 to 26 quad-HPV infected clearance rate 
12 to 26 quad-progression1 among 12 to 26 quad, Initially HPV infected women from 
US census for quad not CIN1) 
 Initally susceptible women 12 to 26 from US census for FiveAdditionalTypes= Total 
initial population 12 to 26 from US census-(Initially HPV infected 12 to 26 women 
with FiveAdditionalTypes who are at CIN1+initially infected HPV women 12 to 26 
from US census for FiveAdditionalTypes that are not CIN1) 
 Initially HPV infected women 27 and above from US census for quad not CIN1= 
Initial 27 and above HPV quad infected women from US census including CIN1-
Inital 27 and above CIN1 infected women from HPV quad infected 
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 Initial susceptible women 27 and above from US census FiveAdditionalTypes= 
total initial population 27 and above from US census-(initially HPV infected 
women 27 and above not CIN1 FiveAdditionalTypes+ Initial 27 and above at 
CIN1 from HPV infected women with FiveAdditionalTypes strain) 
 total population of women 27 and above quadrivalent= HPV infected 27and 
above quad+ Susceptible 27and above quad+CIN1 27 and above quad +CIN2 
27 and above quad+CIN3 27 and above quad+Immune via vaccination 27 and 
above quad+ Immune after HPV clearance 27 and above quad 
 Initially susceptible women 27 and above from US census= total initial population 
27 and above from US census-(Initially HPV infected women 27 and above from 
US census for quad not CIN1+Initial 27 and above CIN1 infected women from 
HPV quad infected) 
 Initial 27 and above HPV quad infected women from US census including CIN1= 
fraction of women 27 from US census who are infected with HPV quad 
strain*total initial population 27 and above from US census 
 initially HPV infected women 27 and above not CIN1 FiveAdditionalTypes= 
Initially infected 27 and above with HPV FiveAdditionalTypes including CIN1-
Inital 27 and above at CIN1 from HPV infected women with FiveAdditionalTypes 
strain 
 total population of women 12 to 26 quadrivalent= HPV infected 12 to 26 quad+ 
Susceptible12to26 quad+CIN1 12 to 26 quad+ CIN2 12 to 26 quad+CIN3 12 to 
26 quad +Immune via vaccination 12to26 quad+Immune after HPV infection 
clearance 12 to 26 quad 
 total population of women 12 to 26 FiveAdditionalTypesvalent= CIN1 12 to26 
FiveAdditionalTypes+CIN2 12to 26 FiveAdditionalTypes+CIN3 12to26 
FiveAdditionalTypes+ HPV infected 12to26 FiveAdditionalTypes +susceptible 12 
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to26 FiveAdditionalTypes+ immune via vacc 12 to 26 FiveAdditionalTypes 
+Immune after HPV infection 12 to26 FiveAdditionalTypes 
 Initially HPV infected women from US census for quad not CIN1= Initially HPV 
infected women from US census for quad including CIN1-Initially CIN1 infected 
women from HPV infected women 
 total population of women 27 and above FiveAdditionalTypesvalent= CIN1 27 
and above FiveAdditionalTypes+CIN2 27 and above FiveAdditionalTypes+CIN3 
27 and above FiveAdditionalTypes +HPV infected 27 and above 
FiveAdditionalTypes+ Susceptible 27and above FiveAdditionalTypes +immune 
via vaccination 27 and above FiveAdditionalTypes +Immune after HPV infection 
27and above FiveAdditionalTypes 
 HPV infected 27and above quad= INTEG (Aging into HPV infected 27+"infection 
27&above quad"-clearance of HPV infected 27 and above quad-"deaths of 
infected 27&above quad"-prog1 27and above quad, Initially HPV infected women 
27 and above from US census for quad not CIN1) 
 Immune after HPV clearance 27 and above quad= INTEG (aging into immune 
after HPV clearance 27 and above quad+"clear2 27 & above quad"+"clear3 
27&above quad"+ clearance of HPV infected 27 and above quad+"clearance1 
27&above quad"+"rx1 27&above quad"+"rx2 27&above quad"+"rx3 27&above 
quad"-death of immune after HPV clearance 27 and above-waning immunity after 
infection among 27 and above quad,0) 
 Susceptible 27and above quad= INTEG (Aging into susceptible 27+waning 
immunity after infection among 27 and above quad-"infection 27&above quad"-
susceptible27 deaths+"waning immunity among 27 and above (quad)”, Initially 
susceptible women 27 and above from US census) 
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 Immune after HPV infection 27and above FiveAdditionalTypes= INTEG (aging 
into immune after HPV infection 27 and above FiveAdditionalTypes+"clearance 
of infection 27&above FiveAdditionalTypes"+"clearance1 27 & above 
FiveAdditionalTypes"+clearance2 FiveAdditionalTypes+clearance3 
FiveAdditionalTypes+"rx1 27& above FiveAdditionalTypes"+"rx2 27& above 
FiveAdditionalTypes"+"rx3 27&above FiveAdditionalTypes" -Deaths of immune 
after vaccination 27 and above FiveAdditionalTypes-waning immunity after 
infection 27 and above nano,0) 
 susceptible 12 to26 FiveAdditionalTypes= INTEG ("Aging females <12 
FiveAdditionalTypes"+waning immunity after vaccination 12to 26 nano +waning 
immunity of 27 and above FiveAdditionalTypes-death of susceptibles 12to 26no-
infection 12to26FiveAdditionalTypes-Susceptible 12 to 26 FiveAdditionalTypes 
aging-vacc FiveAdditionalTypes, Initally susceptible women 12 to 26 from US 
census for FiveAdditionalTypes) 
 immune via vacc 12 to 26 FiveAdditionalTypes= INTEG (vacc 
FiveAdditionalTypes-aging of immune 12 to 26 FiveAdditionalTypes-deaths of 
immune 12 to 26 FiveAdditionalTypes-waning immunity after vaccination 12to 26 
nano-waning immunity after vaccination 12to 26 nano,0) 
 "rx2 27& above FiveAdditionalTypes"=Fraction of CIN2 successfully 
cured*screening rate FiveAdditionalTypes*sensitivity CIN2and CIN3*CIN2 27 
and above FiveAdditionalTypes 
 Immune via vaccination 12to26 quad= INTEG (vacc quad-aging immune via 
vaccination 12 to 26 quad-deaths of immune 12 to 26 quad-waning immunity 
after vaccination among 12to26quad,0) 
 Susceptible12to26 quad= INTEG ("Aging of female <12"-aging susceptible 12to 
26 quad-deaths of susceptible 12 to 26 quad-infection rate among 12to26 quad-
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vacc quad+ Waning immunity after infection 12 to 26 quad+ waning immunity 
after vaccination among 12to26quad, Initially susceptible women 12 to 26 from 
US census) 
 waning immunity after infection among 27 and above quad=Immune after HPV 
clearance 27 and above quad/Time until waning immunity after infection 
 Susceptible 27and above FiveAdditionalTypes= INTEG (aging into susceptible 
27 and FiveAdditionalTypes+waning immunity after infection 27 and above nano-
"infection 27&above FiveAdditionalTypes"-susceptible 27 and above 
deaths+waning immunity after vaccination 27 and above FiveAdditionalTypes, 
Initial susceptible women 27 and above from US census FiveAdditionalTypes) 
 time until waning immunity after vaccination=10 
 waning immunity after vaccination among 12to26quad= (Immune via vaccination 
12to26 quad/time until waning immunity after vaccination)*"enable waning 
immunity after vaccination?" 
 "enable waning immunity after vaccination?"=0 
 waning immunity after vaccination 12to 26 nano=(immune via vacc 12 to 26 
FiveAdditionalTypes/time until waning immunity after vaccination)*"enable 
waning immunity after vaccination?" 
 rx2 12to26 quad= screening rate*sensitivity CIN2and CIN3*Fraction of CIN2 
successfully cured*CIN2 12 to 26 quad 
 waning immunity after vaccination 27 and above FiveAdditionalTypes= (immune 
via vaccination 27 and above FiveAdditionalTypes/time until waning immunity 
after vaccination)* "enable waning immunity after vaccination?" 
 waning immunity after infection 27 and above nano= Immune after HPV infection 
27and above FiveAdditionalTypes/Time until waning immunity after infection 
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 "waning immunity among 27 and above (quad)"= (Immune via vaccination 27 and 
above quad/time until waning immunity after vaccination) *"enable waning 
immunity after vaccination?" 
 fraction of women 12to26 immune via vaccination quad= Immune via vaccination 
12to26 quad/total population of women 12 to 26 quadrivalent 
 
 waning immunity of 27 and above FiveAdditionalTypes= Immune after HPV 
infection 12 to26 FiveAdditionalTypes/Time until waning immunity after infection 
 aging of immune after HPV infection 12 to 26 FiveAdditionalTypes= 
 Immune after HPV infection 12 to26 FiveAdditionalTypes/mean years until aging 
 aging into immune after HPV clearance 27 and above quad= aging of immune 
after HPV infection clearance 12 to 26 quad 
 Immune after HPV infection 12 to26 FiveAdditionalTypes= INTEG (clearance1 
12to26 FiveAdditionalTypes+clearance2 12to 26 
FiveAdditionalTypes+clearance3 12to26 FiveAdditionalTypes+rx1 12to26 
FiveAdditionalTypes+rx2 12to26 FiveAdditionalTypes+rx3 12to26 
FiveAdditionalTypes-deaths of immune after HPV infection 12 to 26 
FiveAdditionalTypes-waning immunity of 27 and above FiveAdditionalTypes-
aging of immune after HPV infection 12 to 26 FiveAdditionalTypes+ clearance 
hpv infected 12 to 26FiveAdditionalTypes,0) 
 deaths of immune after HPV infection 12 to 26 FiveAdditionalTypes= death rate 
12 to 26*Immune after HPV infection 12 to26 FiveAdditionalTypes 
 Deaths of immune after vaccination 27 and above FiveAdditionalTypes= "death 




 aging into immune after HPV infection 27 and above FiveAdditionalTypes= aging 
of immune after HPV infection 12 to 26 FiveAdditionalTypes 
 Waning immunity after infection 12 to 26 quad= Immune after HPV infection 
clearance 12 to 26 quad/Time until waning immunity after infection 
 Time until waning immunity after infection= 5 
 incidence of cc per 100000 12to26= (Progression4 among 12 to 26 quad/total 
population of women 12 to 26 quadrivalent)*100000 
 aging of immune after HPV infection clearance 12 to 26 quad= Immune after 
HPV infection clearance 12 to 26 quad/mean years until aging 
 deaths of immune after HPV infection clearance= Immune after HPV infection 
clearance 12 to 26 quad*death rate 12 to 26 
 death of immune after HPV clearance 27 and above= Immune after HPV 
clearance 27 and above quad*"death rate for 27&above" 
 Immune after HPV infection clearance 12 to 26 quad= INTEG (HPV infected 
clearance rate 12 to 26 quad+clearance1 among 12to26 quad+clearance2 
among 12to26 quad+clearance3 among 12 to 26 quad+rx1 12to26 quad+rx2 
12to26 quad+rx3 12 to 26 quad -Waning immunity after infection 12 to 26 quad-
aging of immune after HPV infection clearance 12 to 26 quad-deaths of immune 
after HPV infection clearance,0) 
 force of infection 12to26 quad=mean partner acquisition 12 to 26*(Fraction of 
partners of 12 to 26 year old women that are in 12 to 26 year of age* HPV 
prevalence 12 to 26 quad+ (1-Fraction of partners of 12 to 26 year old women 
that are in 12 to 26 year of age) * HPV prevalence 27 and above quad) 
*transmission rate 12to26 
 force of infection 12 to 26 FiveAdditionalTypes= mean partner acquistion 12 to 
26*(Fraction of partners of 12 to 26 year old women that are in 12 to 26 year of 
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age* HPV prevalence 12to26FiveAdditionalTypes+ (1-Fraction of partners of 12 
to 26 year old women that are in 12 to 26 year of age) * HPV prevalence 27 and 
above FiveAdditionalTypes)* transmission rate 12to26 
 transmission rate 12to26= 0.4 
 CIN3 27 and above deaths FiveAdditionalTypes= "death rate for 
27&above"*CIN3 27 and above FiveAdditionalTypes 
 CIN3 12to26 FiveAdditionalTypes= INTEG (prog3 12 to 26FiveAdditionalTypes-
CIN3 12 to 26 FiveAdditionalTypes aging-CIN3 deaths 
12to26FiveAdditionalTypes-clearance3 12to26 FiveAdditionalTypes-reg2 26no-
reg3 12 to 26FiveAdditionalTypes-rx3 12to26 FiveAdditionalTypes +prog3 12 to 
26FiveAdditionalTypes-progression4 12to26 FiveAdditionalTypes,0) 
 "CIN3 27 & above death quad"= "death rate for 27&above"*CIN3 27 and above 
quad 
 CIN3 27 and above FiveAdditionalTypes= INTEG (aging into cin3 
FiveAdditionalTypes+"prog3 27& above FiveAdditionalTypes"-CIN3 27 and 
above deaths FiveAdditionalTypes-clearance3 FiveAdditionalTypes-"prog4 
27&above FiveAdditionalTypes"-"reg2 27 &above FiveAdditionalTypes"-"reg3 
27&above FiveAdditionalTypes"-"rx3 27&above FiveAdditionalTypes"+"prog3 
27& above FiveAdditionalTypes"-"prog4 27&above FiveAdditionalTypes", 0) 
 CIN3 27 and above quad= INTEG ("Aging into CIN3 27&above quad"+prog3 
27and above quad-"CIN3 27 & above death quad"-"clear3 27&above quad"-"reg2 
27&above quad"-reg3 27 and above quad-"rx3 27&above quad"+prog3 27and 
above quad-prog4 27and above quad,0) 




 immune via vacc deaths quad= Immune via vaccination 27 and above 
quad*"death rate for 27&above" 
 Cumulative cervical cancer cases 12 to 26 FiveAdditionalTypes= INTEG 
(progression4 12to26 FiveAdditionalTypes,0) 
 Cumulative Cervical Cancer cases 27 and above FiveAdditionalTypes= INTEG 
("prog4 27&above FiveAdditionalTypes", 0) 
 "cumulative cervical cancer cases quad 27&above"= INTEG (prog4 27and above 
quad,0) 
 infected 27 and above deaths FiveAdditionalTypes= "death rate for 
27&above"*HPV infected 27 and above FiveAdditionalTypes 
 prog4 27and above quad= CIN3 27 and above quad*CIN3 to cervical cancer 
hazard rate quad 
 "death rate for 27&above"= 0.005417 
 Progression4 among 12 to 26 quad= CIN3 to cervical cancer hazard rate 
quad*CIN3 12 to 26 quad 
 "CIN1 27 &above deaths FiveAdditionalTypes"= CIN1 27 and above 
FiveAdditionalTypes*"death rate for 27&above" 
 susceptible27 deaths= Susceptible 27and above quad*"death rate for 27&above" 
 "CIN2 27&above deaths FiveAdditionalTypes"= CIN2 27 and above 
FiveAdditionalTypes*"death rate for 27&above" 
 deaths of immune 27 and above FiveAdditionalTypes="death rate for 
27&above"*immune via vaccination 27 and above FiveAdditionalTypes 
 susceptible 27 and above deaths="death rate for 27&above"*Susceptible 27and 
above FiveAdditionalTypes 
 prog4 27 and above quad per 100000= (prog4 27and above quad/total 
population of women 27 and above quadrivalent)*100000 
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 CIN3 12 to 26 quad= INTEG (-Aging CIN3 12 to 26 FiveAdditionalTypes-
clearance3 among 12 to 26 quad-deaths of CIN3 12 to 26 quad-regression2 
12to26 quad-Regression3 12to26 quad-rx3 12 to 26 quad+progression3 among 
12 to 26 quad-Progression4 among 12 to 26 quad,0) 
 CIN2 deaths among 27 and above quad= CIN2 27 and above quad*"death rate 
for 27&above" 
 "deaths of infected 27&above quad"= HPV infected 27and above quad*"death 
rate for 27&above" 
 Cumulative cervical cancer cases 12 to 26 quad= INTEG (Progression4 among 
12 to 26 quad,0) 
 total population of men and women FiveAdditionalTypes= total population of 
women FiveAdditionalTypesvalent*(1+Ratio of male to female population) 
 "Initial susceptible women <12 years FiveAdditionalTypesvalent"= 37112 
 "Female <12 FiveAdditionalTypes"= INTEG (birth FiveAdditionalTypes-"Aging 
females <12 FiveAdditionalTypes"-"death of females <12 years", "Initial 
susceptible women <12 years FiveAdditionalTypesvalent") 
 total population of men and women quad= total population of women 
quadrivalent*(1+Ratio of male to female population) 
 birth FiveAdditionalTypes= birth rate for female babies*total population of men 
and women FiveAdditionalTypes 
 birth quad= total population of men and women quad*birth rate for female babies 
 Ratio of male to female population= 0.96 
 rx3 12 to 26 quad= screening rate*sensitivity CIN2and CIN3*Fraction of CIN3 
successfully cured*CIN3 12 to 26 quad 
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 "rx3 27&above FiveAdditionalTypes"= Fraction of CIN3 successfully 
cured*screening rate FiveAdditionalTypes*sensitivity CIN2and CIN3*CIN3 27 
and above FiveAdditionalTypes 
 "rx1 27& above FiveAdditionalTypes"= Fraction of CIN1 successfully 
cured*screening rate FiveAdditionalTypes*sensitivity CIN1*CIN1 27 and above 
FiveAdditionalTypes 
 rx1 12to26 quad= sensitivity CIN1*screening rate*Fraction of CIN1 successfully 
cured*CIN1 12 to 26 quad 
 HPV infected FiveAdditionalTypes per 100000= (HPV infected 27 and above 
FiveAdditionalTypes/total population of women 27 and above 
FiveAdditionalTypesvalent)*100000 
 CIN3 among 12 to 26 per 100000 quad= (CIN3 12 to 26 quad/total population of 
women 12 to 26 quadrivalent)*100000 
 CIN2 12to26 quad per 100000= (CIN2 12 to 26 quad/total population of women 
12 to 26 quadrivalent)*100000 
 CIN3 FiveAdditionalTypes per 100000= (CIN3 27 and above 
FiveAdditionalTypes/total population of women 27 and above 
FiveAdditionalTypesvalent)*100000 
 CIN2 27 and above per 100000 quad=(CIN2 27 and above quad/total population 
of women 27 and above quadrivalent)*100000 
 CIN1 12to26 per 100000 quad= (CIN1 12 to 26 quad/total population of women 
12 to 26 quadrivalent)*100000 
 CIN1 26FiveAdditionalTypes per 100000= (CIN1 12 to26 




 hpv infected 27 and above per 100000 quad=(HPV infected 27and above 
quad/total population of women 27 and above quadrivalent)*100000 
 "CIN1 27& above FiveAdditionalTypes per 100000"= (CIN1 27 and above 
FiveAdditionalTypes/total population of women 27 and above 
FiveAdditionalTypesvalent)*100000 
 CIN3 12 to 26 per 100000 FiveAdditionalTypes= (CIN3 12to26 
FiveAdditionalTypes/total population of women 12 to 26 
FiveAdditionalTypesvalent)*100000 
 "CIN1 27&above per 100000 quad"= (CIN1 27 and above quad/total population 
of women 27 and above quadrivalent)*100000 
 CIN3 27 and above per 100000 quad= (CIN3 27 and above quad/total population 
of women 27 and above quadrivalent)*100000 
 CIN2 12 to 26per 100000 FiveAdditionalTypes= (CIN2 12to 26 
FiveAdditionalTypes/total population of women 12 to 26 
FiveAdditionalTypesvalent)*100000 
 "total population of women (quad+FiveAdditionalTypes)"= total population of 
women 12 to 26 FiveAdditionalTypesvalent+total population of women 12 to 26 
quadrivalent +total population of women 27 and above 
FiveAdditionalTypesvalent+total population of women 27 and above quadrivalent 
 total population="total population of women (quad+FiveAdditionalTypes)"*ratio of 
total population to total population of women 
 "CIN2 27&above FiveAdditionalTypes per 100000"= (CIN2 27 and above 
FiveAdditionalTypes/total population of women 27 and above 
FiveAdditionalTypesvalent)*100000 
 HPV infected 12 to 26 per 100000 quad=(HPV infected 12 to 26 quad/total 
population of women 12 to 26 quadrivalent)*100000 
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 hpv infected 12 to 26FiveAdditionalTypes per 100000= (HPV infected 12to26 
FiveAdditionalTypes/total population of women 12 to 26 
FiveAdditionalTypesvalent)*100000 
 Aging into HPV infected 27= aging hpv infected 12 to 26 quad 
 "Females <12 quad"= INTEG (birth quad-"Aging of female <12"-"death of 
females< 12 years of age", "Initial susceptible females <12 quad") 
 "Initial susceptible females <12 quad"= 37112 
 total population of women FiveAdditionalTypesvalent= total population of women 
12 to 26 FiveAdditionalTypesvalent+total population of women 27 and above 
FiveAdditionalTypesvalent 
 "HPV Infection (quad) among 12 to 26 count"= CIN1 12 to 26 quad+CIN2 12 to 
26 quad+CIN3 12 to 26 quad+HPV infected 12 to 26 quad 
 HPV prevalence 27 and above FiveAdditionalTypes= ("HPV infection among 27 
and above (FiveAdditionalTypes) count")/total population of women 27 and 
above FiveAdditionalTypesvalen 
 HPV prevalence 12 to 26 quad= ("HPV Infection (quad) among 12 to 26 
count")/total population of women 12 to 26 quadrivalent 
 "HPV infection among 12 to 26 (FiveAdditionalTypes) count"=CIN1 12 to26 
FiveAdditionalTypes+CIN2 12to 26 FiveAdditionalTypes+CIN3 12to26 
FiveAdditionalTypes +HPV infected 12to26 FiveAdditionalTypes 
 "HPV infection among 27 and above (FiveAdditionalTypes) count"= HPV infected 
27 and above FiveAdditionalTypes+CIN1 27 and above FiveAdditionalTypes+ 




 "HPV infection among 27 and above (quad) count"= CIN1 27 and above 
quad+CIN2 27 and above quad+CIN3 27 and above quad+HPV infected 27and 
above quad 
 HPV prevalence 12to26FiveAdditionalTypes= ("HPV infection among 12 to 26 
(FiveAdditionalTypes) count")/total population of women 12 to 26 
FiveAdditionalTypesvalent 
 HPV prevalence 27 and above quad= ("HPV infection among 27 and above 
(quad) count")/total population of women 27 and above quadrivalent 
 CIN1 12 to 26 quad= INTEG (progression1 among 12 to 26 quad+regression1 
12to26 quad+Regression3 12to26 quad-aging CIN1 12to26 quad-clearance1 
among 12to26 quad-deaths of CIN1 12to26 quad-progression2 among 12 to 26 
quad-rx1 12to26 quad, Initially CIN1 infected women from HPV infected women) 
 CIN1 27 and above FiveAdditionalTypes= INTEG (aging into CIN1 
FiveAdditionalTypes+"prog1 27 & above FiveAdditionalTypes"+"reg1 27&above 
FiveAdditionalTypes"+"reg3 27&above FiveAdditionalTypes"-"CIN1 27 &above 
deaths FiveAdditionalTypes"-"clearance1 27 & above FiveAdditionalTypes"-
"prog2 27& above FiveAdditionalTypes"-"rx1 27& above FiveAdditionalTypes", 
Initial 27 and above at CIN1 from HPV infected women with FiveAdditionalTypes 
strain) 
 total population of women quadrivalent= total population of women 12 to 26 
quadrivalent+total population of women 27 and above quadrivalent 
 deaths of immune 12 to 26 FiveAdditionalTypes= death rate 12 to 26*immune via 
vacc 12 to 26 FiveAdditionalTypes 
 aging into immune via vaccination 27 and above quad= aging immune via 
vaccination 12 to 26 quad 
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 deaths of immune 12to 26 FiveAdditionalTypes= death rate 12 to 26*immune via 
vacc 12 to 26 FiveAdditionalTypes 
 aging immune via vaccination 12 to 26 quad= Immune via vaccination 12to26 
quad/mean years until aging 
 aging into immune via vacc 27 and above FiveAdditionalTypes= aging of immune 
12 to 26 FiveAdditionalTypes 
 immune via vaccination 27 and above FiveAdditionalTypes= INTEG (aging into 
immune via vacc 27 and above FiveAdditionalTypes-deaths of immune 27 and 
above FiveAdditionalTypes-waning immunity after vaccination 27 and above 
FiveAdditionalTypes,0) 
 Immune via vaccination 27 and above quad= INTEG (aging into immune via 
vaccination 27 and above quad-"waning immunity among 27 and above (quad)"-
immune via vacc deaths quad,0) 
 aging of immune 12 to 26 FiveAdditionalTypes= immune via vacc 12 to 26 
FiveAdditionalTypes/mean years until aging 
 vacc FiveAdditionalTypes= susceptible 12 to26 FiveAdditionalTypes*"vacc rate 
(FiveAdditionalTypes)"*vaccine efficacy 
 HPV prevalence 27 and above per 100 quad= HPV prevalence 27 and above 
quad*100 
 HPV prevalence 12 to 26 per 100 FiveAdditionalTypes= HPV prevalence 
12to26FiveAdditionalTypes*100 
 HPV prevalence 27 and above FiveAdditionalTypes per 100= HPV prevalence 27 
and above FiveAdditionalTypes*100 
 HPV prevalence 12 to 26 quad per 100= HPV prevalence 12 to 26 quad*100 
 CIN1 27 and above quad= INTEG ("Aging into CIN1 27&above quad"+prog1 
27and above quad+reg1 27 and above quad+reg3 27 and above quad-"CIN1 
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27&above deaths quad"-"clearance1 27&above quad"-prog2 27and above quad-
"rx1 27&above quad", Initial 27 and above CIN1 infected women from HPV quad 
infected) 
 fraction of women 27 and above who were infected with quad and are CIN1= 
0.09 
 Total initial population 12 to 26 from US census= 38736 
 total initial population 27 and above from US census=67313 
 Initially HPV infected 12 to 26 women with FiveAdditionalTypes who are at CIN1= 
Initially infected HPV women 12 to 26 from US census including CIN1 for 
FiveAdditionalTypes*Fraction of 12 to 26 years who are initially infected with 
HPV FiveAdditionalTypes who have CIN1 
 Initially HPV infected women from US census for quad including CIN1=Total 
initial population 12 to 26 from US census*Fraction of women 12 to 26 from US 
cenus who are HPV infected for quad strain 
 Initially infected HPV women 12 to 26 from US census including CIN1 for 
FiveAdditionalTypes = Fraction of US 12 to 26 census population that is initially 
infected with FiveAdditionalTypes strain of HPV *Total initial population 12 to 26 
from US census 
 
 Fraction of women 27 and above from HPV FiveAdditionalTypes infected that are 
CIN1= 0.1184 
 
 fraction of women 27 and above from susceptible that are infected with HPV 
FiveAdditionalTypes=0.08 
 Fraction of 12 to 26 years old who are initially infected with quad strains of HPV 
who have CIN1=0.09 
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 Initially CIN1 infected women from HPV infected women= Initially HPV infected 
women from US census for quad including CIN1*Fraction of 12 to 26 years old 
who are initially infected with quad strains of HPV who have CIN1 
 
 Initially infected 27 and above with HPV FiveAdditionalTypes including CIN1= 
fraction of women 27 and above from susceptible that are infected with HPV 
FiveAdditionalTypes*total initial population 27 and above from US census 
 Inital 27 and above at CIN1 from HPV infected women with FiveAdditionalTypes 
strain= Fraction of women 27 and above from HPV FiveAdditionalTypes infected 
that are CIN1*Initally infected 27 and above with HPV FiveAdditionalTypes 
including CIN1 
 Fraction of women 12 to 26 from US cenus who are HPV infected for quad 
strain= 0.15 
 Fraction of 12 to 26 years who are intially infected with HPV FiveAdditionalTypes 
who have CIN1=0.09 
 Fraction of US 12 to 26 census population that is initially infected with 
FiveAdditionalTypes strain of HPV= 0.27 
 death of susceptible 12to 26no= susceptible 12 to26 FiveAdditionalTypes*death 
rate 12 to 26 
 CIN1 deaths 12to 26FiveAdditionalTypes= CIN1 12 to26 
FiveAdditionalTypes*death rate 12 to 26 
 deaths of CIN3 12 to 26 quad= death rate 12 to 26*CIN3 12 to 26 quad 
 deaths of immune 12 to 26 quad= Immune via vaccination 12to26 quad*death 
rate 12 to 26 




 CIN3 deaths 12to26FiveAdditionalTypes= CIN3 12to26 
FiveAdditionalTypes*death rate 12 to 26 
 CIN2 deaths 12to 26 FiveAdditionalTypes= CIN2 12to 26 
FiveAdditionalTypes*death rate 12 to 26 
 CIN2 27 and above quad= INTEG (Aging into CIN2 27 and above quad-"clear2 
27 & above quad"+prog2 27and above quad-prog3 27and above quad +"reg2 
27&above quad"-CIN2 deaths among 27 and above quad-reg1 27 and above 
quad-"rx2 27&above quad",0) 
 deaths infected 12to 26 FiveAdditionalTypes= HPV infected 12to26 
FiveAdditionalTypes*death rate 12 to 26 
 deaths of CIN2 12 to 26 quad= death rate 12 to 26*CIN2 12 to 26 quad 
 CIN2 27 and above FiveAdditionalTypes= INTEG (aging into cin2 
FiveAdditionalTypes+"prog2 27& above FiveAdditionalTypes"+"reg2 27 &above 
FiveAdditionalTypes"-"CIN2 27&above deaths FiveAdditionalTypes"-clearance2 
FiveAdditionalTypes-"prog3 27& above FiveAdditionalTypes"-"reg1 27&above 
FiveAdditionalTypes"-"rx2 27& above FiveAdditionalTypes",0) 
 deaths of CIN1 12to26 quad= CIN1 12 to 26 quad*death rate 12 to 26 
 deaths of susceptible 12 to 26 quad= Susceptible12to26 quad*death rate 12 to 
26 
 Ref Rate of clearance of CIN1 quad 12 to 26= 0.4606 
 Ref Rate of clearance of CIN2 quad 12 to 26= 0.21 
 Ref Rate of clearance of CIN3 quad 12 to 26= 0.11 
 vaccine efficacy= 0.9 
 "death of females< 12 years of age"= "death rate of females <12 
years"*"Females <12 quad" 
 "death rate of females <12 years"= 0.0002195 
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 "death of females <12 years"= "death rate of females <12 years"*"Female <12 
FiveAdditionalTypes" 
 force of infection 27 and above quad= mean partner acquisition rate 27 and 
above*(fraction of partners 27 years and older women that are in 27 years and 
older *HPV prevalence 27 and above quad +(1-fraction of partners 27 years and 
older women that are in 27 years and older)* HPV prevalence 12 to 26 
quad)*transmission rate 27 and above 
 force of infection 27 and above FiveAdditionalTypes= mean partner acquisition 
rate 27 and above * (fraction of partners 27 years and older women that are in 27 
years and older * HPV prevalence 27 and above FiveAdditionalTypes + (1-
fraction of partners 27 years and older women that are in 27 years and older) * 
HPV prevalence 12to26FiveAdditionalTypes)*transmission rate 27 and above 
 fraction of partners 27 years and older women that are in 27 years and older= 
0.915 
 Fraction of partners of 12 to 26 year old women that are in 12 to 26 year of age= 
0.33 
 "Aging females <12 FiveAdditionalTypes"= "Female <12 
FiveAdditionalTypes"/"mean years of aging for <12 years old" 
 "Aging of female <12"= "Females <12 quad"/"mean years of aging for <12 years 
old" 
 "mean years of aging for <12 years old"= 12 
 reg3 27 and above quad= CIN3 27 and above quad*Rate of Reg CIN3 to CIN1 
quad 
 Fraction of CIN1 successfully cured= 0.96 




 regression2 12to26 quad= Rate of Reg CIN3 to CIN2 quad*CIN3 12 to 26 quad 
 Regression3 12to26 quad= Rate of Reg CIN3 to CIN1 quad*CIN3 12 to 26 quad 
 Rate of Reg CIN3 to CIN2 quad= 0.03 
 regression1 12to26 quad= Rate of regression CIN2 to CIN1 quad*CIN2 12 to 26 
quad 
 reg1 27 and above quad= CIN2 27 and above quad*Rate of regression CIN2 to 
CIN1 quad 
 Rate of Reg CIN3 to CIN1 quad= 0.03 
 Fraction of CIN3 successfully cured= 0.92 
 Rate of regression CIN2 to CIN1 quad= 0.133 
 Fraction of CIN2 successfully cured= 0.92 
 CIN3 to cervical cancer hazard rate quad= 0.546 
 progression1 among 12 to 26 quad= HPV infected to CIN1 hazard rate 
quad*HPV infected 12 to 26 quad 
 progression2 among 12 to 26 quad= CIN1 to CIN2 hazard rate quad*CIN1 12 to 
26 quad 
 progression3 among 12 to 26 quad= CIN2 to CIN3 hazard rate quad*CIN2 12 to 
26 quad 
 HPV infected to CIN1 hazard rate quad= 0.1692 
 prog2 27and above quad= CIN1 to CIN2 hazard rate quad*CIN1 27 and above 
quad 
 prog3 27and above quad= CIN2 to CIN3 hazard rate quad*CIN2 27 and above 
quad 
 CIN2 to CIN3 hazard rate quad=0.252 
 prog1 27and above quad= HPV infected to CIN1 hazard rate quad*HPV infected 
27and above quad 
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 CIN1 to CIN2 hazard rate quad= 0.2448 
 "Aging into CIN1 27&above quad"= aging CIN1 12to26 quad 
 aging into CIN1 FiveAdditionalTypes= CIN1 12 to 26 FiveAdditionalTypes aging 
 Aging into CIN2 27 and above quad= aging CIN2 12to 26 quad 
 aging into cin2 FiveAdditionalTypes= CIN2 12to26 FiveAdditionalTypes aging 
 "Aging into CIN3 27&above quad"= Aging CIN3 12 to 26 FiveAdditionalTypes 
 aging into cin3 FiveAdditionalTypes= CIN3 12 to 26 FiveAdditionalTypes aging 
 aging into hpv infected FiveAdditionalTypes= hpv infected 12 to 
26FiveAdditionalTypes aging 
 Aging into susceptible 27= aging susceptible 12to 26 quad 
 aging into susceptible 27 and FiveAdditionalTypes= Susceptible 12 to 26 
FiveAdditionalTypes aging 
 CIN1 12 to 26 FiveAdditionalTypes aging= CIN1 12 to26 
FiveAdditionalTypes/mean years until aging 
 ratio of total population to total population of women=2 
 mean partner acquistion 12 to 26= 1.64 
 aging CIN1 12to26 quad= CIN1 12 to 26 quad/mean years until aging 
 aging CIN2 12to 26 quad= CIN2 12 to 26 quad/mean years until aging 
 aging hpv infected 12 to 26 quad= HPV infected 12 to 26 quad/mean years until 
aging 
 aging susceptible 12to 26 quad=Susceptible12to26 quad/mean years until aging 
 Susceptible 12 to 26 FiveAdditionalTypes aging= susceptible 12 to26 
FiveAdditionalTypes/mean years until aging 
 CIN2 12to 26 FiveAdditionalTypes= INTEG (prog2 
12to26FiveAdditionalTypes+reg2 26no-CIN2 deaths 12to 26 
FiveAdditionalTypes-clearance2 12to 26 FiveAdditionalTypes-prog3 12 to 
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26FiveAdditionalTypes-reg1 12 to 26FiveAdditionalTypes-rx2 12to26 
FiveAdditionalTypes-CIN2 12to26 FiveAdditionalTypes aging,0) 
 CIN2 12to26 FiveAdditionalTypes aging= CIN2 12to 26 
FiveAdditionalTypes/mean years until aging 
 hpv infected 12 to 26FiveAdditionalTypes aging= HPV infected 12to26 
FiveAdditionalTypes/mean years until aging 
 CIN3 12 to 26 FiveAdditionalTypes aging= CIN3 12to26 
FiveAdditionalTypes/mean years until aging 
 CIN2 12 to 26 quad= INTEG (+progression2 among 12 to 26 quad+regression2 
12to26 quad-clearance2 among 12to26 quad-progression3 among 12 to 26 
quad-regression1 12to26 quad-rx2 12to26 quad-aging CIN2 12to 26 quad-deaths 
of CIN2 12 to 26 quad,0) 
 Aging CIN3 12 to 26 FiveAdditionalTypes= CIN3 12 to 26 quad/mean years until 
aging 
 mean years until aging= 15 
 birth rate for female babies= (0.0124 / 2) 
 death rate 12 to 26= 0.000647 
 "total infected HPV 16 &18"= HPV infected 12 to 26 per 100000 quad+hpv 
infected 27 and above per 100000 quad 
 "total infected (5 additional types)"= hpv infected 12 to 26FiveAdditionalTypes per 
100000+HPV infected FiveAdditionalTypes per 100000 
 "total CIN1 HPV 16&18"= CIN1 12to26 per 100000 quad+"CIN1 27&above per 
100000 quad" 
 "total CIN1 (5 additional types)"= CIN1 26FiveAdditionalTypes per 100000+"CIN1 
27& above FiveAdditionalTypes per 100000" 
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 "total CIN2 HPV 16 &18"= CIN2 12to26 quad per 100000+CIN2 27 and above 
per 100000 quad 
 "total CIN2 (5 additional types)"= CIN2 12 to 26per 100000 
FiveAdditionalTypes+"CIN2 27&above FiveAdditionalTypes per 100000" 
 "total CIN3 HPV 16&18"= CIN3 among 12 to 26 per 100000 quad+CIN3 27 and 
above per 100000 quad 
 "total CIN3 (5 additional types)"= CIN3 12 to 26 per 100000 
FiveAdditionalTypes+CIN3 FiveAdditionalTypes per 100000 
 total infected= HPV infected FiveAdditionalTypes per 100000+HPV infected 12 to 
26 per 100000 quad+ hpv infected 12 to 26FiveAdditionalTypes per 100000+hpv 
infected 27 and above per 100000 quad 
 total CIN 1= CIN1 12to26 per 100000 quad+"CIN1 27& above 
FiveAdditionalTypes per 100000"+CIN1 26FiveAdditionalTypes per 
100000+"CIN1 27&above per 100000 quad" 
 "infection 27&above quad"= force of infection 27 and above quad*Susceptible 
27and above quad 
 infection 12to26FiveAdditionalTypes= force of infection 12 to 26 
FiveAdditionalTypes*susceptible 12 to26 FiveAdditionalTypes 
 total CIN2= "CIN2 27&above FiveAdditionalTypes per 100000"+CIN2 12to26 
quad per 100000+CIN2 12 to 26per 100000 FiveAdditionalTypes+CIN2 27 and 
above per 100000 quad 
 total CIN3= CIN3 FiveAdditionalTypes per 100000+CIN3 among 12 to 26 per 
100000 quad+CIN3 12 to 26 per 100000 FiveAdditionalTypes+CIN3 27 and 
above per 100000 quad 
 screening rate FiveAdditionalTypes= 0.73 
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 "infection 27&above FiveAdditionalTypes"= force of infection 27 and above 
FiveAdditionalTypes*Susceptible 27and above FiveAdditionalTypes 
 infection rate among 12to26 quad= force of infection 12to26 
quad*Susceptible12to26 quad 
 Ref Rate of clearance of HPV infected quad 12 to 26= 0.3619 
 mean partner acquisition rate 27 and above= 1.19 
 screening rate= 0.73 
 sensitivity CIN1= 0.28 
 sensitivity CIN2and CIN3= 0.59 
 transmission rate 27 and above= 0.4 
 
 
HPV Model Equations for White Population 
 cumulative count of cancer cases nonavalent= Cumulative cervical cancer cases 
12 to 26 FiveAdditionalTypes+Cumulative Cervical Cancer cases 27 and above 
FiveAdditionalTypes+Cumulative cervical cancer cases 12 to 26 
quad+"cumulative cervical cancer cases quad 27&above" 
 "Cancer cases lived per life year per 100000(five adiditional types)"= cancer 
cases lived per life year five additional types*100000 
 "Cancer cases lived per life year per 100,000 (nona)"= cancer cases lived per life 
year nonavalent*100000 
 "Cancer cases lived per life year per 100,000 quad"= Cancer cases lived per life 
year quad*100000 
 prospective nona vaccination rate= 0.053 
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 "vacc rate (FiveAdditionalTypes)"= IF THEN ELSE(Time <8, 0 , prospective nona 
vaccination rate ) 
 cumulative life years lived five additional types= INTEG (total population five 
additional types,0) 
 cumulative cervical cancer cases count five additional types= Cumulative cervical 
cancer cases 12 to 26 FiveAdditionalTypes+Cumulative Cervical Cancer cases 
27 and above FiveAdditionalTypes 
 cancer cases lived per life year five additional types= zidz(cumulative cervical 
cancer cases count five additional types,cumulative life years lived five additional 
types) 
 total population of women quad= total population of women quadrivalent 
 cumulative count of cervical cancer cases of quad= Cumulative cervical cancer 
cases 12 to 26 quad+"cumulative cervical cancer cases quad 27&above" 
 total population nona= total population nonavalent 
 cumulative life years lived nonavalent= INTEG (total population nona, 0) 
 cumulative life years lived quad= INTEG (total population of women quad,0) 
 Cancer cases lived per life year quad=zidz(cumulative count of cervical cancer 
cases of quad, cumulative life years lived quad) 
 total population five additional types=total population of women 
FiveAdditionalTypesvalent 
 total population nonavalent= total population of women 12 to 26 
FiveAdditionalTypesvalent+ total population of women 27 and above 
FiveAdditionalTypesvalent 
 cancer cases lived per life year nonavalent= zidz(cumulative count of cancer 
cases nonavalent,cumulative life years lived nonavalent) 
 Ref Rate of clearance of HPV infected quad 27 and above= 0.483 
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 clearance3 FiveAdditionalTypes= Rate of clearance of CIN3 five additional types 
27 and above*CIN3 27 and above FiveAdditionalTypes 
 "clearance of infection 27&above FiveAdditionalTypes"= Rate of clearance of 
HPV infected five additional types 27 and above*HPV infected 27 and above 
FiveAdditionalTypes 
 clearance2 FiveAdditionalTypes= Rate of clearance of CIN2five additional types 
27 and above*CIN2 27 and above FiveAdditionalTypes 
 Rate of clearance of CIN3 five additional types 27 and above= 0.11 
 Ref rate of clearance of CIN1 quad 27 and above= 0.483 
 clearance of HPV infected 27 and above quad=HPV infected 27and above 
quad*Ref Rate of clearance of HPV infected quad 27 and above*Coefficient of 
clearance for quad 
 "clearance1 27 & above FiveAdditionalTypes"= Rate of clearance of CIN1 five 
additional types 27 and above*CIN1 27 and above FiveAdditionalTypes 
 Ref rate of clearance of CIN3 quad 27 and above= 0.11 
 Rate of clearance of HPV infected five additional types 27 and above= 0.41125 
 Rate of clearance of CIN1 five additional types 27 and above= 0.329 
 "clear2 27 & above quad"= Ref rate of clearance of CIN2 quad 27 and 
above*CIN2 27 and above quad*Coefficient of clearance for quad 
 "clear3 27&above quad"= Ref rate of clearance of CIN3 quad 27 and 
above*CIN3 27 and above quad*Coefficient of clearance for quad 
 "clearance1 27&above quad"= Ref rate of clearance of CIN1 quad 27 and 
above*CIN1 27 and above quad*Coefficient of clearance for quad 
 Ref rate of clearance of CIN2 quad 27 and above= 0.21 
 Rate of clearance of CIN2five additional types 27 and above= 0.21 
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 rx1 12to26 FiveAdditionalTypes= Fraction of CIN1 sucessfully cured*screening 
rate FiveAdditionalTypes*sensitivity CIN1 *CIN1 12 to26 FiveAdditionalTypes 
 "rx3 27&above quad"= Fraction of CIN3 successfully cured*sensitivity CIN2and 
CIN3*screening rate*CIN3 27 and above quad 
 "rx2 27&above quad"= screening rate*Fraction of CIN2 successfully 
cured*sensitivity CIN2and CIN3*CIN2 27 and above quad 
 "rx1 27&above quad"= Fraction of CIN1 sucessfully cured*screening 
rate*sensitivity CIN1*CIN1 27 and above quad 
 rx2 12to26 FiveAdditionalTypes= Fraction of CIN2 successfully cured*screening 
rate FiveAdditionalTypes*sensitivity CIN2and CIN3*CIN2 12to 26 
FiveAdditionalTypes 
 rx3 12to26 FiveAdditionalTypes=Fraction of CIN3 successfully cured*screening 
rate FiveAdditionalTypes*sensitivity CIN2and CIN3*CIN3 12to26 
FiveAdditionalTypes 
 clearance1 among 12to26 quad= Ref Rate of clearance of CIN1 quad 12 to 
26*CIN1 12 to 26 quad*Coefficient of clearance for quad 
 clearance3 among 12 to 26 quad= Ref Rate of clearance of CIN3 quad 12 to 
26*CIN3 12 to 26 quad*Coefficient of clearance for quad 
 clearance2 among 12to26 quad= Ref Rate of clearance of CIN2 quad 12 to 
26*CIN2 12 to 26 quad*Coefficient of clearance for quad 
 Coefficient of clearance for quad= 0.74 
 HPV infected clearance rate 12 to 26 quad= HPV infected 12 to 26 quad*Ref 
Rate of clearance of HPV infected quad 12 to 26*Coefficient of clearance for 
quad 
 prog2 12to26FiveAdditionalTypes= CIN1 to CIN2 hazard rate 
FiveAdditionalTypes*CIN1 12 to26 FiveAdditionalTypes 
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 "prog2 27& above FiveAdditionalTypes"= CIN1 to CIN2 hazard rate 
FiveAdditionalTypes*CIN1 27 and above FiveAdditionalTypes 
 clearance2 12to 26 FiveAdditionalTypes= Rate of clearance of CIN2 
FiveAdditionalTypes 12 to 26*CIN2 12to 26 FiveAdditionalTypes 
 prog3 12 to 26FiveAdditionalTypes= CIN2 to CIN3 hazard rate 
FiveAdditionalTypes*CIN2 12to 26 FiveAdditionalTypes 
 clearance3 12to26 FiveAdditionalTypes= Rate of clearance of CIN3 
FiveAdditionalTypes 12 to 26*CIN3 12to26 FiveAdditionalTypes 
 "prog1 27 & above FiveAdditionalTypes"= HPV infected to CIN1 hazard rate 
FiveAdditionalTypes*HPV infected 27 and above FiveAdditionalTypes 
 Rate of clearance of CIN3 FiveAdditionalTypes 12 to 26= 0.11 
 clearance hpv infected 12 to 26FiveAdditionalTypes= Rate of clearance of HPV 
infected FiveAdditionalTypes 12 to 26*HPV infected 12to26 FiveAdditionalTypes 
 Rate of clearance of HPV infected FiveAdditionalTypes 12 to 26= 0.27965 
 CIN3 to cervical cancer hazard rate FiveAdditionalTypes= 0.42 
 CIN1 12 to26 FiveAdditionalTypes= INTEG (prog1 12 to 
26FiveAdditionalTypes+reg1 12 to 26FiveAdditionalTypes+reg3 12 to 
26FiveAdditionalTypes-CIN1 12 to 26 FiveAdditionalTypes aging-CIN1 deaths 
12to 26FiveAdditionalTypes-clearance1 12to26 FiveAdditionalTypes -prog2 
12to26FiveAdditionalTypes-rx1 12to26 FiveAdditionalTypes, Initially HPV 
infected 12 to 26 women with FiveAdditionalTypes who are at CIN1) 
 "prog3 27& above FiveAdditionalTypes"= CIN2 to CIN3 hazard rate 
FiveAdditionalTypes*CIN2 27 and above FiveAdditionalTypes 
 Rate of clearance of CIN1 FiveAdditionalTypes 12 to 26=0.329 
 CIN2 to CIN3 hazard rate FiveAdditionalTypes= 0.14 
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 "prog4 27&above FiveAdditionalTypes"= CIN3 to cervical cancer hazard rate 
FiveAdditionalTypes*CIN3 27 and above FiveAdditionalTypes 
 HPV infected to CIN1 hazard rate FiveAdditionalTypes= 0.094 
 CIN1 to CIN2 hazard rate FiveAdditionalTypes= 0.136 
 progression4 12to26 FiveAdditionalTypes= CIN3 12to26 
FiveAdditionalTypes*CIN3 to cervical cancer hazard rate FiveAdditionalTypes 
 HPV infected 12to26 FiveAdditionalTypes= INTEG (infection 
12to26FiveAdditionalTypes-clearance hpv infected 12 to 26FiveAdditionalTypes-
deaths infected 12to 26 FiveAdditionalTypes-hpv infected 12 to 
26FiveAdditionalTypes aging-prog1 12 to 26FiveAdditionalTypes, initially infected 
HPV women 12 to 26 from US census for FiveAdditionalTypes that are not CIN1) 
 clearance1 12to26 FiveAdditionalTypes= Rate of clearance of CIN1 
FiveAdditionalTypes 12 to 26*CIN1 12 to26 FiveAdditionalTypes 
 Rate of clearance of CIN2 FiveAdditionalTypes 12 to 26= 0.21 
 prog1 12 to 26FiveAdditionalTypes= HPV infected to CIN1 hazard rate 
FiveAdditionalTypes*HPV infected 12to26 FiveAdditionalTypes 
 total cumulative cervical cancer cases 5 additional types= Cumulative cervical 
cancer cases 12 to 26 FiveAdditionalTypes+Cumulative Cervical Cancer cases 
27 and above FiveAdditionalTypes 
 total cumulative cervical cancer cases quad= Cumulative cervical cancer cases 
12 to 26 quad+"cumulative cervical cancer cases quad 27&above" 
 Total cumulative cervical cancer nona=Cumulative cervical cancer cases 12 to 
26 FiveAdditionalTypes+Cumulative cervical cancer cases 12 to 26 
quad+Cumulative Cervical Cancer cases 27 and above 
FiveAdditionalTypes+"cumulative cervical cancer cases quad 27&above" 
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 women 27 and above who have been vaccinated quad= INTEG (aging into 
women 27 and above who have been vaccinated quad-death of women 27 and 
above who have been vaccinated quad,0) 
 aging into women 27 and above who have been vaccinated 
FiveAdditionalTypes= aging women 12 to 26 who have been vaccinated 
FiveAdditionalTypes 
 aging into women 27 and above who have been vaccinated quad= aging number 
of women 12 to 26 who are vaccinated quad 
 death of women 27 and above who have been vaccinated quad= women 27 and 
above who have been vaccinated quad*"death rate for 27&above" 
 death of number of women 12 to 26 who are vaccinated FiveAdditionalTypes= 
women 12 to 26 FiveAdditionalTypes who have been vaccinated*death rate 12 to 
26 
 new vaccination of 12to 26 FiveAdditionalTypes= total population of women 12 to 
26 FiveAdditionalTypesvalent*"vacc rate (FiveAdditionalTypes)" 
 death of women 27 and above who have been vaccinated FiveAdditionalTypes= 
 Women 27 and above who have been vaccinated FiveAdditionalTypes*"death 
rate for 27&above" 
 Women 27 and above who have been vaccinated FiveAdditionalTypes= INTEG 
(aging into women 27 and above who have been vaccinated 
FiveAdditionalTypes-death of women 27 and above who have been vaccinated 
FiveAdditionalTypes, 0) 
 fraction of women 12 to 26 who have been vaccinated = women 12 to 26 





 aging women 12 to 26 who have been vaccinated FiveAdditionalTypes= women 
12 to 26 FiveAdditionalTypes who have been vaccinated/mean years until aging 
 women 12 to 26 FiveAdditionalTypes who have been vaccinated= INTEG (new 
vaccination of 12to 26 FiveAdditionalTypes-death of number of women 12 to 26 
who are vaccinated FiveAdditionalTypes-aging women 12 to 26 who have been 
vaccinated FiveAdditionalTypes,0) 
 Women 12 to 26 who have been vaccinated quad= INTEG (new vaccinations of 
12 to 26 women-aging number of women 12 to 26 who are vaccinated quad-
death of number of women 12 to 26 who are vaccinated, 0) 
 new vaccinations of 12 to 26 women= total population of women 12 to 26 
quadrivalent*vacc rate 
 aging number of women 12 to 26 who are vaccinated quad= Women 12 to 26 
who have been vaccinated quad/mean years until aging 
 death of number of women 12 to 26 who are vaccinated= Women 12 to 26 who 
have been vaccinated quad*death rate 12 to 26 
 vacc quad= Susceptible12to26 quad* vacc rate*vaccine efficacy 
 fraction of women 12 to 26 who have been vaccinated quad= 
 Women 12 to 26 who have been vaccinated quad/total population of women 12 
to 26 quadrivalent 
 vacc rate= 0.053 
 fraction of susceptible women 27 and above FiveAdditionalTypes= Susceptible 
27and above FiveAdditionalTypes/total population of women 27 and above 
FiveAdditionalTypesvalent 
 Fraction of women susceptible 12 to 26 quad= Susceptible12to26 quad/total 
population of women 12 to 26 quadrivalent 
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 Fraction of women susceptible 12 to 26 FiveAdditionalTypes= susceptible 12 
to26 FiveAdditionalTypes/total population of women 12 to 26 
FiveAdditionalTypesvalent 
 fraction of women that are susceptible for 27 and above quad= Susceptible 
27and above quad/total population of women 27 and above quadrivalent 
 Inital 27 and above CIN1 infected women from HPV quad infected= fraction of 
women 27 and above who were infected with quad and are CIN1*Initial 27 and 
above HPV quad infected women from US census including CIN1 
 HPV infected 27 and above FiveAdditionalTypes= INTEG (aging into hpv infected 
FiveAdditionalTypes+"infection 27&above FiveAdditionalTypes"-"clearance of 
infection 27&above FiveAdditionalTypes"-infected 27 and above deaths 
FiveAdditionalTypes-"prog1 27 & above FiveAdditionalTypes", initially HPV 
infected women 27 and above not CIN1 FiveAdditionalTypes) 
 fraction of women 27 from US census who are infected with HPV quad strain= 
0.24 
 initially infected HPV women 12 to 26 from US census for FiveAdditionalTypes 
that are not CIN1= Initially infected HPV women 12 to 26 from US census 
including CIN1 for FiveAdditionalTypes-Initially HPV infected 12 to 26 women 
with FiveAdditionalTypes who are at CIN1 
 Initially susceptible women 12 to 26 from US census=Total initial population 12 to 
26 from US census-(Initially CIN1 infected women from HPV infected 
women+Initially HPV infected women from US census for quad not CIN1) 
 HPV infected 12 to 26 quad= INTEG (infection rate among 12to26 quad-aging 
hpv infected 12 to 26 quad-deaths of infected 12 to 26 quad-HPV infected 
clearance rate 12 to 26 quad-progression1 among 12 to 26 quad, Initially HPV 
infected women from US census for quad not CIN1) 
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 Initially susceptible women 12 to 26 from US census for FiveAdditionalTypes= 
Total initial population 12 to 26 from US census-(Initially HPV infected 12 to 26 
women with FiveAdditionalTypes who are at CIN1+initially infected HPV women 
12 to 26 from US census for FiveAdditionalTypes that are not CIN1) 
 Initially HPV infected women 27 and above from US census for quad not CIN1= 
Initial 27 and above HPV quad infected women from US census including CIN1-Inital 
27 and above CIN1 infected women from HPV quad infected 
 Initial susceptible women 27 and above from US census FiveAdditionalTypes= 
total initial population 27 and above from US census-(initially HPV infected 
women 27 and above not CIN1 FiveAdditionalTypes +Initial 27 and above at 
CIN1 from HPV infected women with FiveAdditionalTypes strain) 
 total population of women 27 and above quadrivalent= HPV infected 27and 
above quad+ Susceptible 27and above quad+CIN1 27 and above quad +CIN2 
27 and above quad+CIN3 27 and above quad+ Immune via vaccination 27 and 
above quad+ Immune after HPV clearance 27 and above quad 
 Initially susceptible women 27 and above from US census= total initial population 
27 and above from US census-(Initially HPV infected women 27 and above from 
US census for quad not CIN1+Initial 27 and above CIN1 infected women from 
HPV quad infected) 
 Initial 27 and above HPV quad infected women from US census including CIN1= 
fraction of women 27 from US census who are infected with HPV quad 
strain*total initial population 27 and above from US census 
 initially HPV infected women 27 and above not CIN1 FiveAdditionalTypes= 
Initially infected 27 and above with HPV FiveAdditionalTypes including CIN1-




 total population of women 12 to 26 quadrivalent= HPV infected 12 to 26 quad+ 
Susceptible12to26 quad+CIN1 12 to 26 quad+ CIN2 12 to 26 quad+CIN3 12 to 
26 quad+ Immune via vaccination 12to26 quad+ Immune after HPV infection 
clearance 12 to 26 quad 
 total population of women 12 to 26 FiveAdditionalTypesvalent= CIN1 12 to26 
FiveAdditionalTypes+CIN2 12to 26 FiveAdditionalTypes+CIN3 12to26 
FiveAdditionalTypes+HPV infected 12to26 FiveAdditionalTypes +susceptible 12 
to26 FiveAdditionalTypes+immune via vacc 12 to 26 FiveAdditionalTypes 
+Immune after HPV infection 12 to26 FiveAdditionalTypes 
 Initially HPV infected women from US census for quad not CIN1= Initially HPV 
infected women from US census for quad including CIN1-Initially CIN1 infected 
women from HPV infected women 
 total population of women 27 and above FiveAdditionalTypesvalent= CIN1 27 
and above FiveAdditionalTypes+CIN2 27 and above FiveAdditionalTypes+CIN3 
27 and above FiveAdditionalTypes +HPV infected 27 and 
aboveFiveAdditionalTypes+ Susceptible 27and above FiveAdditionalTypes 
+immune via vaccination 27 and above FiveAdditionalTypes +Immune after HPV 
infection 27and above FiveAdditionalTypes 
 HPV infected 27and above quad= INTEG (Aging into HPV infected 27+"infection 
27&above quad"-clearance of HPV infected 27 and above quad-"deaths of 
infected 27&above quad"-prog1 27and above quad, Initially HPV infected women 
27 and above from US census for quad not CIN1) 
 Immune after HPV clearance 27 and above quad= INTEG (aging into immune 
after HPV clearance 27 and above quad+"clear2 27 & above quad"+"clear3 
27&above quad"+clearance of HPV infected 27 and above quad+"clearance1 
27&above quad"+"rx1 27&above quad"+"rx2 27&above quad"+"rx3 27&above 
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quad"-death of immune after HPV clearance 27 and above-waning immunity after 
infection among 27 and above quad,0) 
 Susceptible 27and above quad= INTEG (Aging into susceptible 27+waning 
immunity after infection among 27 and above quad-"infection 27&above quad" -
susceptible27 deaths+ "waning immunity among 27 and above (quad)", Initially 
susceptible women 27 and above from US census) 
 Immune after HPV infection 27and above FiveAdditionalTypes= INTEG (aging 
into immune after HPV infection 27 and above FiveAdditionalTypes+"clearance 
of infection 27&above FiveAdditionalTypes"+"clearance1 27 & above 
FiveAdditionalTypes"+clearance2 FiveAdditionalTypes+clearance3 
FiveAdditionalTypes+"rx1 27& above FiveAdditionalTypes"+"rx2 27& above 
FiveAdditionalTypes"+"rx3 27&above FiveAdditionalTypes"-Deaths of immune 
after vaccination 27 and above FiveAdditionalTypes-waning immunity after 
infection 27 and above nano, 0) 
 susceptible 12 to26 FiveAdditionalTypes= INTEG ("Aging females <12 
FiveAdditionalTypes"+waning immunity after vaccination 12to 26 nano +waning 
immunity of 27 and above FiveAdditionalTypes-death of susceptible 12to 26no-
infection 12to26FiveAdditionalTypes-Susceptible 12 to 26 FiveAdditionalTypes 
aging-vacc FiveAdditionalTypes, Initially susceptible women 12 to 26 from US 
census for FiveAdditionalTypes) 
 immune via vacc 12 to 26 FiveAdditionalTypes= INTEG (vacc 
FiveAdditionalTypes-aging of immune 12 to 26 FiveAdditionalTypes-deaths of 
immune 12 to 26 FiveAdditionalTypes -waning immunity after vaccination 12to 26 
nano-waning immunity after vaccination 12to 26 nano,0) 
157 
 
 "rx2 27& above FiveAdditionalTypes"= Fraction of CIN2 successfully 
cured*screening rate FiveAdditionalTypes*sensitivity CIN2and CIN3 *CIN2 27 
and above FiveAdditionalTypes 
 Immune via vaccination 12to26 quad= INTEG (vacc quad-aging immune via 
vaccination 12 to 26 quad-deaths of immune 12 to 26 quad-waning immunity 
after vaccination among 12to26quad, 0) 
 Susceptible12to26 quad= INTEG ("Aging of female <12"-aging susceptible 12to 
26 quad-deaths of susceptible 12 to 26 quad-infection rate among 12to26 quad-
vacc quad+ Waning immunity after infection 12 to 26 quad +waning immunity 
after vaccination among 12to26quad, Initially susceptible women 12 to 26 from 
US census) 
 waning immunity after infection among 27 and above quad= Immune after HPV 
clearance 27 and above quad/Time until waning immunity after infection 
 Susceptible 27and above FiveAdditionalTypes= INTEG (aging into susceptible 
27 and FiveAdditionalTypes+waning immunity after infection 27 and above nano-
"infection 27&above FiveAdditionalTypes"-susceptible 27 and above 
deaths+waning immunity after vaccination 27 and above FiveAdditionalTypes, 
Initial susceptible women 27 and above from US census FiveAdditionalTypes) 
 time until waning immunity after vaccination= 10 
 waning immunity after vaccination among 12to26quad= (Immune via vaccination 
12to26 quad/time until waning immunity after vaccination) *"enable waning 
immunity after vaccination?" 
 "enable waning immunity after vaccination?"=0 
 waning immunity after vaccination 12to 26 nano= (immune via vacc 12 to 26 
FiveAdditionalTypes/time until waning immunity after vaccination)*"enable 
waning immunity after vaccination?" 
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 rx2 12to26 quad= screening rate*sensitivity CIN2and CIN3*Fraction of CIN2 
successfully cured*CIN2 12 to 26 quad 
 waning immunity after vaccination 27 and above FiveAdditionalTypes= (immune 
via vaccination 27 and above FiveAdditionalTypes/time until waning immunity 
after vaccination) *"enable waning immunity after vaccination?" 
 waning immunity after infection 27 and above nano= Immune after HPV infection 
27and above FiveAdditionalTypes/Time until waning immunity after infection 
 "waning immunity among 27 and above (quad)"= (Immune via vaccination 27 and 
above quad/time until waning immunity after vaccination) *"enable waning 
immunity after vaccination?" 
 fraction of women 12to26 immune via vaccination quad= Immune via vaccination 
12to26 quad/total population of women 12 to 26 quadrivalent 
 waning immunity of 27 and above FiveAdditionalTypes= Immune after HPV 
infection 12 to26 FiveAdditionalTypes/Time until waning immunity after infection 
 aging of immune after HPV infection 12 to 26 FiveAdditionalTypes= Immune after 
HPV infection 12 to26 FiveAdditionalTypes/mean years until aging 
 aging into immune after HPV clearance 27 and above quad= aging of immune 
after HPV infection clearance 12 to 26 quad 
 Immune after HPV infection 12 to26 FiveAdditionalTypes= INTEG (clearance1 
12to26 FiveAdditionalTypes+clearance2 12to 26FiveAdditionalTypes+clearance3 
12to26 FiveAdditionalTypes +rx1 12to26 FiveAdditionalTypes+rx2 12to26 
FiveAdditionalTypes+rx3 12to26 FiveAdditionalTypes-deaths of immune after 
HPV infection 12 to 26 FiveAdditionalTypes-waning immunity of 27 and above 
FiveAdditionalTypes -aging of immune after HPV infection 12 to 26 
FiveAdditionalTypes+clearance hpv infected 12 to 26FiveAdditionalTypes,0) 
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 deaths of immune after HPV infection 12 to 26 FiveAdditionalTypes= death rate 
12 to 26*Immune after HPV infection 12 to26 FiveAdditionalTypes 
 Deaths of immune after vaccination 27 and above FiveAdditionalTypes="death 
rate for 27&above"*Immune after HPV infection 27and above 
FiveAdditionalTypes 
 aging into immune after HPV infection 27 and above FiveAdditionalTypes= aging 
of immune after HPV infection 12 to 26 FiveAdditionalTypes 
 Waning immunity after infection 12 to 26 quad= Immune after HPV infection 
clearance 12 to 26 quad/Time until waning immunity after infection 
 Time until waning immunity after infection=5 
 incidence of cc per 100000 12to26= (Progression4 among 12 to 26 quad/total 
population of women 12 to 26 quadrivalent) * 100000 
 aging of immune after HPV infection clearance 12 to 26 quad= Immune after 
HPV infection clearance 12 to 26 quad/mean years until aging 
 deaths of immune after HPV infection clearance= Immune after HPV infection 
clearance 12 to 26 quad*death rate 12 to 26 
 death of immune after HPV clearance 27 and above= Immune after HPV 
clearance 27 and above quad*"death rate for 27&above" 
 Immune after HPV infection clearance 12 to 26 quad= INTEG (HPV infected 
clearance rate 12 to 26 quad+clearance1 among 12to26 quad+clearance2 
among 12to26 quad+clearance3 among 12 to 26 quad+rx1 12to26 quad+rx2 
12to26 quad+rx3 12 to 26 quad-Waning immunity after infection 12 to 26 quad-
aging of immune after HPV infection clearance 12 to 26 quad-deaths of immune 




 force of infection 12to26 quad= mean partner acquisition 12 to 26*(Fraction of 
partners of 12 to 26 year old women that are in 12 to 26 year of age* HPV 
prevalence 12 to 26 quad + (1-Fraction of partners of 12 to 26 year old women 
that are in 12 to 26 year of age) * HPV prevalence 27 and above quad) 
*transmission rate 12to26 
 force of infection 12 to 26 FiveAdditionalTypes= mean partner acquisition 12 to 
26*(Fraction of partners of 12 to 26 year old women that are in 12 to 26 year of 
age* HPV prevalence 12to26FiveAdditionalTypes + (1-Fraction of partners of 12 
to 26 year old women that are in 12 to 26 year of age) * HPV prevalence 27 and 
above FiveAdditionalTypes)* transmission rate 12to26 
 transmission rate 12to26= 0.4 
 CIN3 27 and above deaths FiveAdditionalTypes= "death rate for 
27&above"*CIN3 27 and above FiveAdditionalTypes 
 CIN3 12to26 FiveAdditionalTypes= INTEG (prog3 12 to 26FiveAdditionalTypes-
CIN3 12 to 26 FiveAdditionalTypes aging-CIN3 deaths 
12to26FiveAdditionalTypes-clearance3 12to26 FiveAdditionalTypes-reg2 26no-
reg3 12 to 26FiveAdditionalTypes-rx3 12to26 FiveAdditionalTypes+prog3 12 to 
26FiveAdditionalTypes-progression4 12to26 FiveAdditionalTypes,0) 
 "CIN3 27 & above death quad"= "death rate for 27&above"*CIN3 27 and above 
quad 
 CIN3 27 and above FiveAdditionalTypes= INTEG (aging into cin3 
FiveAdditionalTypes+"prog3 27& above FiveAdditionalTypes"-CIN3 27 and 
above deaths FiveAdditionalTypes-clearance3 FiveAdditionalTypes-"prog4 
27&above FiveAdditionalTypes"-"reg2 27 &above FiveAdditionalTypes" -"reg3 
27&above FiveAdditionalTypes"-"rx3 27&above FiveAdditionalTypes"+"prog3 
27& above FiveAdditionalTypes"-"prog4 27&above FiveAdditionalTypes", 0) 
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 CIN3 27 and above quad= INTEG ("Aging into CIN3 27&above quad"+prog3 
27and above quad-"CIN3 27 & above death quad"- "clear3 27&above quad"-
"reg2 27&above quad"-reg3 27 and above quad-"rx3 27&above quad"+prog3 
27and above quad-prog4 27and above quad, 0) 
 "CIN1 27&above deaths quad"= "death rate for 27&above"*CIN1 27 and above 
quad 
 immune via vacc deaths quad= Immune via vaccination 27 and above 
quad*"death rate for 27&above" 
 Cumulative cervical cancer cases 12 to 26 FiveAdditionalTypes= INTEG 
(progression4 12to26 FiveAdditionalTypes,0) 
 Cumulative Cervical Cancer cases 27 and above FiveAdditionalTypes= INTEG 
("prog4 27&above FiveAdditionalTypes",0) 
 "cumulative cervical cancer cases quad 27&above"= INTEG (prog4 27and above 
quad,0) 
 infected 27 and above deaths FiveAdditionalTypes= "death rate for 
27&above"*HPV infected 27 and above FiveAdditionalTypes 
 prog4 27and above quad= CIN3 27 and above quad*CIN3 to cervical cancer 
hazard rate 
 "death rate for 27&above"= 0.00541 
 Progression4 among 12 to 26 quad= CIN3 to cervical cancer hazard rate*CIN3 
12 to 26 quad 
 "CIN1 27 &above deaths FiveAdditionalTypes"=CIN1 27 and above 
FiveAdditionalTypes*"death rate for 27&above" 
 susceptible27 deaths=Susceptible 27and above quad*"death rate for 27&above" 
 "CIN2 27&above deaths FiveAdditionalTypes"=CIN2 27 and above 
FiveAdditionalTypes*"death rate for 27&above" 
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 deaths of immune 27 and above FiveAdditionalTypes="death rate for 
27&above"*immune via vaccination 27 and above FiveAdditionalTypes 
 susceptible 27 and above deaths="death rate for 27&above"*Susceptible 27and 
above FiveAdditionalTypes 
 prog4 27 and above quad per 100000=(prog4 27and above quad/total population 
of women 27 and above quadrivalent)*100000 
 CIN3 12 to 26 quad= INTEG (-Aging CIN3 12 to 26 FiveAdditionalTypes-
clearance3 among 12 to 26 quad-deaths of CIN3 12 to 26 quad-regression2 
12to26 quad-Regression3 12to26 quad-rx3 12 to 26 quad+progression3 among 
12 to 26 quad-Progression4 among 12 to 26 quad,0) 
 CIN2 deaths among 27 and above quad= CIN2 27 and above quad*"death rate 
for 27&above" 
 "deaths of infected 27&above quad"=HPV infected 27and above quad*"death 
rate for 27&above" 
 Cumulative cervical cancer cases 12 to 26 quad= INTEG (Progression4 among 
12 to 26 quad,0) 
 total population of men and women FiveAdditionalTypes= total population of 
women FiveAdditionalTypesvalent*(1+Ratio of male to female population) 
 "Initial susceptible women <12 years FiveAdditionalTypesvalent"= 37112 
 "Female <12 FiveAdditionalTypes"= INTEG (birth FiveAdditionalTypes-"Aging 
females <12 FiveAdditionalTypes"-"death of females <12 years","Initial 
susceptible women <12 years FiveAdditionalTypesvalent") 
 total population of men and women quad=total population of women 
quadrivalent*(1+Ratio of male to female population) 
 birth FiveAdditionalTypes= birth rate for female babies*total population of men 
and women FiveAdditionalTypes 
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 birth quad= total population of men and women quad*birth rate for female babies 
 Ratio of male to female population= 0.98 
 rx3 12 to 26 quad= screening rate*sensitivity CIN2and CIN3*Fraction of CIN3 
successfully cured*CIN3 12 to 26 quad 
 "rx3 27&above FiveAdditionalTypes"= Fraction of CIN3 successfully 
cured*screening rate FiveAdditionalTypes*sensitivity CIN2and CIN3*CIN3 27 
and above FiveAdditionalTypes 
 "rx1 27& above FiveAdditionalTypes"= Fraction of CIN1 sucessfully 
cured*screening rate FiveAdditionalTypes*sensitivity CIN1*CIN1 27 and above 
FiveAdditionalTypes 
 rx1 12to26 quad= sensitivity CIN1*screening rate*Fraction of CIN1 sucessfully 
cured*CIN1 12 to 26 quad 
 HPV infected FiveAdditionalTypes per 100000= (HPV infected 27 and above 
FiveAdditionalTypes/total population of women 27 and above 
FiveAdditionalTypesvalent)*100000 
 CIN3 among 12 to 26 per 100000 quad= (CIN3 12 to 26 quad/total population of 
women 12 to 26 quadrivalent)*100000 
 CIN2 12to26 quad per 100000=(CIN2 12 to 26 quad/total population of women 
12 to 26 quadrivalent)*100000 
 CIN3 FiveAdditionalTypes per 100000= (CIN3 27 and above 
FiveAdditionalTypes/total population of women 27 and above 
FiveAdditionalTypesvalent)*100000 
 CIN2 27 and above per 100000 quad= (CIN2 27 and above quad/total population 
of women 27 and above quadrivalent)*100000 
 CIN1 12to26 per 100000 quad= (CIN1 12 to 26 quad/total population of women 
12 to 26 quadrivalent)*100000 
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 CIN1 26FiveAdditionalTypes per 100000= (CIN1 12 to26 
FiveAdditionalTypes/total population of women 12 to 26 
FiveAdditionalTypesvalent)*100000 
 hpv infected 27 and above per 100000 quad= (HPV infected 27and above 
quad/total population of women 27 and above quadrivalent)*100000 
 "CIN1 27& above FiveAdditionalTypes per 100000"= (CIN1 27 and above 
FiveAdditionalTypes/total population of women 27 and above 
FiveAdditionalTypesvalent)*100000 
 CIN3 12 to 26 per 100000 FiveAdditionalTypes= (CIN3 12to26 
FiveAdditionalTypes/total population of women 12 to 26 
FiveAdditionalTypesvalent)*100000 
 "CIN1 27&above per 100000 quad"= (CIN1 27 and above quad/total population 
of women 27 and above quadrivalent)*100000 
 CIN3 27 and above per 100000 quad= (CIN3 27 and above quad/total population 
of women 27 and above quadrivalent)*100000 
 CIN2 12 to 26per 100000 FiveAdditionalTypes= (CIN2 12to 26 
FiveAdditionalTypes/total population of women 12 to 26 
FiveAdditionalTypesvalent)*100000 
 "total population of women (quad+FiveAdditionalTypes)"=total population of 
women 12 to 26 FiveAdditionalTypesvalent+total population of women 12 to 26 
quadrivalent+total population of women 27 and above 
FiveAdditionalTypesvalent+total population of women 27 and above quadrivalent 
 
 total population= "total population of women (quad+FiveAdditionalTypes)"*ratio of 
total population to total population of women 
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 "CIN2 27&above FiveAdditionalTypes per 100000"= (CIN2 27 and above 
FiveAdditionalTypes/total population of women 27 and above 
FiveAdditionalTypesvalent)*100000 
 HPV infected 12 to 26 per 100000 quad= (HPV infected 12 to 26 quad/total 
population of women 12 to 26 quadrivalent)*100000 
 hpv infected 12 to 26FiveAdditionalTypes per 100000= (HPV infected 12to26 
FiveAdditionalTypes/total population of women 12 to 26 
FiveAdditionalTypesvalent)*100000 
 Aging into HPV infected 27= aging hpv infected 12 to 26 quad 
 "Females <12 quad"= INTEG ( birth quad-"Aging of female <12"-"death of 
females< 12 years of age", "Initial susceptible females <12 quad") 
 "Initial susceptible females <12 quad"= 724633 
 total population of women FiveAdditionalTypesvalent= total population of women 
12 to 26 FiveAdditionalTypesvalent+total population of women 27 and above 
FiveAdditionalTypesvalent 
 "HPV Infection (quad) among 12 to 26 count"= CIN1 12 to 26 quad+CIN2 12 to 
26 quad+CIN3 12 to 26 quad+HPV infected 12 to 26 quad 
 HPV prevalence 27 and above FiveAdditionalTypes= ("HPV infection among 27 
and above (FiveAdditionalTypes) count")/total population of women 27 and 
above FiveAdditionalTypesvalent 
 HPV prevalence 12 to 26 quad=("HPV Infection (quad) among 12 to 26 
count")/total population of women 12 to 26 quadrivalent 
 "HPV infection among 12 to 26 (FiveAdditionalTypes) count"= CIN1 12 to26 
FiveAdditionalTypes+CIN2 12to 26 FiveAdditionalTypes+CIN3 12to26 
FiveAdditionalTypes+HPV infected 12to26 FiveAdditionalTypes 
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 "HPV infection among 27 and above (FiveAdditionalTypes) count"= HPV infected 
27 and above FiveAdditionalTypes+CIN1 27 and above FiveAdditionalTypes+ 
CIN2 27 and above FiveAdditionalTypes+CIN3 27 and above 
FiveAdditionalTypes 
 "HPV infection among 27 and above (quad) count"= CIN1 27 and above 
quad+CIN2 27 and above quad+CIN3 27 and above quad+HPV infected 27and 
above quad 
 HPV prevalence 12to26FiveAdditionalTypes= ("HPV infection among 12 to 26 
(FiveAdditionalTypes) count")/total population of women 12 to 26 
FiveAdditionalTypesvalent 
 HPV prevalence 27 and above quad= ("HPV infection among 27 and above 
(quad) count")/total population of women 27 and above quadrivalent 
 CIN1 12 to 26 quad= INTEG (progression1 among 12 to 26 quad+regression1 
12to26 quad+Regression3 12to26 quad-aging CIN1 12to26 quad-clearance1 
among 12to26 quad-deaths of CIN1 12to26 quad-progression2 among 12 to 26 
quad-rx1 12to26 quad, Initially CIN1 infected women from HPV infected women) 
 CIN1 27 and above FiveAdditionalTypes= INTEG (aging into CIN1 
FiveAdditionalTypes+"prog1 27 & above FiveAdditionalTypes"+"reg1 27&above 
FiveAdditionalTypes"+"reg3 27&above FiveAdditionalTypes"-"CIN1 27 &above 
deaths FiveAdditionalTypes"-"clearance1 27 & above FiveAdditionalTypes"-
"prog2 27& above FiveAdditionalTypes"-"rx1 27& above FiveAdditionalTypes", 
Initial 27 and above at CIN1 from HPV infected women with FiveAdditionalTypes 
strain) 
 total population of women quadrivalent= total population of women 12 to 26 
quadrivalent+total population of women 27 and above quadrivalent 
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 deaths of immune 12 to 26 FiveAdditionalTypes= death rate 12 to 26*immune via 
vacc 12 to 26 FiveAdditionalTypes 
 aging into immune via vaccination 27 and above quad= aging immune via 
vaccination 12 to 26 quad 
 deaths of immune 12to 26 FiveAdditionalTypes= death rate 12 to 26*immune via 
vacc 12 to 26 FiveAdditionalTypes 
 aging immune via vaccination 12 to 26 quad=Immune via vaccination 12to26 
quad/mean years until aging 
 aging into immune via vacc 27 and above FiveAdditionalTypes= aging of immune 
12 to 26 FiveAdditionalTypes 
 immune via vaccination 27 and above FiveAdditionalTypes= INTEG (aging into 
immune via vacc 27 and above FiveAdditionalTypes-deaths of immune 27 and 
above FiveAdditionalTypes-waning immunity after vaccination 27 and above 
FiveAdditionalTypes, 0) 
 Immune via vaccination 27 and above quad= INTEG (aging into immune via 
vaccination 27 and above quad-"waning immunity among 27 and above (quad)"-
immune via vacc deaths quad,0) 
 aging of immune 12 to 26 FiveAdditionalTypes= immune via vacc 12 to 26 
FiveAdditionalTypes/mean years until aging 
 vacc FiveAdditionalTypes= susceptible 12 to26 FiveAdditionalTypes*"vacc rate 
(FiveAdditionalTypes)"*vaccine efficacy 
 HPV prevalence 27 and above per 100 quad= HPV prevalence 27 and above 
quad*100 




 HPV prevalence 27 and above FiveAdditionalTypes per 100= HPV prevalence 27 
and above FiveAdditionalTypes*100 
 HPV prevalence 12 to 26 quad per 100= HPV prevalence 12 to 26 quad*100 
 CIN1 27 and above quad= INTEG ("Aging into CIN1 27&above quad"+prog1 
27and above quad+reg1 27 and above quad+reg3 27 and above quad-"CIN1 
27&above deaths quad"-"clearance1 27&above quad"-prog2 27and above quad-
"rx1 27&above quad", Initial 27 and above CIN1 infected women from HPV quad 
infected) 
 fraction of women 27 and above who were infected with quad and are CIN1=0.1 
 Total initial population 12 to 26 from US census=976958 
 total initial population 27 and above from US census=3.43899e+006 
 Initially HPV infected 12 to 26 women with FiveAdditionalTypes who are at CIN1= 
Initially infected HPV women 12 to 26 from US census including CIN1 
forFiveAdditionalTypes *Fraction of 12 to 26 years who are intially infected with 
HPV FiveAdditionalTypes who have CIN1 
 Initially HPV infected women from US census for quad including CIN1=Total 
initial population 12 to 26 from US census*Fraction of women 12 to 26 from US 
census who are HPV infected for quad strain 
 Initially infected HPV women 12 to 26 from US census including CIN1 for 
FiveAdditionalTypes= Fraction of US 12 to 26 census population that is initially 
infected with FiveAdditionalTypes strain of HPV*Total initial population 12 to 26 
from US census 
 Fraction of women 27 and above from HPV FiveAdditionalTypes infected that are 
CIN1=0.1184 




 Fraction of 12 to 26 years old who are initially infected with quad strains of HPV 
who have CIN1= 0.09 
 Initially CIN1 infected women from HPV infected women= Initially HPV infected 
women from US census for quad including CIN1*Fraction of 12 to 26 years old 
who are initially infected with quad strains of HPV who have CIN1 
 Initally infected 27 and above with HPV FiveAdditionalTypes including CIN1= 
fraction of women 27 and above from susceptible that are infected with HPV 
FiveAdditionalTypes *total intial population 27 and above from US census 
 Initial 27 and above at CIN1 from HPV infected women with FiveAdditionalTypes 
strain= Fraction of women 27 and above from HPV FiveAdditionalTypes infected 
that are CIN1*Initially infected 27 and above with HPV FiveAdditionalTypes 
including CIN1 
 Fraction of women 12 to 26 from US cenus who are HPV infected for quad 
strain= 0.18 
 Fraction of 12 to 26 years who are intially infected with HPV FiveAdditionalTypes 
who have CIN1= 0.09 
 Fraction of US 12 to 26 census population that is initially infected with 
FiveAdditionalTypes strain of HPV=0.12 
 death of susceptible 12to 26no= susceptible 12 to26 FiveAdditionalTypes*death 
rate 12 to 26 
 CIN1 deaths 12to 26FiveAdditionalTypes= CIN1 12 to26 
FiveAdditionalTypes*death rate 12 to 26 
 deaths of CIN3 12 to 26 quad= death rate 12 to 26*CIN3 12 to 26 quad 
 deaths of immune 12 to 26 quad= Immune via vaccination 12to26 quad*death 
rate 12 to 26 
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 deaths of infected 12 to 26 quad= death rate 12 to 26*HPV infected 12 to 26 
quad 
 CIN3 deaths 12to26FiveAdditionalTypes= CIN3 12to26 
FiveAdditionalTypes*death rate 12 to 26 
 CIN2 deaths 12to 26 FiveAdditionalTypes= CIN2 12to 26 
FiveAdditionalTypes*death rate 12 to 26 
 CIN2 27 and above quad= INTEG (Aging into CIN2 27 and above quad-"clear2 
27 & above quad"+prog2 27and above quad-prog3 27and above quad+"reg2 
27&above quad"-CIN2 deaths among 27 and above quad-reg1 27 and above 
quad-"rx2 27&above quad",0) 
 deaths infected 12to 26 FiveAdditionalTypes= HPV infected 12to26 
FiveAdditionalTypes*death rate 12 to 26 
 deaths of CIN2 12 to 26 quad=death rate 12 to 26*CIN2 12 to 26 quad 
 CIN2 27 and above FiveAdditionalTypes= INTEG (aging into cin2 
FiveAdditionalTypes+"prog2 27& above FiveAdditionalTypes"+"reg2 27 &above 
FiveAdditionalTypes"-"CIN2 27&above deaths FiveAdditionalTypes"-clearance2 
FiveAdditionalTypes-"prog3 27& above FiveAdditionalTypes"-"reg1 27&above 
FiveAdditionalTypes"-"rx2 27& above FiveAdditionalTypes", 0) 
 deaths of CIN1 12to26 quad= CIN1 12 to 26 quad*death rate 12 to 26 
 deaths of susceptible 12 to 26 quad=Susceptible12to26 quad*death rate 12 to 26 
 Ref Rate of clearance of CIN1 quad 12 to 26= 0.483  
 Ref Rate of clearance of CIN2 quad 12 to 26= 0.21 
 Ref Rate of clearance of CIN3 quad 12 to 26= 0.11 
 vaccine efficacy= 0.9 
 "death of females< 12 years of age"= "death rate of females <12 
years"*"Females <12 quad" 
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 "death rate of females <12 years"= 0.0002195 
 "death of females <12 years"= "death rate of females <12 years"*"Female <12 
FiveAdditionalTypes" 
 force of infection 27 and above quad= mean partner acquisition rate 27 and 
above*(fraction of partners 27 years and older women that are in 27 years and 
older *HPV prevalence 27 and above quad +(1-fraction of partners 27 years and 
older women that are in 27 years and older) *HPV prevalence 12 to 26 
quad)*transmission rate 27 and above 
 force of infection 27 and above FiveAdditionalTypes= mean partner acquisition 
rate 27 and above * (fraction of partners 27 years and older women that are in 27 
years and older * HPV prevalence 27 and above FiveAdditionalTypes + (1-
fraction of partners 27 years and older women that are in 27 years and older) * 
HPV prevalence 12to26FiveAdditionalTypes)*transmission rate 27 and above 
 fraction of partners 27 years and older women that are in 27 years and older= 
0.915 
 Fraction of partners of 12 to 26 year old women that are in 12 to 26 year of age= 
0.33 
 "Aging females <12 FiveAdditionalTypes"= "Female <12 
FiveAdditionalTypes"/"mean years of aging for <12 years old” 
 "Aging of female <12"= "Females <12 quad"/"mean years of aging for <12 years 
old" 
 "mean years of aging for <12 years old"= 12 
 reg3 27 and above quad= CIN3 27 and above quad*Rate of Reg CIN3 to CIN1 
 Fraction of CIN1 sucessfully cured=0.96 




 reg2 26no= Rate of Reg CIN3 to CIN2*CIN3 12to26 FiveAdditionalTypes 
 "reg2 27&above quad"= Rate of Reg CIN3 to CIN2*CIN3 27 and above quad 
 "reg2 27 &above FiveAdditionalTypes"= Rate of Reg CIN3 to CIN2*CIN3 27 and 
above FiveAdditionalTypes 
 reg3 12 to 26FiveAdditionalTypes= Rate of Reg CIN3 to CIN1*CIN3 12to26 
FiveAdditionalTypes 
 regression2 12to26 quad= Rate of Reg CIN3 to CIN2*CIN3 12 to 26 quad 
 Regression3 12to26 quad= Rate of Reg CIN3 to CIN1*CIN3 12 to 26 quad 
 Rate of Reg CIN3 to CIN2=0.03 
 regression1 12to26 quad= Rate of regression CIN2 to CIN1*CIN2 12 to 26 quad 
 "reg1 27&above FiveAdditionalTypes"= Rate of regression CIN2 to CIN1*CIN2 
27 and above FiveAdditionalTypes 
 reg1 27 and above quad= CIN2 27 and above quad*Rate of regression CIN2 to 
CIN1 
 Rate of Reg CIN3 to CIN1= 0.03 
 Fraction of CIN3 successfully cured= 0.92 
 Rate of regression CIN2 to CIN1= 0.133 
 "reg3 27&above FiveAdditionalTypes"= Rate of Reg CIN3 to CIN1*CIN3 27 and 
above FiveAdditionalTypes 
 Fraction of CIN2 successfully cured= 0.92 
 CIN3 to cervical cancer hazard rate= 0.42 
 progression1 among 12 to 26 quad= HPV infected to CIN1 hazard rate*HPV 
infected 12 to 26 quad 





 progression3 among 12 to 26 quad= CIN2 to CIN3 hazard rate*CIN2 12 to 26 
quad 
 HPV infected to CIN1 hazard rate= 0.094 
 prog2 27and above quad= CIN1 to CIN2 hazard rate*CIN1 27 and above quad 
 prog3 27and above quad= CIN2 to CIN3 hazard rate*CIN2 27 and above quad 
 CIN2 to CIN3 hazard rate= 0.154 
 prog1 27and above quad=HPV infected to CIN1 hazard rate*HPV infected 27and 
above quad 
 CIN1 to CIN2 hazard rate= 0.136 
 "Aging into CIN1 27&above quad"= aging CIN1 12to26 quad 
 aging into CIN1 FiveAdditionalTypes= CIN1 12 to 26 FiveAdditionalTypes aging 
 Aging into CIN2 27 and above quad= aging CIN2 12to 26 quad 
 aging into cin2 FiveAdditionalTypes= CIN2 12to26 FiveAdditionalTypes aging 
 "Aging into CIN3 27&above quad"=Aging CIN3 12 to 26 FiveAdditionalTypes 
 aging into cin3 FiveAdditionalTypes= CIN3 12 to 26 FiveAdditionalTypes aging 
 aging into hpv infected FiveAdditionalTypes= hpv infected 12 to 
26FiveAdditionalTypes aging 
 Aging into susceptible 27= aging susceptible 12to 26 quad 
 aging into susceptible 27 and FiveAdditionalTypes= Susceptible 12 to 26 
FiveAdditionalTypes aging 
 CIN1 12 to 26 FiveAdditionalTypes aging= CIN1 12 to26 
FiveAdditionalTypes/mean years until aging 
 ratio of total population to total population of women= 2 
 mean partner acquistion 12 to 26=1.64 
 aging CIN1 12to26 quad= CIN1 12 to 26 quad/mean years until aging 
 aging CIN2 12to 26 quad= CIN2 12 to 26 quad/mean years until aging 
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 aging hpv infected 12 to 26 quad= HPV infected 12 to 26 quad/mean years until 
aging 
 aging susceptible 12to 26 quad= Susceptible12to26 quad/mean years until aging 
 Susceptible 12 to 26 FiveAdditionalTypes aging= susceptible 12 to26 
FiveAdditionalTypes/mean years until aging 
 CIN2 12to 26 FiveAdditionalTypes= INTEG (prog2 
12to26FiveAdditionalTypes+reg2 26no-CIN2 deaths 12to 26 
FiveAdditionalTypes-clearance2 12to 26 FiveAdditionalTypes -prog3 12 to 
26FiveAdditionalTypes-reg1 12 to 26FiveAdditionalTypes-rx2 12to26 
FiveAdditionalTypes -CIN2 12to26 FiveAdditionalTypes aging, 0) 
 CIN2 12to26 FiveAdditionalTypes aging= CIN2 12to 26 
FiveAdditionalTypes/mean years until aging 
 hpv infected 12 to 26FiveAdditionalTypes aging= HPV infected 12to26 
FiveAdditionalTypes/mean years until aging 
 CIN3 12 to 26 FiveAdditionalTypes aging= CIN3 12to26 
FiveAdditionalTypes/mean years until aging 
 CIN2 12 to 26 quad= INTEG (+progression2 among 12 to 26 quad+regression2 
12to26 quad-clearance2 among 12to26 quad-progression3 among 12 to 26 
quad-regression1 12to26 quad-rx2 12to26 quad-aging CIN2 12to 26 quad-deaths 
of CIN2 12 to 26 quad,0) 
 Aging CIN3 12 to 26 FiveAdditionalTypes= CIN3 12 to 26 quad/mean years until 
aging 
 mean years until aging= 15 
 birth rate for female babies= (0.0124 / 2) 
 death rate 12 to 26= 0.000647 
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 "total infected HPV 16 &18"= HPV infected 12 to 26 per 100000 quad+hpv 
infected 27 and above per 100000 quad 
 "total infected (5 additional types)"= hpv infected 12 to 26FiveAdditionalTypes per 
100000+HPV infected FiveAdditionalTypes per 100000 
 "total CIN1 HPV 16&18"= CIN1 12to26 per 100000 quad+"CIN1 27&above per 
100000 quad" 
 "total CIN1 (5 additional types)"= CIN1 26FiveAdditionalTypes per 100000+"CIN1 
27& above FiveAdditionalTypes per 100000" 
 "total CIN2 HPV 16 &18"= CIN2 12to26 quad per 100000+CIN2 27 and above 
per 100000 quad 
 "total CIN2 (5 additional types)"= CIN2 12 to 26per 100000 
FiveAdditionalTypes+"CIN2 27&above FiveAdditionalTypes per 100000" 
 "total CIN3 HPV 16&18"= CIN3 among 12 to 26 per 100000 quad+CIN3 27 and 
above per 100000 quad 
 "total CIN3 (5 additional types)"= CIN3 12 to 26 per 100000 
FiveAdditionalTypes+CIN3 FiveAdditionalTypes per 100000 
 total infected= HPV infected FiveAdditionalTypes per 100000+HPV infected 12 to 
26 per 100000 quad+hpv infected 12 to 26FiveAdditionalTypes per 100000+hpv 
infected 27 and above per 100000 quad 
 total CIN 1= CIN1 12to26 per 100000 quad+"CIN1 27& above 
FiveAdditionalTypes per 100000"+CIN1 26FiveAdditionalTypes per 100000 
+"CIN1 27&above per 100000 quad" 
 "infection 27&above quad"= force of infection 27 and above quad*Susceptible 
27and above quad 
 infection 12to26FiveAdditionalTypes=force of infection 12 to 26 
FiveAdditionalTypes*susceptible 12 to26 FiveAdditionalTypes 
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 total CIN2= "CIN2 27&above FiveAdditionalTypes per 100000"+CIN2 12to26 
quad per 100000+CIN2 12 to 26per 100000 FiveAdditionalTypes+CIN2 27 and 
above per 100000 quad 
 total CIN3=CIN3 FiveAdditionalTypes per 100000+CIN3 among 12 to 26 per 
100000 quad+CIN3 12 to 26 per 100000 FiveAdditionalTypes+CIN3 27 and 
above per 100000 quad 
 screening rate FiveAdditionalTypes=0.728 
 "infection 27&above FiveAdditionalTypes"= force of infection 27 and above 
FiveAdditionalTypes*Susceptible 27and above FiveAdditionalTypes 
 infection rate among 12to26 quad= force of infection 12to26 
quad*Susceptible12to26 quad 
 Ref Rate of clearance of HPV infected quad 12 to 26= 0.483 
 mean partner acquisition rate 27 and above= 1.19 
 screening rate=0.728 
 sensitivity CIN1= 0.28 
 sensitivity CIN2and CIN3=0.59 
 transmission rate 27 and above= 0.4 
 
 
